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Abstract 
Numerous care and treatment guidelines pinpoint vaccination as a crucial preventive strategy for 
HIV-infected patients, but data regarding these vaccines among children living with HIV are still 
very scanty. There are knowledge gaps concerning the understanding of the mediators of vaccine 
protection, adverse effects and fundamental aspects of the epidemiology of various vaccine-
preventable diseases. Likewise, there is also limited information on the determinants of vaccine 
non-uptake within the HIV-infected population, and on the association between maternal HIV 
status and the vaccination status of her HIV-exposed child. Further synthesis of all available 
evidence is required to provide reliable and easily accessible information for decision-makers and 
healthcare workers. We completed evidence synthesis of existing studies and secondary analyses 
of existing data sets using different research methods such as systematic review, meta-analysis, 
meta-regression and multivariable logistic regression models.  
We found that the burden of vaccine-preventable diseases is still high among HIV-infected and 
HIV-exposed children in sub-Saharan Africa. Several routine vaccines show possibilities for direct 
and indirect protection against various vaccine-preventable diseases among HIV-infected and 
HIV-exposed children. However, HIV-infected children are less likely to be protected against 
vaccine-preventable diseases when compared to non-exposed children. There is no significant 
difference in the uptake of the full series of three doses of diphtheria-tetanus-pertussis containing 
vaccines (DTP3) among infants of HIV-infected mothers and those of uninfected mothers in sub-
Saharan Africa. Vaccination coverage for both HIV-exposed children and non-exposed children is 
still sub-optimal.  
Furthermore, individual and contextual factors such as maternal age, educational level, 
unemployment, and adult literacy level contributed significantly to non-uptake of DTP3 among 
the children of HIV-infected women across sub-Saharan Africa. The symptoms of acute 
respiratory infections show no statistical difference in the overall estimates between the children 
of HIV-infected mothers who were vaccinated with DTP3 and the ones who were not vaccinated. 
The data for episodes of diarrhoea were pooled together with resultant nil significant difference in 
the overall estimates between the children of HIV-infected mothers who were vaccinated with 
DTP3 and those not vaccinated. Many African countries also recorded high rates of respiratory 
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infections and diarrhoeal diseases among both HIV-exposed and unexposed children. Residency 
in communities with high unemployment was an independent predictor of acute respiratory 
infections among immunised and HIV-exposed children while those born to women aged 15-24 
or 25-34 years old were significantly more likely to develop diarrhoeal diseases. 
There is a need to address sub-optimal uptake of vaccines among HIV-exposed and non-exposed 
children. Epidemiological studies on vaccine-preventable diseases and the development of more 
efficacious vaccines are required for vaccine-preventable diseases studies with respect to HIV-
infected and HIV-exposed uninfected children. The findings of this research would be useful in 
advocating for a more equitable share of healthcare resources especially for preventive services 
such as vaccination of both HIV-exposed and non-exposed children with subsequent reduction in 
the burden of vaccine-preventable diseases.   
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Opsomming 
Verskeie sorg- en behandelingsriglyne dui op inenting as ’n noodsaaklike voorkomingstrategie vir 
MIV-positiewe pasiënte. Tog is daar nog weinig data beskikbaar oor hierdie inentings onder 
kinders wat met MIV leef. Daar bestaan kennisleemtes in die begrip van die bemiddelaars van 
inentingsbeskerming, die nadelige gevolge van inenting, en fundamentele aspekte van die 
epidemiologie van verskeie siektes wat met inentings voorkom kan word. Eweneens is daar 
beperkte inligting oor die redes waarom die MIV-positiewe populasie nié van inenting gebruik 
maak nie, en die verband tussen die ma se MIV-status en die inentingstatus van haar MIV-
blootgestelde kind. Verdere sintese van alle beskikbare bewyse word vereis om betroubare en 
maklik toeganklike inligting aan besluitnemers en gesondheidsorgwerkers te voorsien. In hierdie 
navorsing is die bewyse uit bestaande studies gesintetiseer en sekondêre ontledings van die 
bestaande datastelle onderneem. Hiervoor is verskillende navorsingsmetodes gebruik, waaronder 
stelselmatige oorsig, meta-ontleding, meta-regressie en meerveranderlike logistiese regressie. 
Die ontledings toon dat die las van inentingsvoorkombare siektes steeds hoog is onder MIV-
positiewe én -blootgestelde kinders in Afrika suid van die Sahara. ’n Aantal roetine-inentings blyk 
MIV-positiewe en -blootgestelde kinders moontlike direkte sowel as indirekte beskerming teen ’n 
verskeidenheid inentingsvoorkombare siektes te bied. Tog is die waarskynlikheid dat MIV-
positiewe kinders teen inentingsvoorkombare siektes ingeënt sal word kleiner as by 
nieblootgestelde kinders. Daar is geen beduidende verskil tussen die gebruik van die volle reeks 
van drie dosisse difterie-tetanus-pertussis-inentings (DTP3) onder die babas van MIV-positiewe 
ma’s en die babas van MIV-negatiewe ma’s in Afrika suid van die Sahara nie. Nietemin is 
inentingsdekking vir sowel MIV-blootgestelde as -nieblootgestelde kinders steeds suboptimaal. 
Daarbenewens het individuele en kontekstuele faktore, soos die ma se ouderdom, opvoedingsvlak, 
werkstatus en geletterdheidsvlak, ’n aansienlike invloed op die niegebruik van DTP3 onder die 
kinders van MIV-positiewe vroue in Afrika suid van die Sahara. Die simptome van akute 
respiratoriese infeksies toon geen statistiese verskil in algehele ramings tussen MIV-positiewe 
ma’s se kinders wat met DTP3 ingeënt is en kinders wat nié ingeënt is nie. Die data vir gevalle 
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van diarree is saamgevoeg, en dui ook op geen beduidende verskil in algehele ramings tussen MIV-
positiewe ma’s se kinders mét DTP3-inenting en diegene sónder sodanige inenting nie. Baie 
Afrikalande meld ’n hoë voorkoms van respiratoriese infeksies en diarreesiektes onder sowel 
MIV-blootgestelde as -nieblootgestelde kinders aan. Verblyf in gemeenskappe met hoë 
werkloosheidsyfers is ’n onafhanklike voorspeller van akute respiratoriese infeksies onder 
geïmmuniseerde en MIV-blootgestelde kinders, terwyl die kinders van vroue in die 
ouderdomskategorie 15–24 of 25–34 ’n aansienlik groter geneigdheid tot diarreesiektes toon. 
Die suboptimale gebruik van inentings onder MIV-blootgestelde en -nieblootgestelde kinders verg 
aandag. Meer studies oor inentingsvoorkombare siektes by MIV-positiewe en MIV-blootgestelde 
dog -negatiewe kinders word vereis met betrekking tot epidemiologie sowel as die ontwikkeling 
van doeltreffender entstowwe. Die bevindinge van hierdie navorsing sal nuttig wees om 
voorspraak te doen vir ’n billike toewysing van gesondheidsorghulpbronne aan voorkomende 
dienste, waaronder die inenting van sowel MIV-blootgestelde as -nieblootgestelde kinders, wat die 
las van inentingsvoorkombare siektes sal verlig. 
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CHAPTER 1: General Introduction 
 
Background 
 
HIV epidemiology among children in sub-Saharan Africa 
 
Human immunodeficiency virus (HIV) infection is a major health challenge and a leading cause 
of disability-adjusted life years/disease burden especially in the low- and middle-income 
countries.1,2 The epidemic mainly affects sub-Saharan Africa with about 75% of the global burden 
of the disease.3,4 HIV thrived in these countries due to the combination of factors such as 
inadequate access to healthcare, poor socio-economic conditions, political unrest leading to 
displacement, gender inequalities and harmful cultural practices, among others. 5  
Between 2001 and 2014, new HIV infections declined across all age groups with the most rapid 
reduction in children under-five years of age.6 This decline was mainly due to the comprehensive 
implementation of prevention of mother-to-child transmission of HIV programmes and the 
provision of antiretroviral therapy (ART). Notwithstanding the progress made, many HIV-infected 
children still lack access to ART. Globally, about 1.8 million children aged under 15 years were 
living with HIV with 90% of these coming from sub-Saharan Africa and about 31% having access 
to ART in 2017 4 (as shown in Figure 1). The incidence of new HIV infections among children 
also declined in 2017 but there were still 180,000 new infections that year alone.4  
This recent progress is very different from the situation in the early 1980s when Kaposi’s Sarcoma 
started emerging in younger patients as well as an aggressive form of pneumonia known as 
Pneumocystis pneumonia.7 Additional opportunistic infections started evolving leading to the full-
blown disease state of HIV known as Acquired Immune Deficiency Syndrome (AIDS). By the 
1990s, AIDS became a leading cause of death in many countries. In 2010, The US Agency for 
International Development (USAID) estimated that 40 million African children had lost one or 
both parents to AIDS.7 
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Vaccination among HIV-infected and HIV-exposed children in sub-Saharan Africa 
 
Vaccination has been demonstrated to be a cost-effective and beneficial public-health intervention 
to protect children, adolescents and adults from vaccine-preventable diseases. HIV-infected 
children are more susceptible to vaccine-preventable diseases such as tuberculosis, pneumonia, 
viral hepatitis etc. 8,9 Vaccination is essential in HIV-infected patients because of their increased 
risk of developing various infectious diseases due to their defective immune systems. It is therefore 
paramount to focus on the vaccination of HIV-infected patients in developing countries where 
many still have limited access to HIV diagnosis, treatment and care.3 Studies from sub-Saharan 
Africa show that the coverage of routine vaccinations is low in some of these countries and 
inadequate to meet the Global Vaccine Action Plan (GVAP) targets.10-12 Some African countries 
have low, stagnant or even decreasing immunisation coverage over the years. Only 26% of African 
countries had achieved ≥ 90% national coverage for vaccines included in their national 
immunisation schedule by World Health Organization (WHO) in 2014.13 Africa accounts for about 
34% of the global vaccine-preventable disease burden, and is also responsible for the highest 
proportion of under-five mortality from these diseases.14  
Immunisation of children is one of the essential services that are vital for the attainment of 
Universal Health Coverage. However, lack of access and infrastructure is a big challenge in the 
provision of this service in sub-Saharan Africa. About 400 million people lack access to at least 
one of the six essential health services such as child immunisation or family planning services.15,16 
This lack of accessibility to service and infrastructures is responsible for significant inequalities 
across various subgroups among sub-Saharan African countries. Some African countries are also 
in a state of conflict including parts of Nigeria, South Sudan and the Democratic Republic of 
Congo with resultant disruption or collapse of essential primary healthcare services. In a conflict 
situation, the immunisation services are adversely affected. Although polio is no longer endemic 
in sub-Sahara Africa, many countries are still at risk of re-infection, particularly those in the 
‘poliovirus importation belt’ which stretches from West Africa to the Horn of Africa.17  
The World Health Organization Expanded Programme on Immunisation in conjunction with the 
United Nations Children’s Fund recommends an accelerated immunisation schedule for both HIV-
infected children and non-infected children (Table 1).18 However, the childhood immunisation 
schedule may vary slightly among the countries. Adequate vaccination coverage is essential in 
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HIV-infected and HIV-exposed children because they are highly susceptible to more severe forms 
of some vaccine-preventable diseases with increased risk of mortality.19,20 
 
 
 13k+ 
 3.3k – 13k 
 420- 3.3k 
 < 420 
 No data 
 
Figure 1: A map showing the number of children aged 0-14 years old living with HIV in sub-Saharan Africa 
(2017) 4 
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Vaccination of both HIV-infected and non-infected children played the critical role in achieving 
the Millennium Development Goal 4 targeted at reducing deaths in children under-five years of 
age.17  In 2008, vaccine-preventable diseases were responsible for about 1.5 million deaths in 
children under-five years of age and this is estimated to be about 17% of all under-five deaths in 
that particular year.21 Sustainable Development Goal 3.8 is also concerned with 
vaccination/immunisation strategies especially regarding the attainment of Universal Health 
Coverage via vaccines for all age groups.22  
 
Table 1: Adapted summary of WHO position papers for recommended routine immunisations 
for children in most sub-Saharan African countries1 8  
Antigens  Frequency of dosage 
Bacillus Calmette–Guérin One dose  
Hepatitis B 3-4-doses  
Oral polio/Inactivated polio  3-4 doses 
Diphtheria, Tetanus and Pertussis  Three doses with two boosters at 12-23 months and 4-7 years  
Haemophilus Influenzae type b   
Option 1 
 
Three doses 
Option 2 2 or 3 doses, with a booster at least six months after the last dose  
Pneumococcal conjugate  
 
 
Option 1 
 
Three doses 
Option 2 Two doses before six months of age, plus booster dose at 9-15 months 
of age 
Rotavirus 2 or 3 doses  
Measles Two doses  
Rubella One dose 
Yellow Fever One dose 
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Maternal HIV status and its association with childhood vaccination coverage  
 
The association between maternal HIV status and childhood vaccination is of public health 
significance in countries with high HIV prevalence. Studies have shown that household wealth, 
maternal age, distance to healthcare facilities and maternal education are the main determinants of 
childhood vaccination in some African population.23-25 However, HIV-exposed children have 
increased risk of mortality because HIV-infected mothers may not be predisposed to take the 
children for vaccination due to their generalised physical weakness as well as lack of transportation 
fees to access the services at the health centres.26,27 The mothers may also avoid the healthcare 
clinics in their communities due to fear of stigma and discrimination.28 There is uncertainty on 
maternal HIV status and its association to childhood vaccination coverage among HIV-exposed 
and infected children in Africa. Findings from both Ugandan and South Africa cohorts showed 
that children of HIV-infected mothers were less likely to be vaccinated for all routine vaccines 
than children born to non–infected mothers.26,29 However, these findings cannot be generalised for 
the African population.  HIV-exposed infants are those born to HIV-infected mothers and whose 
HIV status is not yet determined, while HIV-infected infants are the ones with confirmed HIV-
infected status. 
 
Study rationale 
The vaccination rates of children remain insufficient for vaccine-preventable diseases in many 
African countries.13  Low vaccination coverage translates to having numerous unvaccinated and 
under-vaccinated HIV-infected and HIV-exposed children who will eventually die from 
preventable diseases at a higher rate than their immunocompetent age counterparts.19,20 Different 
care and treatment guidelines pinpoint vaccination as a crucial preventive strategy for HIV-
infected patients 30,31 but data regarding the use of some of the vaccines among people living with 
HIV are still very scanty.32 Experts using evidenced-based approaches on vaccination of 
immunocompromised individuals made specific recommendations for vaccination against major 
vaccine-preventable diseases for these patients but with limited proofs.33 There have been few 
previous reviews on efficacy and effectiveness of pneumococcal and Haemophilus influenzae b 
vaccines against diseases in HIV-infected and exposed children but these studies were not 
systematic reviews and did not specify the disease outcomes.34,35 The experts also identified 
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research gaps for future investigation. One of the gaps in knowledge was that of understanding the 
mediators of vaccine protection, adverse effects and basic aspects of the epidemiology of various 
vaccine-preventable diseases.31 The changing pattern of some vaccine-preventable diseases is 
poorly understood, and this changing pattern and epidemiology makes it paramount to have a better 
understanding of these diseases because of possible resurgence and epidemics in the future.33 The 
suboptimal uptake of vaccines in sub-Saharan Africa coupled with the high HIV burden is a risk 
factor that may facilitate future outbreaks. 33,36  
Ndirangu et al. 29 showed that there is a lesser likelihood of vaccination in children whose mothers 
are living with HIV and that this contributes significantly to the disparity in vaccination coverage 
between infants of HIV-infected and non-infected mothers. There is, however, limited information 
on whether the maternal HIV-infection status is associated with childhood immunisation coverage 
in general African populations.29 Understanding the association between the mother’s HIV status 
and the vaccination status of her HIV-exposed child is of great importance in sub-Saharan African 
countries with high HIV prevalence. 37 Valour et al. also showed that determinants for vaccine 
uptake among the HIV-infected population were mostly not evidence-based.32 Exploring the effect 
of maternal HIV status on childhood vaccination among children in sub-Saharan Africa is critical 
to inform vaccine-preventable disease-prevention strategies and to develop interventions to 
improve vaccination coverage in HIV-infected and exposed children.  
The identified gaps warrant the use of evidence-based research approaches to have a better 
understanding of vaccine-preventable diseases and coverage amongst HIV-infected children in 
sub-Saharan Africa. An evidence-based practice approach 38 will go a long way in improving the 
effectiveness, efficiency and sustainability of vaccination and immunisation policies targeted at 
HIV-infected and HIV-exposed children in sub-Saharan Africa. Evidence-based practice will also 
assist in developing appropriate remedial public-health interventions to address the observed 
challenges working against vaccination programmes among HIV-infected children including the 
Expanded Programme on Immunisation in some African countries.39,40 Evidence-based research 
addresses the issue of information overload and helps decision-makers to filter growing quantities 
of published systematic reviews.40 Further synthesis of all available evidence is required to provide 
reliable and easily accessible information to decision-makers, healthcare workers and the 
community of people living with HIV.   
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This research study focuses on the vaccines that are part of the Expanded Programme on 
Immunisation in African countries with high HIV prevalence. The study will concentrate on the 
following vaccine antigens: Hepatitis B; Bacillus Calmette–Guérin; diphtheria, tetanus and 
pertussis; Haemophilus influenzae type b; polio; pneumococcal conjugate; measles; rotavirus; 
rubella and yellow fever. The vaccine-preventable diseases of interest are as follows: tuberculosis, 
poliomyelitis, rotavirus gastroenteritis, diphtheria, tetanus, pertussis, pneumococcal diseases, 
measles, rubella and yellow fever.  
 
Aim and objectives 
Overall study goal 
This research project set out general and specific objectives as described below:                    
The goal of this study is to determine: 
 the burden of vaccine-preventable diseases;  
 efficacy and effectiveness of vaccines;  
 association between vaccination coverage and maternal HIV status and; 
 differential morbidity benefit concerning HIV infection among sub-Saharan African 
children.  
 
Specific objectives: 
Workstream #1 (Evidence synthesis of existing studies) 
1.  To assess the burden of vaccine-preventable diseases among HIV-infected and HIV-exposed 
children in sub-Saharan African countries. 
2.  To evaluate the efficacy and effectiveness of vaccines among HIV-infected and HIV-exposed 
children.  
 
Workstream #2 (Secondary analyses of existing data sets) 
1. To examine the vaccination coverage and the relationship between various country-level 
characteristics among sub-Saharan African children with respect to the maternal HIV status. 
2. To develop and test models for non-uptake of vaccines among the children of HIV-infected 
mothers. 
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3. To determine the prevalence of symptoms of acute respiratory infections and episodes of 
diarrhoea; and the relationship of maternal HIV status with morbidity benefits of vaccine 
uptake among sub-Saharan African children. 
4. To examine the role of the socio-economic factors in relation to uptake of DTP3 vaccines 
among HIV-exposed children.  
 
Data sources 
The study used various vaccines, vaccination, and HIV data from selected electronic databases, 
demographic and health surveys (DHS), WHO position papers, trial registers and experts. Articles 
and data were identified from 1980 to the date of commencement of each section of the doctoral 
research studies. DHS are nationally-representative household surveys conducted in low-and-
middle-income countries.41 The surveys provide data for a wide range of indicators in the areas of 
population, health, and nutrition. 
This research used the three doses of diphtheria-tetanus-pertussis vaccines (DTP3) as a variable 
for vaccination status.  DTP3 is a key indicator used by international and national organisations 
such as the United Nations Children’s Fund (UNICEF) and WHO for assessing the effectiveness 
of childhood immunisation services.36 The series of immunisations known as DTP can prevent 
diphtheria, pertussis (whooping cough) and tetanus, but these three diseases still kill 600,000 
children and afflict millions of others every year in developing countries. The percentage of 
children receiving the final dose (DTP3) is therefore a revealing and vital gauge of how well 
countries are providing immunisation coverage for their children.36 To be fully protected, DTP-
containing vaccines are normally given in three doses at the age of 6, 10 and 14 weeks with three 
booster doses at 12-23 months, 4-7 years and 9-15 years. Diphtheria toxoid-containing vaccines 
are given to the older children as a booster vaccine.18 
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CHAPTER 2: The burden of vaccine-preventable diseases 
among HIV-infected and HIV-exposed children in sub-
Saharan Africa: a systematic review and meta-analysis 
 
Olatunji O. Adetokunboh, Ajibola Awotiwon, Duduzile Ndwandwe, Olalekan A. Uthman, 
Charles S. Wiysonge  
Abstract 
There are knowledge gaps regarding evidence-based research on the burden of vaccine-
preventable diseases among human immunodeficiency virus (HIV)-infected and HIV-exposed 
children aged <18years in sub-Saharan Africa. It is therefore essential to determine the trend and 
current burden of vaccine-preventable disease epidemiology. We completed a systematic review 
of the literature and a meta-analysis to identify the incidence, prevalence and case-fatality rates 
(CFR) attributed to various vaccine-preventable diseases among HIV-infected and HIV-exposed 
children in sub-Saharan Africa. The trends in the prevalence of vaccine-preventable diseases 
among HIV-infected and HIV-exposed children were also determined. Nine studies on 
tuberculosis (TB) were pooled to give an overall incidence rate estimate of 60 (95% confidence 
interval [CI] 30 – 70) per 1,000 child-years. The incidence of pneumococcal infections varied 
between 109-1509 per 100,000 while pertussis was between 2.9 and3.7 per 1000 child-year. 
Twenty-two TB prevalence studies reported an estimated prevalence of 16%. Fifteen prevalence 
studies on hepatitis B infection were pooled together with an estimated prevalence of 5%. The 
pooled prevalence for pneumococcal infections was 2% while rotavirus diarrhoea reported a 
prevalence of 13%. Twenty-nine studies on TB were pooled to give an overall case-fatality rate 
estimate of 17% while pneumococcal infections in HIV-infected and exposed children were pooled 
together with a resultant rate of 15%. Some of the vaccine-preventable diseases still have high 
incidences, prevalence and CFR among HIV-infected and HIV-exposed children in sub-Saharan 
Africa. There is also a dearth of research data on the burden of several vaccine-preventable diseases 
among HIV-infected and exposed children and a need for more studies in this area.  
Keywords: HIV; vaccine-preventable diseases; sub-Saharan Africa; burden 
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Background 
Human immunodeficiency virus (HIV) infection remains a leading public-health challenge and a 
principal cause of the infectious disease burden in low- and middle-income countries especially in 
sub-Saharan Africa.1 This region accounts for the bulk of HIV infection with about 36.7 million 
people living with the disease an estimated 75% of the global burden.2,3 It was also estimated that 
approximately 2.1 million children aged under 15 years were living with HIV with the majority 
coming from sub-Saharan Africa and about 31% having access to antiretroviral therapy in 2014.4 
The incidence of HIV infections among children declined in 2014 but there were still 220,000 new 
infections that year alone.4 HIV-infected children have an increased risk of developing various 
vaccine-preventable diseases due to their defective immune systems.5 This makes it crucial to 
focus on the vaccination of HIV-infected and exposed children. The majority of these children are 
also residents of low-and-middle-income countries characterised by limited access to HIV 
diagnosis, treatment and care.2  
Vaccination against various vaccine-preventable diseases has been proven to be a beneficial and 
cost-effective public-health measure for protecting children, adolescents and adults from these 
diseases, thereby reducing the morbidity and mortality attributable to them.6,7 Coverage of routine 
vaccinations is still low in some developing countries and not sufficient to meet the Global Vaccine 
Action Plan (GVAP) targets.8–10 Some African countries have low or decreasing immunisation 
coverage over the years with some not achieving ≥ 90% national coverage for vaccines included 
in their national immunisation schedule by the World Health Organization (WHO) in 2016.11 Sub-
Saharan African countries account for about 34% of the global vaccine-preventable diseases 
burden, and are also responsible for the highest proportion of under-five mortality from these 
diseases.12   
Recently, most developing countries have included routine childhood vaccines such as hepatitis 
B; Bacillus Calmette–Guérin (BCG); diphtheria, tetanus and pertussis (DTP); Haemophilus 
influenzae type b (Hib); polio; pneumococcal conjugate; measles; rotavirus (RV), rubella and 
yellow fever vaccines in their national Expanded Programme on Immunisation (EPI).13 These 
vaccines also protect against diseases such as tuberculosis, poliomyelitis, rotavirus gastroenteritis, 
diphtheria, tetanus, pertussis, pneumococcal diseases, hepatitis B infection, rubella, measles and 
yellow fever.  
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The gap in knowledge, especially in terms of evidence-based research, on the burden of vaccine-
preventable diseases among HIV-infected and HIV-exposed children in sub-Saharan Africa, 
warrants this study.14 This study completed a systematic review of literature and meta-analysis to 
identify the incidence, prevalence and mortality due to various vaccine-preventable diseases 
among HIV-infected and HIV-exposed children in sub-Saharan Africa since the advent of HIV in 
the 1980s. This study is essential in determining the trend and current burden of vaccine-
preventable disease epidemiology in sub-Saharan Africa.  
 
Objectives 
Primary objectives 
1. To appraise all available published literature on the incidence and prevalence of vaccine-
preventable diseases such as tuberculosis, poliomyelitis, hepatitis B virus infection, 
rotavirus gastroenteritis, diphtheria, tetanus, pertussis, pneumococcal diseases, measles,  
rubella and yellow fever among HIV-infected and HIV-exposed children in sub-Saharan 
Africa.  
2. To determine the trend in the incidence and/or prevalence of vaccine-preventable diseases 
such as tuberculosis, poliomyelitis, hepatitis B virus infection, rotavirus gastroenteritis, 
diphtheria, tetanus, pertussis, pneumococcal diseases, measles,  rubella and yellow fever 
among HIV-infected and HIV-exposed children in sub-Saharan Africa from 1980 to 2018. 
Secondary objective 
1. To describe the case-fatality rate ascribed to vaccine-preventable diseases such as 
tuberculosis, poliomyelitis, hepatitis B virus infection, rotavirus gastroenteritis, diphtheria, 
tetanus, pertussis, pneumococcal diseases, measles,  rubella and yellow fever among HIV-
infected and HIV-exposed children in sub-Saharan Africa. 
 
Methods and design 
This systematic review was developed in line with the Preferred Reporting Items for Systematic 
Review and Meta-Analysis (PRISMA) 2015 statement.15 The review was registered with 
PROSPERO (International prospective register of systematic reviews) (CRD42018095341). 
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Inclusion criteria 
Type of participants: The review included sub-Saharan African children who are HIV-infected or 
HIV-exposed  and aged <18 years old. 
Types of outcome:  
We included studies that reported the incidence, prevalence and case-fatality rates (CFR) as 
outcomes in HIV-infected and HIV-exposed children. 
Primary outcomes 
Prevalence was defined as proportions of all individuals suspected of having specific vaccine-
preventable diseases with confirmed laboratory diagnosis or proportions of individuals fulfilling 
clinical case definition for specific vaccine-preventable diseases. Incidence was defined as the 
number of new cases of different vaccine-preventable diseases that occur during a given period in 
the defined population. 
We also determined the trend in the incidence and/or prevalence of vaccine-preventable diseases 
among HIV-infected and HIV-exposed children in sub-Saharan Africa from 1980 to 2018. 
Secondary outcomes 
We included CFRs associated with vaccine-preventable diseases. Case fatality was described as 
mortality among confirmed or probable cases for a specific vaccine-preventable disease. 
Type of studies: The review included cohort studies, case-control studies, cross-sectional studies 
and other observational studies. We planned to include studies that involved any of the following 
vaccine-preventable diseases: 
i. Tuberculosis (TB) 
ii. Poliomyelitis 
iii. Hepatitis B virus infection (HBV) 
iv. Rotavirus gastroenteritis 
v. Diphtheria 
vi. Tetanus 
vii. Pertussis 
viii. Pneumococcal diseases 
ix. Measles  
x. Rubella 
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xi. Yellow fever 
 
Exclusion criteria 
 Intervention studies 
 Unclear diagnostic criteria 
 
Search strategy methods for the identification of studies 
A comprehensive search strategy was developed to identify relevant studies up to August 2018, 
regardless of publication status or language. Scopus, Web of Science, MEDLINE via PubMed and 
CINAHL were searched for relevant publications. The search process was complemented by 
reviewing citations of all identified eligible studies. We also searched relevant World Health 
Organization position papers and documents on vaccines. (See Appendix for PubMed search 
strategy).  
Selection of eligible studies 
Two of the authors, (OOA and AA) screened the search results using the abstract titles. They also 
independently went through the full text of potential studies to assess whether they met the required 
inclusion criteria. Non-human studies, reviews, intervention studies, letters, commentaries and 
editorials were excluded. Studies not written in English, French, German, Spanish, Portuguese or 
Dutch were excluded. We resolved disagreements by consensus.  
Data collection process 
The two authors then extracted data from text, tables and figures. The data were recorded on a 
standardised form. We planned to contact authors of included studies in case of unclear or missing 
data.                                  
The following data were extracted from selected studies: 
 Study characteristics including period and design. 
 Vaccine-preventable diseases patient characteristics such as age and HIV status.  
 Prevalence or incidence of vaccine-preventable diseases: confirmed cases and cases 
meeting the clinical definition. 
 Diagnostic methods: laboratory methods and clinical case definitions. 
 Death attributed to vaccine-preventable diseases. 
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Risk of bias in individual studies 
The risk of bias and quality of the included studies were assessed with the Newcastle-Ottawa 
Quality Scale.16 The criteria assessed included the following (1) selection of participants, (2) 
comparability, (3) exposure, and (4) outcome.  
 
Data synthesis 
OOA summarised the incidence and prevalence of various vaccine-preventable diseases. Where 
possible, incidence and prevalence data from each of the included studies were combined by 
random effects meta-analysis in accordance with the Mantel-Haenszel method. 
Heterogeneity was evaluated using the Chi-squared test of homogeneity (significant for P < 0.1) 
and quantified using the I-squared statistic (>50% substantial heterogeneity).17 Subgroup analyses 
were conducted in cases with substantial heterogeneity. Subgroup analysis was conducted using 
the following variables: period of study (1991- 2000, 2001-2010 and 2011 – 2018). We also used 
funnel plot regression to assess publication bias. STATA software version 14.0 (STATA 
Corporation, College Station, TX, USA) was used to do all calculations, the meta-analysis and 
generate forest plots.18 
Additional analyses: Trend analysis 
We examined time trends in the incidence and prevalence of vaccine-preventable diseases 
estimates using Poisson regression models with the prevalence estimates as the outcome variable 
and the calendar year of the publication as the predictor. This method allows for estimation of time 
trends across individual calendar years to obtain average annual percentage change (AAPC), 
assuming that the rate of change is at a constant rate of the previous year. 19 The Poisson regression 
procedure fits a model of the following form: 
                             
  0 1log log( )yprevalence b b y sample size                                (1) 
where ‘cases’ equal prevalence estimates reported per year, log is the natural log, b0 is the 
intercept, b1 is the trend, y is the year – given as 0, 1, 2, … 18 (year 0 is 1970, year 1 is 1971, and 
so on to 2014), and log of ‘sample size’ was entered as the offset. The AAPC was calculated using 
the following formula: 
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 1 1 100bAAPC e  
                                                (2) 
Results 
 
Literature search and result 
Figure 1 shows the study selection process reported in line with PRISMA guidelines. We identified 
3430 publications through the search of different databases. We also identified 13 additional 
articles through the screening of reference lists of various related articles. We screened 188 full-
text articles and selected 76 articles for inclusion in the review and 70 articles were suitable for 
the meta-analysis (Figure 1). 
Study characteristics 
Table 1 provides a summary of the included studies and the vaccine-preventable diseases of 
interest.  The table shows that 45 articles reported on tuberculosis, 14 on hepatitis B virus infection, 
ten studies focused on pneumococcal infections, two on rotavirus gastroenteritis, three on measles 
and three on pertussis. The included articles consist of 41 cross-sectional studies, 31 cohort studies, 
four case-control studies and one time-series analysis.  
South Africa had the highest number of published articles with 35 articles, Nigeria produced 10 
articles, four were from Kenya, four from Ethiopia and two studies were conducted in multiple 
countries. The other studies were conducted in Rwanda, Tanzania, Cote d' Ivoire, Uganda, Malawi, 
Botswana, Zimbabwe, Zambia, Mozambique and Swaziland (Table 1). A total of 46,882 children 
were included in this review.  HIV-infected children were included in 71 studies while two studies 
had both HIV-infected and HIV-exposed uninfected children, and one study with only HIV-
exposed children. The included studies were conducted between 1992 and 2016. 
Using the Newcastle-Ottawa Quality Scale for the quality assessment of the eligible studies, 11 
articles scored eight points; 15 articles scored seven points; 27 articles scored six points; 15 articles 
scored five points; seven articles scored four points and two articles scored three points. The 
characteristics of the eligible studies are summarised in Table 1. 
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Figure 1: Flow diagram of the selection process 
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Table 1: Characteristics of the study population 
First author and year Study period Study design Country Sample size  VPD Outcomes HIV 
status 
Quality 
scores 
Abuogi 201320 2009 - 2010 Cohort Kenya 689 Tuberculosis C, I, P HI 7 
Adams 201421 2006 - 2012 Cross-sectional Tanzania 1193 Tuberculosis C, P HI 4 
Alemu 201622 2009 - 2014 Cohort Ethiopia 645 Tuberculosis I HI 6 
Anigilaje 201623 2010 - 2013 Cohort  Nigeria 368 Tuberculosis P HI 8 
Auld 201424 2004 - 2008 Cohort  Cote d' Ivoire 2110 Tuberculosis I, P HI 8 
Bakeera 201125 2003 - 2006 Cohort  Uganda 1806 Tuberculosis I, C HI 8 
Bonnet 201826 2012 - 2014 Cohort Uganda 113 Tuberculosis C HI 7 
Braitstein 200927 2001 - 2007 Cohort Kenya 6,535 Tuberculosis I, P HI 8 
Buck 201328 2010 Cohort Malawi 4874 Tuberculosis C, P HI 8 
Carlucci 201729 2012 - 2014 Cohort  Multiple  386 Tuberculosis C HI 8 
Cavanaugh 201230 2006 - 2007 Cross-sectional Kenya 323 Tuberculosis C HI 6 
Chaya 201631 2006 - 2011 Cross-sectional South Africa 47 Tuberculosis I  HI 6 
Cruz 201532 NR Cohort Botswana 100 Tuberculosis P HI 6 
Dangor 201333 2005 - 2009 Time-series analysis South Africa 1985 Tuberculosis I HI 7 
De Maayar 201134 NR Cross-sectional South Africa 58 Tuberculosis P HI 7 
Ebonyi 201635 2005 - 2013 Cohort  Nigeria 260 Tuberculosis C HI 8 
Ebonyi 2016b36 2005-2012 Cohort  Nigeria 876 Tuberculosis P HI 8 
Elenga 200537 2000-2003 Cohort Cote d' Ivoire 282 Tuberculosis I HI 8 
Ferrand 201038 2007-2008 Cross-sectional Zimbabwe 139 Tuberculosis P HI 7 
Hall 201739 2005-2008 Cohort South Africa 224 Tuberculosis C HI 8 
Hesseling 2009a40 2004-2006 Cross-sectional  South Africa 3321 Tuberculosis C HI 6 
Hesseling 200541 1992-2000 Cohort South Africa 93 Tuberculosis C HI 8 
Hesseling 200642 2002-2005 Cohort South Africa 108 Tuberculosis C, P HI 7 
Hesseling 2009b43 2004-2006 Cross-sectional South Africa 3321 Tuberculosis I, P HI 7 
Hicks 201444 2009-2010 Cohort  South Africa 64 Tuberculosis C HI 6 
Jeena 200045 1995-1998 Cross-sectional  South Africa 27 Tuberculosis P HI 5 
Kasambira 201146 2006-2009 Cross-sectional  South Africa 270 Tuberculosis P HI 6 
Madhi 2000b47 1996-1997 Cross-sectional South Africa 67 Tuberculosis C HI 5 
Meyers 200048 1996 Cross-sectional South Africa 144 Tuberculosis P HI 5 
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Mwangwa 201749 2012-2013 Cohort Multiple  17 Tuberculosis C HI 7 
Obiagwu 201350 2010 Cross-sectional Nigeria 22 
Tuberculosis, 
Measles P HI 
6 
Okechukwu 201151 2007-2008 Cross-sectional Nigeria 210 Tuberculosis C, P HI 6 
Osman 201752 2005-2012 Cohort South Africa 3143 Tuberculosis C HI 6 
Padayatchi 200653 1993-2002 Cross-sectional South Africa 6 Tuberculosis C HI 5 
Palme 200254 1995-1997 Cohort Ethiopia 58 Tuberculosis C HI 6 
Patel 201355 2007-2009 Cohort Congo DRC 31 Tuberculosis C HI 7 
Robinson 200756 1999-2001 Case-control South Africa 47 Tuberculosis P HI 6 
Rose 201257 2008-2010 Cohort Tanzania 54 Tuberculosis P HI 6 
Schaaf 200758 2003-2005 Cross-sectional South Africa 133 Tuberculosis C HI 5 
Soeters 200559 2000-2001 Cross-sectional South Africa 43 Tuberculosis C HI 4 
Walters 201460 2003-2010 Cohort South Africa 494 Tuberculosis C HI 6 
Walters 200861 2003-2005 Cross-sectional South Africa 137 Tuberculosis C HI 6 
Westerlund 201462 2003-2008 Cohort Ethiopia 138 Tuberculosis P HI 7 
Wiseman 201163 2004-2006 Cross-sectional South Africa 52 Tuberculosis C HI 5 
Yotebieng 201064 2004-2008 Cohort South Africa 573 Tuberculosis C HI 6 
Kouakoussui 200465 2003 Cohort Cote d’Ivoire 270 Tuberculosis I HI 7 
Abera 201466 2014 Cross-sectional Ethiopia 253 HBV infection P HI 6 
Ashir 200967 2007 Case-control Nigeria 284 HBV infection P HI 5 
Beghin 201768 2014 Cross-sectional South Africa 183 HBV infection P HI 6 
Chotun 201569 2011 - 2012 Cross-sectional  South Africa 1000 HBV infection P HE 6 
Uleanya 201670 NR Cross-sectional Nigeria 140 HBV infection P HI 4 
Dziuban 201371 2009 - 2011 Cross-sectional Swaziland 500 HBV infection P HI 3 
Ikpeme 201372 2010-2011 Cross-sectional Nigeria 166 HBV infection P HI 4 
Jooste 201673 2015-2016 Cohort South Africa 625 HBV infection P HI 7 
Muro 201374 2006-2008 Cross-sectional Tanzania 157 HBV infection P HI 5 
Mutwa 201375 2010 Cohort Rwanda 88 HBV infection P HI 7 
Nwolisa 201376 2010 Cross-sectional Nigeria 139 HBV infection P HI 4 
Sadoh 201177 NR Cross-sectional Nigeria 155 HBV infection P HI 5 
Telatela 200778 2006 Cross-sectional Tanzania 167 HBV infection P HI 4 
Varo 201679 2008-2010 Cross-sectional Malawi 91 HBV infection P HI 3 
Moss 200280 1998-2000 Cross-sectional Zambia 93 Measles P HI 6 
Wirth 201581 2009-2010 Case-control Botswana 189 Measles C HI 5 
du Plessis 201814 2013 - 2015 Cross-sectional South Africa 300 Pertussis  P HI 6 
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Gill 201682 2015 Cohort Zambia 347 Pertussis I HI 7 
Soofie 201683 2015 Cross-sectional South Africa 599 Pertussis C, I, P HE 5 
Johnson 200084 1996-1997 Cross-sectional South Africa 31 
Rotavirus 
gastroenteritis P HI 
6 
Moyo 201485 2010-2011 Case-control Tanzania 26 
Rotavirus 
gastroenteritis P HI 
5 
Asbjörnsdóttir 201386 
1999-2002 Cohort Kenya 
388 
Pneumococcal 
infection C,I HI 
6 
Nathoo 199687 1993-1994 Cohort Zimbabwe 168 
Pneumococcal 
infection P HI 
7 
Zar 200188 1998 Cross-sectional South Africa 151 
Pneumococcal 
infection P HI 
6 
Jones 199889 1996 Cross-sectional South Africa 25 
Pneumococcal 
infection C HI 
5 
Roca 201090 2004-2006 Cross-sectional Mozambique 54 
Pneumococcal 
infection C HI 
6 
Cohen 201691 2009 - 2013 Cross-sectional South Africa 211 
Pneumococcal 
infection I HEU,HI 
4 
Nunes 201192 2003-2008 Cross-sectional South Africa 938 
Pneumococcal 
infection I HI 
6 
von Mollendorf 2017a93 2009–2013 Cross-sectional South Africa 495 
Pneumococcal 
infection C, I HI 
5 
von Gottberg 201394 2003-2008 Cross-sectional  South Africa 1749 
Pneumococcal 
infection I HI 
5 
Nyasulu 201195 2003-2005 Cross-sectional South Africa 1124 
Pneumococcal 
infection C HI 
6 
  
NR- Not recorded; C- Case-fatality rate; I – Incidence; P – Prevalence; Hib- Haemophilus influenzae type b; HI- HIV-infected; HE- HIV-exposed; HEU – HIV-exposed uninfected; VPD - vaccine–
preventable diseases. 
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Incidence rates  
Tuberculosis: Nine studies20,22-25,27,37,40 on TB were pooled to give an overall incidence rate 
estimate of 60 (95% CI 30 – 70) per 1,000 child-years at risk for tuberculosis based on a random-
effects model (I2 = 99%; Figure 2). Subgroup analysis established change over time in incidence 
rates when comparing studies conducted before and after 2011. The pooled incidence rates for 
tuberculosis in those conducted before 2010 was 70 (95% CI -20 - 160) per 1,000 child-years37,40 
and 40 (95% CI 20 - 50) per 1,000 child-years in studies conducted between 2011 and 2018.20,22-
25,27 The heterogeneity of the TB incidence could not be explained by the subgroup analysis. 
Kouakoussui et al. reported TB incidence of 0.71 per 100 child/months before initiation of highly 
active antiretroviral therapy (HAART) and 0.16 per 100 child/months during HAART treatment 
among Ivorian HIV-infected children.65 
Pneumococcal infections: Incidence of invasive pneumococcal disease among HIV-infected 
children aged <1 and 1–4 years was 1022 (95% CI 923–1123) per 100,000 and 198 (95% CI 178–
220) per 100,000 respectively in 2008.94 The incidence of pneumococcus-associated lower 
respiratory tract infection among HIV-exposed uninfected children was 109 (95% CI 47–214) per 
100,000 and 629 (95% CI 130–1838) per 100,000 among HIV-infected children.91 Ásbjörnsdóttir 
et al. reported the incidence of pneumonia among Kenyan HIV-exposed uninfected infants to be 
900 (95% CI 800–1000) per 1,000 child-years.86 Nunes et al. reported the incidence of invasive 
pneumococcal disease to be 1509 (95% CI 1350 – 1680) per 100,000 during early (HAART) and  
742 (95% CI 644 – 851) during established-HAART eras for less than 18-year old South 
Africans.92  
Pertussis: The incidence of pertussis among Zambian HIV-exposed infants was reported to be 3.7 
(95% CI 0.9–10.1) per 1000 person-months 82 while Soofie et al. reported the incidence to be 2.9 
(95% CI 1.8 – 4.5) per 1,000 child-years. 83 
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Figure 2: Forest plot of studies with data on incidence rates of tuberculosis in HIV-exposed children  
 
Prevalence  
Twenty-one TB prevalence studies were pooled together and reported estimated prevalence of 
16% (95% CI 12 - 19, I2 = 99%). For studies conducted within the period 1991-2000, the 
prevalence was 13% (95% CI 8 - 18)45,48; lower in 2001-2010 with an estimate of 8% (95% CI 5 - 
11, I2 = 96%)27,38,42,43,56 and recorded the highest prevalence in recent years with 15% (95% CI 8 
- 22, I2 = 99)20,21,23,24,26,28,32,34,36,46,50,51,57,62 (Figure 3). Fourteen prevalence studies on hepatitis B 
(HBV) infection in HIV-infected children were pooled together with an estimate prevalence of 5% 
(95% CI 4 - 7, I2 = 90%). Studies conducted between 2001 and 2010 had a prevalence of 3% (95% 
CI 2 - 5) 67,68 and 4% (95% CI 3 – 6) between 2011 and 2018 66,68,69,70-77,79  (Figure 4). 
The pooled prevalence for pneumococcal infections was 2% (95% CI 1 – 4). There has been a 
reduction in prevalence from 9% (95% CI 5 - 14)88 in 1996 to 1% (95% CI 0 – 5)89 in 2001. Pooled 
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prevalence for pertussis was 3% (95% CI 2 - 4)14,83 while measles was 6% (95% CI 2 – 10).80,81 
Two rotavirus diarrhoea prevalence studies were pooled together and reported an estimated 
prevalence of 13% (95% CI 8 - 17, I2 = 0%).84,85  
 
 
Figure 3: Forest plot of studies with data on the prevalence of tuberculosis in HIV-infected children 
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Figure 4: Forest plot of studies with data on the prevalence of hepatitis B virus infection in HIV-infected and 
HIV-exposed children 
 
Trend in incidence and prevalence  
We analysed the trend in TB incidence with respect to publication years. The trend was non-linear 
with a downtrend from 2000 to 2010 (at -12.5% per year) and a reduced downward trend from 
2011 to 2018 (at -1.5 per year) as shown in Figure 5. The trend in HBV prevalence was also 
analysed. The trend was not linear, There was evidence of a downtrend from 2000 to 2010 (at -
4.7% per year) and (at -5.3% per year) from 2011 to 2018 as shown in Figure 6. The TB prevalence 
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trend was also non-linear. There was evidence of initial downtrend from 2000 to 2010 (at -3.2% 
per year) and upward trend from 2011 to 2018 (at +32.7 per year). 
 
Figure 5: Trends in the incidence of tuberculosis in HIV-infected and exposed children with respect to 
publication years 
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Figure 6: Trends in the prevalence of hepatitis B virus infection in HIV-infected and exposed children with 
respect to publication years 
 
Case-fatality rates 
Twenty-nine studies on TB were pooled to give an overall CFR estimate of 17% (95% CI: 13 - 20, 
I2 = 95%) which translates to 17% of all TB cases dying from the disease. Subgroup analysis shows 
the CFR was 18% (95% CI 6 – 24)47 in the 1991-2000 period, 6% (17 – 38, I2 = 95%)38,40-
42,53,54,58,59,61,64 in 2001-2010 and 13%  (95% CI 9 – 17, I2 = 96%)20,21,23,25,28-30,35,39,44,49,51,52,55,60,61 
in 2011 – 2018. Four studies were pooled for pneumococcal infections CFRs in HIV-infected and 
exposed children with a resultant rate of 15% (95% CI 4 – 26, I2 = 95%).86,89,90,95  One study shows 
that pertussis has CFRs of 13% (95% CI 2 – 38) 83 and for measles the CFR was 1% (95% CI 0 - 
4).81  
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Publication bias assessment 
Funnel-plot analyses of studies reporting on the prevalence of TB revealed nil significant 
publication bias, with the P value for the Begg’s test being 0.185 while the studies assessing the 
prevalence of HBV infection showed significant Begg’s test with P value of 0.001 (Figure 7 and 
8). Likewise, studies assessing the CFR of TB demonstrated no significant publication bias Begg’s 
test P = 0.385 (Figure 9).  
 
 
Figure 7: Funnel plot of studies reporting on the prevalence of tuberculosis in HIV-infected children  
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Figure 8: Funnel plot of studies reporting on the prevalence of hepatitis B virus infection in HIV-infected 
children 
 
 
Figure 9: Funnel plot of studies reporting on the case-fatality rate of tuberculosis in HIV-infected children 
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Discussion 
This study provides a comprehensive overview of the incidence rate, prevalence and case fatality 
rates of different vaccine-preventable diseases in HIV-infected and HIV-exposed children in sub-
Saharan African countries. The review shows that TB is the most researched vaccine-preventable 
disease in HIV-infected children in various African countries and settings. This is not surprising 
because of the relationship between TB and HIV infection with respect to the high susceptibility 
of TB in HIV-infected individuals,96,97 Other vaccine-preventable diseases like HBV infection, 
pneumococcal infection, measles, rotavirus gastroenteritis, pertussis and Hib infections were also 
studied in several African countries. Important vaccine-preventable diseases such as poliomyelitis, 
diphtheria, tetanus and yellow fever had no eligible studies for inclusion revealing the dearth of 
incidence and prevalence studies on these diseases. The pooled incidence, prevalence and CFRs 
reveal there are still high burdens of several vaccine-preventable diseases in sub-Saharan Africa. 
 
According to WHO, the global incidence of TB has been reducing at an average of 2 percent per 
year.96 TB incidence has declined in the African region by 4 percent annually since 2013.96 
Southern African countries with the highest prevalence and incidence of HIV such as South Africa, 
Lesotho, Zimbabwe, Eswatini, Namibia and Zambia had remarkable reductions in TB incidence.96 
Our study shows that TB incidence reduced over time, however, the event per child-year is still 
high when compared with the End TB strategy goals.98 The World Health Assembly adopted the 
resolution known as “End TB strategy goals” which is about the global strategy and targets for 
tuberculosis prevention, care and control after 2015 98. In spite of the reduction in TB incidence 
among children, there are still cases of high incidence in certain countries bearing in mind that 
many countries in African countries are classified as high-burden.96 A retrospective cohort study 
in a very high TB/HIV prevalent region in Nigeria showed a high incidence rate of 21.2/100 per 
year among children within six months of ART enrollment at a period when others were recording 
much lower incidence.17 TB prevalence has fluctuated over time with about 15% of HIV-infected 
children having the disease at a given point in time.  As of 2017, it was estimated that the global 
CFR was 16% with many African countries recording more than 20%.96 This rate is also far higher 
than the End TB Strategy milestone of 10% by 2020. 
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The pooled HBV infection prevalence among HIV-infected children was 5%, however, a study 
done in Rwanda in 2010 revealed a seroprevalence of 16%.73 Ott et al. showed that Sub-Saharan 
Africa had the highest HBV burden with West African countries having up to 12% hepatitis B 
surface antigen prevalence among children and adolescents in the 1990s.99 There has been a 
reduction within the region largely due to immunisation programmes, however, there is high 
endemicity in some areas. A systematic review of HBV prevalence in Nigeria from studies 
conducted from 2000 to 2013 shows that HBV infection ranged from 0.5% to 46.8% with the 
pooled prevalence estimate for Nigeria being 13.6%.100  
 
Our finding shows that the seroprevalence of rotavirus gastroenteritis among African HIV-infected 
children was 14% although with a small number of included studies. The incidence and CFR of 
diarrhoea and pneumonia are much higher in low-income than in high-income countries and this 
is reflected in many African and southeast Asian countries having the highest burden of the 
diseases.101 The African region has the highest incidence and total death secondary to diarrhoea 
and pneumonia with rotavirus and Streptococcus pneumoniae being the commonest culprits.101 
Studies have shown that there is still a persistent high incidence of some vaccine-preventable 
diseases in HIV-infected individuals than non-exposed ones even after the introduction of highly 
active antiretroviral therapy.102 The incidence of pertussis is also higher in HIV-exposed and 
infected children, however, this decreases as the number of vaccine doses uptake increases.103 
 
Many African countries with high burdens of HIV are critically lagging in terms of antiretroviral 
treatment coverage for HIV-infected children.104 Sub-optimal ART coverage in children will lead 
to viral load increase, immunosuppression, etc. and a subsequent high burden of various vaccine-
preventable diseases. Vaccination coverage in many African countries is still below the expected 
target.105 Low uptake of vaccines by African children exposes them to more diseases than children 
in other regions. 
 
This review revealed research inequalities across the African region regarding the burden of 
vaccine-preventable diseases studies among HIV-infected and HIV-exposed children. South 
Africa contributed about half of the included articles with Nigeria and Kenya following with fewer 
studies. This finding is not different from an earlier study looking at the distribution of 
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epidemiological studies across Africa.106 Some of the Eastern and Southern African countries with 
high HIV prevalence had at least an article included in this study, however, West African countries 
only had publications from Nigeria and Cote d’Ivoire. 
 
Recommendations 
This review has shown that TB is one of the most important vaccine-preventable diseases in Africa 
with the BCG vaccine conferring protection against severe forms of the disease. However, the 
same vaccine is contraindicated in immunocompromised children who ironically are susceptible 
to the disease.13 The dilemma of BCG use in HIV-exposed children warrants the call for newer 
and safer vaccines against TB especially in HIV-infected children. African governments and other 
supporting agencies should ensure that every child has access to routine childhood vaccines. Issues 
of under-vaccination and vaccine hesitancy should be adequately tackled to ensure better vaccine 
uptake and reduction in the burden of vaccine-preventable diseases.  
 
The research capacity of African clinicians, researchers and health administrators should be built 
up for them to conduct basic epidemiological research such as incidence, prevalence, mortality 
and CFR among HIV-exposed children in various health facilities and communities. Researchers 
should be encouraged to disseminate their findings to their immediate communities and 
Departments of Health and to publish their findings in peer-reviewed journals. Established 
research groups such as Global Burden of Diseases Network should include the burden of vaccine-
preventable diseases in HIV-exposed and non-exposed children as part of their regular or annual 
publications. Other African countries should emulate South Africa in increasing their research 
activities and outputs with respect to HIV-exposed children. 
 
There is a need to advocate for an equitable share of healthcare budgeting and finance at every 
level of governance in African countries. This will help in ensuring that there is a fair share of 
resources for preventive and treatment services such as vaccination and antiretroviral therapy for 
HIV-exposed children. African countries should, as a matter of urgency, complete the introduction 
of newer and important vaccines such as rotavirus vaccine, Hib vaccine and pneumococcal 
vaccine. These should be included as part of their current national immunisation programme 
schedule100 According to WHO, the global coverage for both pneumococcal vaccine and rotavirus 
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vaccines were as little as 44 percent and 25 percent respectively.105 African countries should be 
supported in developing vaccine procurement budgets, procurement practices, and capacity 
development for vaccine planning and advocacy.107 
 
Study limitations 
This study was limited by several factors beyond the reviewers’ control. We planned to review all 
the vaccine-preventable diseases associated with vaccines included in the national immunisation 
programme schedule in sub-Saharan Africa, however, we could not find articles that met the 
eligibility criteria for some of the diseases. Secondly, there was high heterogeneity even with sub-
group analysis between included studies, which implies the possibility of other contributory factors 
associated with the diseases. Some of the studies did not include relevant information such as 
antiretroviral coverage, CD4 count, viral load, vaccination status and other contributory factors. 
Thirdly, we could not include many studies because the diagnostic criteria for different vaccine-
preventable diseases were not specified and clearly defined.  
 
Conclusions 
This systematic review and meta-analysis provide an all-inclusive analysis of the incidence rates, 
prevalence and CFR of various vaccine-preventable diseases. This study shows that some vaccine-
preventable diseases still have high incidence, prevalence and CFRs in HIV-infected and HIV-
exposed children. There was also the dearth of research activities on vaccine-preventable disease 
studies with respect to HIV-infected and HIV-exposed uninfected children in many African 
countries. The findings are useful in advocating for a more equitable share of healthcare financing 
especially for preventive services such as vaccination of both HIV-exposed and non-exposed 
children in order to reduce the burden of vaccine-preventable diseases.  
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Appendix 
 
Search strategy - PubMed 
 
 
 
Search 
Add to 
builder 
Query 
Items 
found 
#6  Add  Search ((((#1) AND #2) AND #3) AND #4) AND #5 Sort by: Best Match 1364  
#4  Add  Search (newborn* OR bab* OR infan* OR child* OR adolescen* OR teen*) Sort 
by: Best Match 
3843580  
#2  Add  Search (tuberculosis OR TB OR poliomyelitis OR polio OR rotavirus OR diphtheria 
OR tetanus OR pertussis OR pneumococcal OR pneumonia OR measles OR 
"yellow fever" OR "Hepatitis B" OR "Haemophilus influenza" OR "Hemophilus 
influenza" OR influenza) Sort by: Best Match 
707401  
#5  Add  Search (incidence OR prevalence OR mortality) Sort by: Best Match 3171459  
#3  Add  Search ("HIV infected" OR "HIV exposed" OR "HIV-infected" OR "HIV-exposed" OR 
"HIV positive" OR "HIV exposed uninfected") Sort by: Best Match 
74539  
#1  Add  Search (Angola OR Benin OR Botswana OR "Burkina Faso" OR Burundi OR 
Cameroon OR "Cape Verde" OR "Central African Republic" OR Chad OR Congo OR 
"Democratic Republic of Congo" OR DRC OR Djibouti OR "Equatorial Guinea" OR 
Eritrea OR Ethiopia OR Gabon OR Gambia OR Ghana OR "Guinea Bissau" OR 
Guinea OR "Ivory Coast" OR "Cote d’Ivoire" OR Kenya OR Lesotho OR Liberia OR 
Madagascar OR Malawi OR Mali OR Mauritania OR Mauritius OR Mozambique OR 
Namibia OR Niger OR Nigeria OR "Republic of the Congo" OR Reunion OR Rwanda 
OR Senegal OR Seychelles OR "Sierra Leone" OR "Sao Tome and Principe" OR 
Somalia OR "South Africa" OR "South Sudan" OR Sudan OR Swaziland OR 
Tanzania OR Togo OR Tunisia OR Uganda OR Zambia OR Zimbabwe OR Africa OR 
"sub Saharan Africa") Sort by: Best Match 
558013  
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CHAPTER 3: Vaccination among HIV–infected, HIV-exposed 
uninfected and HIV-uninfected children: A systematic 
review and meta-analysis of evidence related to vaccine 
efficacy and effectiveness 
 
Olatunji O. Adetokunboh, Duduzile Ndwandwe, Ajibola Awotiwon, Olalekan A. Uthman and 
Charles S. Wiysonge 
 
 
Abstract 
Evidence-based approaches were used in making recommendations for vaccination against 
vaccine-preventable diseases for immunocompromised individuals but with limited substantiation. 
It is therefore paramount to investigate the efficacy and effectiveness of vaccines in HIV-infected 
and HIV-exposed children in comparison to HIV unexposed children. Web of Science, Cochrane 
Library, MEDLINE via PubMed and Scopus databases were searched for articles. We conducted 
a systematic review and meta-analysis with randomised-controlled trials (RCTs), cohort and case-
control studies that have efficacy and effectiveness of vaccines in HIV-infected and HIV-exposed 
children as outcomes. Vaccine efficacy of 9-valent pneumococcal conjugate vaccine (PCV9) in 
preventing first episodes of invasive pneumococcal disease was 53% among HIV-infected children 
and 42% among HIV-uninfected children. Efficacy of PCV9 against total vaccine serotype 
invasive pneumococcal disease was 32% in HIV-infected children and 78% among HIV-
uninfected children. Vaccine effectiveness of Bacillus Calmette–Guérin vaccine in preventing 
tuberculosis in HIV-infected children was zero compared to 59% protection in HIV-unexposed 
children. Likewise, HIV-uninfected children have better protection against invasive Haemophilis 
influenzae type b (Hib) disease than the HIV-infected children. Effectiveness studies of rotavirus 
vaccines show that HIV-exposed uninfected children have similar protection against rotavirus 
gastroenteritis compared to the non-exposed children. Children who are severely 
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immunosuppressed are poorly protected against invasive pneumococcal diseases. HIV-infected 
children tend to have lesser vaccine protection against vaccine-preventable diseases when 
compared to unexposed children. HIV-infected children who are immunocompetent are more 
likely to have better vaccine protection against vaccine-preventable diseases than those who are 
immunosuppressed. The overall quality of the observational studies was very low with very little 
confidence in the effect estimate. The overall quality of evidence for the RCT outcomes was 
mainly high. This study reveals a dearth of efficacy and effectiveness studies among HIV-infected 
and exposed children. 
Keywords: HIV; vaccine-preventable diseases; sub-Saharan Africa; efficacy; effectiveness 
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Background 
Immunisation is an essential aspect of preventive medicine and critical in reducing morbidity and 
mortality attributed to vaccine-preventable diseases in children, adolescents and adults.1 The use 
of vaccines against various vaccine-preventable diseases is beneficial and an effective measure for 
protecting different age groups.2,3 The vaccination rates of children remain insufficient for vaccine-
preventable diseases in many developing countries with only 86% of infants vaccinated with three 
doses of diphtheria-tetanus-pertussis containing vaccine in 2016.4 Low vaccination uptake rate 
results in an increase in unvaccinated and under-vaccinated HIV-infected and HIV-exposed 
children who are more likely to die from preventable diseases than their immunocompetent age 
mates.5,6 Several care and treatment guidelines have identified vaccination as a crucial preventive 
strategy for people living with HIV7,8 but information on the use of certain vaccines in this 
population are still scanty.9  
Experts using evidenced-based approaches on the vaccination of immunocompromised individuals 
made specific recommendations for vaccination against major vaccine-preventable diseases for 
these patients but with limited proof.8 Research gaps were also identified by this group for future 
investigation. One of these gaps was that of understanding the mediators of vaccine protection, 
adverse effects and basic aspects of the epidemiology of various vaccine-preventable diseases.8  
Vaccines stimulate immunity that protects against specific disease-causing organisms. However, 
the effectiveness of different recommended vaccines in HIV-infected children may be reduced as 
a result of the decline in vaccine-induced antibodies.10 The changing pattern of some vaccine-
preventable diseases is poorly understood, and this changing pattern and epidemiology makes it 
important to better understand these diseases because of apparent resurgence and epidemics in 
future.11 The suboptimal uptake of vaccines in sub-Saharan Africa coupled with the high HIV 
burden are risk factors that may facilitate future epidemics.11,12  
Previous reviews on the efficacy and effectiveness of vaccines in HIV-infected and exposed 
children were not specific on the vaccine efficacy/effectiveness against disease outcomes and were 
not conducted as systematic reviews13,14. It is paramount to evaluate the available evidence by 
identifying high-quality literature and investigating the reliability of key findings as they relate to 
the pre-licensure efficacy and post-licensure effectiveness of vaccines in HIV-infected and HIV-
exposed children compared to HIV unexposed children. The findings will provide the needed 
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evidence to guide healthcare policymakers, guideline developers, vaccinologists and healthcare 
workers in developing improved long-term vaccination strategies for HIV-infected children. 
Current and reliable evidence-based data on the efficacy and effectiveness of vaccines in HIV-
infected and HIV-exposed children are also vital to inform a better understanding of the prevention 
and management of vaccine-preventable diseases in these children.  
This systematic review and meta-analysis summarised available data from studies which have 
efficacy or effectiveness of vaccines in HIV-infected and HIV-exposed children as outcomes. 
Methods 
Search strategy and selection criteria 
This review followed the Preferred Reporting Items for Systematic Review and Meta-Analysis 
Protocols (PRISMA) guideline.15 The review was registered with PROSPERO (International 
prospective register of systematic reviews) (CRD42018095334).  
 
Eligibility criteria 
 
Inclusion criteria 
 
We included randomised-controlled trials (RCTs), cohort and case-control studies that included 
efficacy or effectiveness of vaccines in HIV-infected in comparison with HIV-exposed or HIV-
uninfected children aged ≤ 18 years. The intervention group included those with standard vaccines 
or dosages while the comparison groups comprised of placebo, non-vaccinated groups, groups that 
were vaccinated with other control vaccines or other dosages among HIV-infected and HIV-
exposed children. For case-control studies, cases were HIV-infected while controls were HIV-
exposed uninfected and HIV-uninfected children.   
The review planned to include the following licensed vaccines: Bacillus Calmette–Guérin (BCG), 
hepatitis B vaccine (HBV), oral polio vaccine, inactivated polio vaccine, diphtheria-tetanus-
pertussis containing vaccines, Haemophilus Influenzae type B vaccine (Hib), pneumococcal 
conjugate vaccine (PCV), rotavirus vaccine (RV), yellow fever vaccine and measles-containing 
vaccines. These vaccines were chosen because they are the frequently used childhood vaccines in 
countries most affected by the HIV epidemic. 
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Exclusion criteria 
Studies having population aged ≥ 18 years old individuals were excluded.  We also excluded non-
human studies and reviews.  
 
Outcomes 
The following were the outcome measures of interest: 
1.  Clinical and/or confirmed cases of vaccine-preventable diseases of interest. 
2.          Pooled/reported vaccine efficacy. 
3.          Pooled/reported vaccine effectiveness. 
 
Data sources 
One of the authors, OOA, searched the Web of Science, Cochrane Library, MEDLINE via PubMed 
and Scopus databases. Reference lists from identified papers and ClinicalTrials.gov trials registry 
platform were also checked. Relevant World Health Organization (WHO) position papers and 
documents on vaccines were also scrutinised. There was no language or date restriction. 
Selection of studies 
 Two authors, OOA and DN, independently screened the search results using the abstract titles. 
They also independently went through the full text of potential studies to determine if the studies 
meet the inclusion criteria. Discrepancies in the selection process were resolved by consensus. 
Data extraction 
The two reviewers extracted data from selected articles using a pre-specified form. The extracts 
included information such as author, journal, year of publication, study design, country of study, 
participants' characteristics, intervention, comparator, type of vaccine and outcomes. Efficacy and 
effectiveness data were separately extracted for each vaccine group, target group (i.e. HIV-infected 
versus HIV-exposed / HIV-uninfected) and study type (interventional versus observational). 
Quality assessment 
The review quality assessment was guided by the use of Cochrane Collaboration’s tool for 
assessing the risk of bias for included trials and the use of adapted Cochrane tool for observational 
studies.16,17  Two authors, OOA and DN, independently assessed the methodological quality of all 
included studies that met the eligibility criteria. The researchers compared notes for each item and 
resolved discrepancies through discussion. 
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Synthesis of data  
Synthesis of data was carried out using meta-analysis where applicable. Where meta-analysis was 
not possible, narrative synthesis was used. We reported the dichotomous outcomes as risk ratios 
or odds ratio with their corresponding 95% confidence intervals (CI) while continuous outcomes 
were reported as mean differences.18 We reported the vaccine effectiveness with the random-
effects odds ratio (OR) using the formula: (1 – OR) × 100 while vaccine efficacy was established 
with risk ratio (RR): (1 – RR) × 100. The efficacy and effectiveness of each vaccine in the 
intervention arm was compared with that of the control arm. We also planned to use funnel-plot 
regression to assess publication bias if we had up to ten studies per vaccine type. RevMan statistical 
software was used to do all calculations, the meta-analysis and to generate the forest plot.19   
Sensitivity analysis 
The certainty of the evidence regarding primary outcomes was determined by the use of the Grades 
of Recommendations, Assessment, Development and Evaluation (GRADE) approach.20 We 
planned to assess substantial heterogeneity if I2 exceeded 50% and the meta-analysis had up to five 
studies and to perform subgroup analyses using pre-specified potential sources of heterogeneity 
such as: type of comparison (i.e. placebo or no vaccine), blinding of patients (only for trials); 
blinding of outcome assessors; and overall methodological quality.  
 
Results 
 
Description of included studies 
The flow diagram in Figure 1 shows the studies identified and selected for this review. We 
identified 725 publications through databases and clinical trial registry search with 479 studies 
after removal of duplicates. A total of 14 publications were included in this review. These 
publications comprise five RCTs,21-25 six case-control studies,26-31 one cohort study32 and two 
cross-sectional studies33,34. Three of the included studies were publications from a particular South 
African trial that reported different vaccine efficacy outcomes.21,23,24 The included studies were 
published from 1993  to 2017.  All the included studies were conducted in sub-Saharan Africa with 
ten publications from South Africa, one each from Malawi, Angola and Zambia, and one 
multinational study conducted in Mali, Kenya and Ghana.  
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By outcomes, three studies reported rotavirus vaccine outcomes, six studies reported on 
pneumococcal vaccine, one study reported on Hib vaccine, two studies on BCG and two studies 
reported on HBV vaccines (Table 1). Two studies compared vaccine strains with placebo among 
HIV-infected children while three studies compared vaccine strains with placebo among HIV-
infected and HIV-unexposed children. Six studies compared HIV-infected children with HIV-
unexposed children, while two studies compared HIV-exposed and uninfected children with HIV-
unexposed children. In total, 66,220 children in comparative studies were involved in the included 
studies. The vaccine schedule and doses for the included studies were according to various national 
programme except for Madhi 200723 participants who were followed up for five years. 
Antiretroviral therapy (ART) usage varied between 22.5% and 67.0% among the HIV-infected 
children.  
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Figure 1: Flow diagram of the search and selection process for this review 
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Table 1: Characteristics of included studies 
Participants Intervention Control 
1st Author 
& Year 
 
Study 
period 
 
Study 
design 
Study 
country 
Sample size 
(n=) 
Participant 
age range 
HIV 
status  
% on 
ART 
CD4 
% or 
count 
Age 
(median or 
mean) 
Vaccine 
strain 
HIV 
status  
% 
on 
ART 
CD4 % 
or 
count 
Age 
(median 
or 
mean) 
Vaccine 
strain 
Beghin 
201733 
2014 Cross- 
sectional 
study 
South 
Africa 
291 5-15y HI NR NR 9.1y  HBV  HU - - 9.0y  HBV 
Cohen 
201727 
2012-
2014 
Case- 
Control 
South 
Africa 
1716 ≥6w HI 58% - 48-53w PCV13 HU - - 36-37w PCV13 
Bar-Zeev 
201631 
1997-
2007 
Case-
control 
Malawi 919 <5y HEU - - NA RV HU - - NA RV 
Van-Dunem 
201528 
 
2005-
2006 
 
Case-
control 
 
Angola 902 
 
18m - 13y 
 
HI 67% NR 4.83y  
 
BCG 
Connaught 
 
HI 61% NR 3.50y  
 
- 
Cohen 
201426 
2010-
2012 
Case- 
Control 
South 
Africa 
1395 ≥8w HI 46% NR 52-54w PCV7 HU - - 38-39w PCV7 
Groome 
201429 
2010-
2012 
Case-
control 
South 
Africa 
1195 18w-23m HEU - - 9m Monovalent 
human RV 
HU - - 10 m Monovalent 
human RV 
Feikin 
201222 
2007-
2009 
RCT Kenya, 
Ghana, 
Mali 
29 4-12w HI NR NR 17.1w PRV HI NR NR 17.0 Placebo 
Steele 
201125 
2005-
2008 
RCT South 
Africa 
100 6-10w (at 
dose 1) 
HI 62% 2074 7w RIX4414  HI 52% 2022 7w Placebo 
Simani 
200834 
2003-
2004 
Cross- 
sectional 
study 
South 
Africa 
303 5-24m 
 
HI  NR NR 8.7m HBV 
 
 
HU - - 11.9m HBV 
Madhi 
200723 
2001 -
2005 
Post RCT  South 
Africa 
 39836 5.57-5.80y HI 22.5% 493; 
627 
5.80y; 5.68y PCV9 HU - - 5.68y; 
5.57y 
Placebo 
Madhi 
200524 
1998 - 
2001 
RCT South 
Africa 
 39836 28-84d HI NR NR NA PCV9 HU - -   Placebo 
Klugman 
200321 
1998 - 
2001 
RCT South 
Africa 
39836 28-84d HI NR NR NA PCV9 HU - - 7w Placebo 
Madhi200232 1997-
2000 
Cohort South 
Africa 
19267 <1y HI NR NR NR HibCV  HU - - NR HibCV 
Bhat 199330 
 
1991 
 
Case-
control 
 
Zambia 270 1m-14y HI NR NR NR BCG HU NR NR NR BCG 
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HI - HIV-infected;   HEU - HIV-exposed uninfected; HU - HIV-uninfected; NR- not reported; m- month; w – week;  d- day; y- year; RCT – randomized controlled trial; HBV – Hepatitis B vaccine; HibCV- 
haemophilus influenzae b conjugate vaccine; PCV7 – 7-valent pneumococcal conjugate vaccine; PCV9 – 9-valent pneumococcal conjugate vaccine; PCV13 – 13-valent pneumococcal conjugate vaccine; 
BCG - Bacillus Calmette–Guérin; PRV – pentavalent rotavirus
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Quality of evidence 
 
Risk of bias assessment of individual studies                                                                                                                            
Risk of bias assessment of the included studies is summarised separately for RCTs (Figure 2) 
and observational studies (Figure 3). All the studies except one contained at least one domain 
classified as high risk of bias or with no clear information.  
Randomised trials 
Only three RCTs were assessed.21,22,25 Klugman 200321 was used in assessing two other included 
studies23,24 since the study participants were the same for all three publications. There was 
insufficient information on random sequence selection in majority of the studies as shown in 
Figure 4. Allocation concealment, performance and detection biases were low for most of the 
studies. Steele 201125 had unclear risk of bias for most of the domains. Feikin 201222 had high risk 
of bias for reporting and other bias domains for not reporting all the pre-specified primary 
outcomes and having numerous limitations.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Risk of bias summary for the included randomised-controlled trials 
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Observational studies 
All the observational studies had one high or unclear risk of bias across different domains except 
one study.21,26,27,29-34 The reasons for the high risk of bias varied and ranged from the use of hospital 
control instead of community controls, imbalanced missing participant numbers and unmeasured 
confounders (Figure 5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Risk of bias summary for the included observational studies 
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Random sequence generation (selection bias)   
Allocation concealment (selection bias)   
Blinding of participants and personnel (performance bias)   
Blinding of outcome assessment (detection bias)   
Incomplete outcome data (attrition bias)  
Selective reporting (reporting bias)   
Other bias   
 0%  25%  50%  75%  100% 
 
 Low risk of bias  Unclear risk of bias  High risk of bias 
 
 
Figure 4: Risk-of-bias graph: review authors' judgements about each risk-of-bias item presented as percentages across all 
included studies 
 
Incomplete outcome data (attrition bias)    
Selection of study population (selection bias)   
Origin of data   
Definition of outcome   
Confounders   
 0%  25%  50%  75%  100% 
 
 Low risk of bias  Unclear risk of bias  High risk of bias 
 
Figure 5: Risk of bias graph: review authors' judgements about each risk-of-bias item presented as percentages 
across all included studies 
 
The quality of the evidence was also evaluated using the GRADE approach. Overall quality for 
the observational studies was very low with very little confidence in the effect estimate. The overall 
quality of evidence for the RCT outcomes was mainly high. This makes our confidence in the 
effect estimate to be moderate. With these results, we are confident that the true effect lies close 
to that of the estimate of the effect and does not require further research. See Summary of findings 
in Tables 2 and 3. 
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Table 2: Summary of findings table for the efficacy of vaccines in HIV-infected, HIV-exposed and HIV-
uninfected children (RCTs) 
Patient or population: HIV-infected, HIV-exposed and HIV-uninfected children  
Intervention: Vaccines  
Comparison: Placebo  
Outcomes Anticipated absolute effects* (95% CI)  Relative effect 
(95% CI)  
№ of participants  
(studies)  
Certainty of the evidence 
(GRADE)  
 Risk with placebo Risk with vaccines 
HI/PRV/RVGE  
0 per 1,000  
0 per 1,000 
(0 to 0)  
RR 2.81 
(0.12 to 63.83)  
29 
(1 RCT)  
⨁⨁◯◯ 
LOW a 
HI/RIX4414/RVGE  
80 per 1,000  
80 per 1,000 
(21 to 270)  
HR 1.00 
(0.26 to 3.78)  
100 
(1 RCT)  
⨁⨁⨁◯ 
MODERATE a 
HI/PCV9/severe 
pneumonia  
280 per 1,000  
233 per 1,000 
(205 to 266)  
RR 0.83 
(0.73 to 0.95)  
2577 
(1 RCT)  
⨁⨁⨁⨁ 
HIGH  
HU/PCV9/severe 
pneumonia  
36 per 1,000  
32 per 1,000 
(28 to 36)  
RR 0.89 
(0.80 to 1.00)  
37259 
(1 RCT)  
⨁⨁⨁⨁ 
HIGH  
HI/PCV9/Total IPD  
26 per 1,000  
18 per 1,000 
(11 to 30)  
RR 0.68 
(0.40 to 1.14)  
2577 
(1 RCT)  
⨁⨁⨁⨁ 
HIGH  
HU/PCV9/Total IPD  
1 per 1,000  
0 per 1,000 
(0 to 0)  
not estimable  37259 
(1 RCT)  
⨁⨁⨁⨁ 
HIGH  
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the 
intervention (and its 95% CI).  
CI: Confidence interval; RR: Risk ratio; HR: Hazard Ratio  
Explanation:  a. A wide confidence interval of the estimate  
GRADE Working Group grades of evidence 
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a 
possibility that it is substantially different 
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect  
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Vaccine efficacy for vaccine-preventable diseases outcomes 
Table 4 shows reported risk ratios and vaccine efficacy for vaccine-preventable diseases outcomes 
in vaccinated versus non-vaccinated participants in trials for several outcomes. Vaccine efficacy 
of 9-valent pneumococcal conjugate vaccine (PCV9) vs. placebo in preventing first episodes of 
invasive pneumococcal disease was 53% (95% CI 21 - 73) among HIV-infected children and 42% 
(95% CI -28 - 75) among HIV-uninfected children. Efficacy of PCV9 against total vaccine 
serotype invasive pneumococcal disease was 32% (95% CI -14 - 60) in HIV-infected and 78% 
(95% CI 34 - 92) among HIV-uninfected children.  
 
Table 3: Summary of findings table for the efficacy of vaccines in HIV-infected, HIV-exposed and HIV-
uninfected children (Observational studies) 
Patient or population: HIV-infected, HIV-exposed and HIV-uninfected children 
Intervention: Vaccine  
Comparison: Placebo  
Outcomes Anticipated absolute effects* (95% CI)  Relative effect 
(95% CI)  
№ of participants  
(studies)  
Certainty of the evidence 
(GRADE)  
 Risk with placebo Risk with vaccine 
HBV/Hepatitis B 
vaccine  3 per 1,000  
18 per 1,000 
(3 to 103)  
OR 6.02 
(0.93 to 38.83)  
594 
(2 observational 
studies)  
⨁◯◯◯ 
VERY LOW a,b 
HI/BCG/Tuberculosis  Low  OR 1.00 
(0.22 to 4.56)  
36 cases 18 controls 
(1 observational 
study)  
⨁◯◯◯ 
VERY LOW b,c 
0 per 1,000  
0 per 1,000 
(0 to 0)  
HU/BCG/Tuberculosis  Low  OR 0.41 
(0.18 to 0.92)  
60 cases 116 controls 
(1 observational 
study)  
⨁◯◯◯ 
VERY LOW b,c 
0 per 1,000  
0 per 1,000 
(0 to 0)  
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the 
intervention (and its 95% CI).  
CI: Confidence interval; OR: Odds ratio  
Explanations: a. Confounders were not taken into account and unclear about the selection of study participants; b. A wide confidence interval around the 
estimate of the effects; c. Confounders not taken into account  
GRADE Working Group grades of evidence 
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a 
possibility that it is substantially different 
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect  
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There was similar response among HIV-infected children who were given RIX4414 vaccine and 
those given placebo for prevention of acute rotavirus diarrhoea (RR= 1.00; 95% CI 0.26 - 3.78) 
(Table 5). The subset of HIV-infected children in a particular trial that compared pentavalent 
rotavirus vaccine (PRV) and placebo showed RR of 2.81 (95% CI 0.12 - 63.83) (Table 5). 
Vaccine effectiveness for vaccine-preventable diseases outcomes 
Table 6 reports vaccine effectiveness for vaccine-preventable diseases outcomes in vaccinated 
versus non-vaccinated participants in observational studies for different outcomes. The pooled 
odds ratio (OR) of two studies on the effectiveness of HBV vaccines between HIV-infected and 
HIV-uninfected children was OR = 6.02 (95% CI 0.93 - 38.83; I2 = 0.00%) (Table 5; Figure 6). 
Vaccine effectiveness of BCG vaccine in preventing tuberculosis in HIV-infected children was 
zero compared to 59 percent protection in HIV-unexposed children (Table 5). Likewise, HIV-
uninfected children have better protection against invasive Hib disease than the HIV-infected 
children (97% versus 44%). Effectiveness studies of rotavirus vaccines show that HIV-exposed 
uninfected children have similar protection against rotavirus gastroenteritis comparable to the non-
exposed children. The adjusted vaccine effectiveness of PCV13 against invasive pneumococcal 
disease was 78% (95% CI 46 to 91) in HIV-uninfected children, 17% (95% CI –304 - 80) in HIV-
infected and –104% (95% CI –1433 - 73) among HIV-infected children who were severely 
immunosuppressed. 
 
 
Figure: 6: Forest plot of comparison: Vaccine effectiveness comparing HIV-infected and HIV-uninfected - 
Hepatitis B vaccine, outcome: HBV/Hepatitis B vaccine 
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Table 4: Reported risk ratios and vaccine efficacy for vaccine-preventable diseases outcomes in vaccinated vs. non-vaccinated participants in randomised-
controlled trials 
Study ID (year) Doses Experimental recipients/vaccine Control recipients/vaccine  Vaccine efficacy (%) Disease of interest 
Klugman 200321 3 HI/PCV9 HI/placebo 53 (21 to 73) First episodes of invasive pneumococcal 
disease Klugman 200321 3 HU/PCV9 HU/placebo 42 (-28 to 75) 
Klugman 200321 3 HI/PCV9 HI/placebo 13 (-7 to 29) First episodes of radiologically confirmed 
pneumonia Klugman 200321 3 HU/PCV9 HU/placebo 20 (2 to 35) 
Madhi 200523 3 HI/PCV9 HI/placebo 17 (5, 27) WHO-defined severe pneumonia 
Madhi 200523 3 HU/PCV9 HU/placebo 11 (1, 20) 
Madhi 200724 3 HI/PCV9 HI/placebo 32 ( -14, 60) Total vaccine serotype invasive 
pneumococcal disease Madhi 200724 3 HU/PCV9 HU/placebo 78 (34, 92) 
Steele 201125 3 HI/ RIX4414 HI/placebo 0 (-278, 74) Acute rotavirus diarrhoea 
Feikin 201222 3 HI/PRV HI/placebo -181 (-6283, 88) 
 
 
Table 5: Calculated vaccine efficacy and effectiveness for various vaccine outcomes 
Outcomes  
Number 
of 
studies Experimental group Control group Relative effects 
Study 
references 
Hepatitis B virus infection 2 HI/HBV HU/HBV OR = 6.02 (0.93, 38.83) 33,34 
Rotavirus gastroenteritis 1 HI/PRV HI/Placebo RR = 2.81 (0.12, 63.83) 22 
Rotavirus gastroenteritis 1 HI/RIX4414 HI/Placebo RR = 1.00 (0.26, 3.78) 25 
Severe pneumonia 1 HI/PCV9 HI/Placebo RR = 0.83 (0.73, 0.95) 23 
Severe pneumonia 1 HU/PCV9 HU/Placebo RR = 0.89 (0.80, 1.00) 23 
Total Invasive Pneumococcal Disease 1 HI/PCV9 HI/Placebo RR = 0.68 (0.40, 1.14) 24 
Total Invasive Pneumococcal Disease 1 HU/PCV9 HU/Placebo RR = 0.22 (0.08, 0.66) 24 
Tuberculosis 1 HI/BCG HI/Unvaccinated OR = 1.00 (0.22, 4.56) 30 
Tuberculosis 1 HU/BCG HU/Unvaccinated OR = 0.41 (0.18, 0.92) 30 
           BCG- Bacillus Calmette–Guérin vaccine; HI- HIV-infected; HU- HIV-uninfected; HBV – Hepatitis B virus; PCV – pneumococcal conjugate vaccine; PRV- pentavalent rotavirus;  
             OR- odds ratio; RR- risk ratio 
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Table 6: Reported vaccine effectiveness against vaccine-preventable diseases in observational studies  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study ID (year) Vaccine type Doses HIV status 
Vaccine effectiveness 
(%) 
Adjusted vaccine 
effectiveness (%) Disease of interest 
Bhat (1993)30 
BCG 
1 
 
HI 0 (−360 to 78) 
  
Tuberculosis 1 
 
HU 59 (8 to 82) 
Madhi  (2002)32 
HibCV 
3 
 
HI 43.9 ( 76.1 to 82.1) 
 
Invasive Hib disease 3 
 
HU 96.5 (74.4 to 99.5) 
 
 
 
Groome (2014)29 
Monovalent RV  2 HEU  
 
58% (16 to 79) Acute rotavirus diarrhoea 
2 HU  
 
52% (23 to 70) 
Cohen (2014)26 
PCV7 
≥3 HI 43 (−108 to 85)  
57 (−371 to 96) 
Invasive pneumococcal 
disease 
≥3 HU 57 (−100 to 91) 
90 (14 to 99) 
 
Van-Dunem (2015)28 
BCG Connaught 
1 HI 8 (−26 to 32) 
30 (−75 to 72) 
Tuberculosis 
Bar-Zeev (2016)31 
Monovalent RV 2 HEU  
 
42.2% (−106.9 - 83.8) Acute rotavirus diarrhoea 
2 
HU 
 
60.5% (13.3–82.0) 
Cohen (2017)27 
 PCV13 
≥2  HI (overall) 26% (–98 to 72)  
17% (–304 to 80) 
Invasive pneumococcal 
disease 
≥2  
HI with severe 
immunosuppression –42% (–723 to 76) 
 –104% (–1433 to 73) 
≥2  
HI with no severe 
immunosuppression 75% (–31 to 95)  
66% (–94 to 94) 
≥2  HU (overall) 83% (61 to 92)  
78% (46 to 91) 
≥2  HEU  91% (60 to 98)  
87% (38 to 97) 
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Discussion 
The findings of this systematic review show that various routine vaccines have varying levels of 
protective efficacy and effectiveness against different vaccine-preventable diseases among HIV-
infected and HIV-exposed children. This study demonstrates that PCV9 and 13-valent 
pneumococcal conjugate vaccine (PCV13) vaccines are efficacious in preventing invasive 
pneumococcal disease, radiologically confirmed pneumonia and severe pneumonia.21 PCV9 also 
reduced the incidence of antibiotic-resistant invasive and vaccine serotype pneumococcal disease 
in both HIV-infected and uninfected children.21 However, PCV vaccines are less efficacious in 
preventing total vaccine serotype invasive pneumococcal disease in HIV-infected children 
compared to HIV-uninfected children.22 Cohen et al.show that HIV-infected children have less 
protection against invasive pneumococcal disease when vaccinated with doses of PCV13.27 HIV-
infected children with severe immunosuppression are unprotected against invasive pneumococcal 
disease even at higher vaccine doses.27 
Vaccine-efficacy studies show that RIX4414 and PRV do not have protective activities against 
acute rotavirus diarrhoea in HIV-infected children.22,25 The poor efficacy of PRV in children living 
with HIV may largely be as a result of the small sample size of the HIV-infected children subset 
in a Kenyan trial.22 However, Feikin et al. show that PRV efficacy against severe rotavirus 
gastroenteritis was 63.9% (95% CI −5.9-89.8) in a study with a large number of both HIV-infected 
and uninfected children in the second year of life and 83% in the first year of life. The study on 
RIX4414 shows that there was no significant difference in the incidence of rotavirus diarrhoea in 
the vaccine and placebo groups thereby deducing that the vaccine did not have any significant 
protective effect in HIV-infected children.23 Monovalent rotavirus vaccines provided at least 40 to 
60 percent protection against acute rotavirus gastroenteritis in both HIV-exposed uninfected and 
HIV-unexposed children but the effectiveness in HIV-infected children is not yet known.29,32  
Vaccine-effectiveness studies show that Hib conjugate vaccine provided more than 50% protection 
against invasive Hib disease in HIV-uninfected children when compared to HIV-infected 
children.30 Hib conjugate vaccine has a protective effect of 83% in preventing overall invasive Hib 
disease in among HIV-infected children and very useful.32 A study among Zambian children shows 
that BCG has 59 percent protective effect against tuberculosis in HIV-uninfected children and 
none in HIV-infected children.30 The findings of a case-control study among Brazilian children 
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also allude to the fact that BCG does not protect against tuberculosis in immunodeficient HIV-
infected children.26 
Studies have shown that most of the vaccines included in this review are safe for use in all 
categories of children.1,21,25,35,36 A number of reviews and safety studies on several routine vaccines 
among HIV-infected/exposed children and HIV-unexposed children show that there was no 
significant difference in these groups of children with respect to adverse events, serious adverse 
events and death.37-39 Most of the serious adverse events and deaths were not vaccine related. 
Reviews also show that immune responses to primary vaccination in HIV-infected children were 
less likely compared to HIV-unexposed and HIV-exposed children and may require booster 
doses.37,38,39  
There is a dearth of vaccine efficacy and effectiveness studies against vaccine-preventable diseases 
among HIV-infected and exposed children. This review shows that some efficacy studies have 
been done for PCV, BCG, rotavirus vaccines and Hib vaccines in HIV-infected children. There is 
a need to close the knowledge gap in relation to pre-licensure vaccine efficacy and post-licensure 
vaccine effectiveness against key vaccine-preventable diseases among these groups of children. 
Closing the gaps will entail conducting efficacy and effectiveness studies for several routine 
vaccines in HIV-infected and exposed children.13 Use of BCG vaccines in HIV-infected children 
can lead to disseminated tuberculosis hence it is contraindicated in immunocompromised children. 
It is therefore, not advisable to do a BCG vaccine-efficacy study in these children.40 BCG is safe 
in immunocompetent infants, however, immunocompromised infants are at high risk of developing 
disseminated BCG disease.41 
Effectiveness research is  essential and relevant for decision making by policy makers, treatment 
guideline researchers, vaccine development researchers and healthcare providers.42 Vaccine-
efficacy research is essential in making the necessary decisions to achieve the goals of the Global 
Health 2035 Grand Convergence.43 The WHO has already recommended many vaccines for use 
in immunocompromised children especially those who have had exposure to HIV, however, most 
of these recommendations were made without specific vaccine-efficacy and effectiveness studies 
conducted in this population but rather from research findings on immunocompetent children or 
by using safety and immunogenicity studies.1,40 Knowing the vaccine efficacy and effectiveness 
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against specific diseases will help steer guideline development and the need for better vaccines if 
the level of protection is low. 
Strengths of this systematic review and meta-analysis are the comprehensive search conducted in 
several databases and the inclusion of several routine vaccines. This review also compiled 
evidence on efficacy and effectiveness of vaccines that could be of use in HIV-infected and HIV-
exposed children especially in sub-Saharan Africa. Lack of direct comparisons between HIV-
infected and unexposed children with respect to various clinical cases of vaccine-preventable 
diseases limited straightforward grading of the evidence for clinical case outcomes. Only seven 
studies could be included in the meta-analysis due to lack of data information on some clinical 
outcomes and reported efficacy and effectiveness as described by the authors. 
 
Conclusions 
Efficacy and effectiveness studies on vaccination exhibit possibilities for direct and indirect 
protection against various vaccine-preventable diseases among HIV-infected and HIV-exposed 
children. HIV-infected children tend to have less protection against vaccine-preventable diseases 
when compared to unexposed children. HIV-infected children who have access to antiretroviral 
therapy and are immunocompetent are more likely to have better vaccine protection against 
vaccine-preventable diseases than the immunosuppressed ones. There is also a need to bridge the 
knowledge gap on vaccine efficacy and effectiveness of several routine vaccines in HIV-infected 
and exposed children. This study reveals that only a few vaccine-efficacy and effectiveness studies 
have been done in HIV-infected and exposed children previously. 
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CHAPTER 4: Effect of maternal HIV status on vaccination 
coverage among sub-Saharan African children: A socio-
ecological analysis 
 
Olatunji O. Adetokunboh, Olalekan A. Uthman and Charles S. Wiysonge  
                                                                                                                                                                                                                                   
Abstract 
We investigated the relationship between maternal HIV status and uptake of the full series of three 
doses of diphtheria-tetanus-pertussis containing vaccines (DTP3) in sub-Saharan African children. 
We used data obtained from demographic and health surveys conducted in sub-Saharan Africa. 
We conducted a meta-analysis and calculated pooled odds ratios (OR) for the association between 
maternal HIV status and DTP3 vaccination status for each country. A total of 4,187 out of 5,537 
children of women living with HIV received DTP3 (75.6%), compared to 71,290 of 113,513 
(62.8%) children of HIV-uninfected women. National DTP3 coverage among children of HIV-
infected women varied between 24% and 96% while among children of HIV-uninfected women it 
was between 26% and 92%. Overall pooled result showed no significant difference in DTP3 
coverage between the two groups (OR = 1.05; 95% confidence interval 0.91 - 1.22), with 
statistically significant heterogeneity (Chi2     = 91.63, P = 0.000, I2 = 71.6%). There was no 
association between DTP3 coverage and maternal HIV status in sub-Saharan Africa. However, 
DTP3 coverage for both HIV-exposed and non-exposed children were below the required target. 
Meta-regression revealed no significant association between DTP3 coverage and country 
characteristics (e.g. HIV prevalence among women, antiretroviral therapy coverage, gross 
domestic product per capita, human development index, adult literacy rate and sub-region). 
Improved prevention of mother-to-child transmission services might have contributed to some 
extent to the higher DTP3 vaccination coverage among the HIV-exposed children. There is also a 
need to address barriers impeding the uptake of vaccination among HIV-exposed and non-exposed 
children.  
Keywords: Immunisation coverage; HIV; vaccine-preventable diseases; sub-Saharan Africa; 
demographic and health surveys 
Stellenbosch University  https://scholar.sun.ac.za
77 
 
Introduction 
 
Human immunodeficiency virus (HIV) infection remains a major public health challenge and a 
foremost cause of disability-adjusted life years in sub-Saharan Africa.1,2 Sub-Saharan Africa 
accounts for about 75% of the global burden of HIV.3,4 It is estimated that approximately 1.5 
million HIV-infected children live in sub-Saharan African countries and these countries also 
account for the highest burden of vaccine-preventable diseases.4,5  
Vaccination has been demonstrated to be a cost-effective and beneficial public-health intervention 
in protecting children.6 Vaccination is essential in HIV-infected individuals because of their 
increased risk of developing various infectious diseases due to their defective immune systems.7 
Unfortunately, the coverage of routine vaccinations for children in many African countries is still 
low and inadequate to meet the Global Vaccine Action Plan (GVAP) targets.8–10 Studies have also 
shown that HIV-exposed and infected children have significantly increased risk of morbidity and 
mortality from various vaccine-preventable diseases when compared with HIV-unexposed and 
uninfected children.11,12 The low vaccination coverage may result in increased susceptibility to 
infection by various vaccine-preventable diseases among the infants of women living with HIV.  
Exploring the effect of maternal HIV status on childhood vaccination among children in sub-
Saharan Africa is critical to inform vaccine-preventable disease-prevention strategies.  A study on 
vaccination coverage in HIV-infected patients shows that patients with a specific indication for a 
given vaccine have better vaccination coverage, however, adherence to vaccination guidelines is 
not likely to be a determinant for vaccination among the HIV-infected patients.13 Research is 
needed to close the evidence gap with respect to the coverage of childhood vaccination and the 
impact of maternal HIV status.13                                                           
This study examined the vaccination coverage of the three doses of diphtheria-tetanus-pertussis 
containing vaccines (DTP3) among children with respect to the maternal HIV status. The study 
also assessed the relationship between various country-level characteristics and the coverage of 
DTP3 among sub-Saharan African children by pooling available survey data. 
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Methods 
 
Data 
The study used data obtained from DHS conducted in sub-Saharan African countries.14 The DHS 
data are cross-sectional and population-based representative sample surveys of households. The 
sampling frame for each survey is made up of a list of enumeration areas covering the whole 
country. The surveys involve a two-stage sample design with standardised questionnaires 
administered to the selected participants in each country. These were implemented by respective 
National Ministry of Health or Research/Statistical agencies with technical support from 
MEASURE DHS, ICF International, Calverton, Maryland, USA and with funding from various 
development partners such as the Global Fund to Fight AIDS, Tuberculosis and Malaria, the 
United States Agency for International Development etc. The included countries were selected 
based on the availability of the DHS surveys with data on the uptake of three doses of DTP and 
whether the mother had had an HIV test as of November 2017.  Based on these criteria, 27 sub-
Saharan African countries were included namely: Angola, Burkina Faso, Burundi, Cameroon, 
Chad, Democratic Republic of the Congo, Cote d'Ivoire, Ethiopia, Gabon, The Gambia, Ghana, 
Guinea, Kenya, Lesotho, Liberia, Malawi, Mali, Namibia, Niger, Rwanda, Sao Tome and Principe, 
Senegal, Sierra Leone, Swaziland, Togo, Zambia and Zimbabwe. 
Eligible women within the age range of 15-49 years old were encouraged during the interview to 
test for HIV voluntarily.. The trained interviewers then collected finger-prick, dried blood-spot 
specimens for HIV testing. The sample collection and analysis protocol is based on the anonymous 
linked protocol. The DHS programme protocol allows the merging of results of the HIV test with 
other data collected per each respondent's questionnaires. 
Main variable 
The main variable was the uptake of three doses of diphtheria-tetanus-pertussis containing 
vaccines among children aged 12-23 months at any time before the survey; as reported on their 
vaccination cards or by their mothers during interviews. The mother’s HIV status was recorded as 
either HIV seropositive or seronegative.  
Country-level variable 
Country-level data were matched within the same time frame when DHS were conducted using 
various reports published by the United Nations Development Programme,15 World Bank16 and 
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Joint United Nations Programme on HIV/AIDS (UNAIDS).4 The country-level characteristics 
included in this study were percentage coverage of pregnant women who received antiretroviral 
drugs for prevention of mother-to-child transmission of HIV (PMTCT), HIV prevalence, 
childhood vaccination coverage level, gross domestic product (GDP) per capita, adult literacy rate, 
and human development index (HDI). We divided the country-level variables into low, medium 
or high categories in order to provide results that were more easily interpretable for policy 
purposes. 
These country-level variables were some of the maternal and developmental factors that are likely 
determinants of vaccination coverage especially among HIV-exposed.15,16 We expected the study 
to show the associations between vaccination coverage and country-level factors by identifying 
differences in country characteristics that might be responsible for variations in the coverage in 
sub-Saharan Africa. 
Ethical considerations 
This study used existing DHS data from various countries with the study data identifier 
information removed. The surveys were approved by the Institutional Review Boards of the ICF 
International, and the Centers for Disease Control and Prevention, Atlanta, USA and by the 
National Ethics Committees of the included countries. All the study respondents gave informed 
consent for participation and the confidentiality of the collected information was maintained.  
 
Statistical analysis 
 
Meta-analysis 
We calculated odds ratios (OR) for the association between maternal HIV status and childhood 
DTP3 vaccination status for each country. The DerSimonian-Laird method (random-effects 
model)17 was used to calculate pooled odds ratio across countries. The study is an individual patient 
data meta-analysis. We evaluated the homogeneity of the results by means of the Chi-square test 
and used the I2 to describe the percentage variation across countries.18-20 We explored substantial 
heterogeneity (I2>50%) by subgroup analysis.   
To investigate sources of heterogeneity, sub-group analysis was conducted using the 
DerSimonian-Laird method. The sub-groups were designed using the following categories:  
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i. GDP (low-income: ≤ $1,025; middle-income: $1,026 - $12,475). GDP middle class 
consists of both lower-middle and upper-middle classes. 
ii. HDI (low: ≤0.549; medium: 0.550 – 0.770), based on the classification by United Nations 
Development Programme. 
iii. Coverage of pregnant women who received antiretroviral drugs for PMTCT (low: ≤ 50.0; 
high: ≥ 50.1).  
iv. HIV prevalence aged 15-49 years old (low: ≤ 10.0; high: ≥ 10.1). The cut off of 10.0 was 
used based on the range of the prevalence for different countries included in this study.  
v.  Adult literacy rate (low: ≤ 50.0; high: ≥ 50.1). 
vi. Sample size (small size if ≤5000 or large size if ≥ 5001). The cut-off point of 5000 was 
before it is the average sample size for the participating countries. 
vii. Sub-region (Central/Eastern, Southern and Western Africa). 
viii. Year of the survey (2003-2010 and 2011-2016). The cut-off point for the years of survey 
was 2010 because 2011 marks the start of the Global Vaccine Action Plan. 
We performed leave-one-country-out sensitivity analysis to determine the stability of the results. 
This analysis evaluated the influence of individual country results by estimating the weighted 
average odds ratio in the absence of each country. 
 
Meta-regression analysis 
We investigated the impact of various country characteristics on odds-ratio estimates through an 
inverse-weighted linear meta-regression analysis. The independent variable was the natural 
logarithm of the odds ratio. The explanatory factors included pre-defined country characteristics 
such as coverage of antiretroviral drugs use during PMTCT, HIV prevalence for females, sample 
size, sub-region and the calendar year of the survey. Other included factors were HDI, GDP and 
adult-literacy rates.  
All the analyses were two-sided with p < 0.05 considered significant. Stata 14 (Stata Corp, College 
Station, TX, USA) software was used for analysis.21 
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Results   
 
Description of included countries 
This study included only 27 countries based on the availability of the required demographic and 
health surveys (DHS) HIV and immunisation data sets. The surveys were conducted between 2003 
and 2016 in the included countries. The years 2013 and 2014 had the highest number of surveys 
totalling five each. The included countries, year of the survey, coverage of antiretroviral drugs 
used for PMTCT, HIV prevalence in females, gross domestic product (GDP) per capita, human 
development index (HDI), adult literacy rate and the sample sizes are shown in Table 1. A total 
number of 119,050 respondents were included in this study. A total of 4,187 out of 5,537 (75.6%) 
children of mothers living with HIV received DTP3, compared to 71,290 out of 113,513 (62.8%) 
children of HIV-uninfected mothers.  
The percentage coverage of pregnant women who received antiretroviral drugs for PMTCT varied 
from 35% in Mali to 96% in Namibia. The HIV prevalence among females aged 15-49 years old 
ranged widely from 0.5% in Niger to 34.7% in Swaziland. Of the 27 countries, two are upper 
middle-income countries (Gabon and Namibia), eight are lower middle-income countries (Angola, 
Cameroon, Cote d’Ivoire, Ghana, Kenya, Senegal, Swaziland and Zambia) and the rest are low-
income countries. The adult literacy rate ranged from 15.5% in Niger to 88.7% in Zimbabwe. The 
DTP3 coverage among the children of HIV-infected mothers varied between 24% in Angola and 
96% in Rwanda while among the children of HIV-uninfected mothers it was 26% in Angola and 
92% in Rwanda.  
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Table 1: Maternal HIV status, childhood DTP3 uptake, and other characteristics of 27 included countries  
 Population sample size 
 
Children of HIV-
infected mothers 
Children of HIV-
uninfected mothers  
Country 
Year 
of 
survey 
HIV 
prevalence  
ARV 
coverage 
during 
PMTCT 
(%) 
GDP per 
capita(US$
) HDI 
Adult 
literacy 
rate   
DTP3 
uptake* 
Total 
number 
of 
children 
DTP3 
uptake* 
Total 
number 
of 
children 
           
Angola 2016 2.2 44 3110.8 0.533 66.0 21 (24) 88 1143 (30) 3757 
Burkina Faso 2010 1.1 83 649.7 0.402 34.6 49 (83) 59 5397 (79) 6794 
Burundi 2011 1.3 84 285.7 0.404 61.6 78 (88) 89 3035 (88) 3458 
Cameroon 2011 5.1 74 1032.6 0.518 71.3 158 (73) 216 3019 (65) 4678 
Chad 2015 1.6 63 664.3 0.396 22.3 27 (40) 67 1410 (26) 5337 
Congo DR 2014 1 70 444.5 0.435 77.0 38 (42) 91 4238 (49) 8571 
Cote d'Ivoire 2012 3.5 73 1526.2 0.474 43.9 67 (58) 115 1879 (57) 3270 
Ethiopia 2003 1.3 69 706.8 0.448 39.0 71 (57) 124 3510 (35) 10094 
Gabon 2012 5.3 76 7179.3 0.697 82.3 59 (35) 167 1309 (36) 3641 
TheGambia 2013 2 69 473.2 0.452 42.0 40 (70) 57 2726 (77) 3528 
Ghana 2014 2.1 56 1513.5 0.579 71.5 43 (77) 56 2129 (77) 2763 
Guinea 2012 1.9 43 508.1 0.414 32.0 27 (52) 52 1440 (44) 3309 
Kenya 2009 6.9 80 1455.4 0.555 78.7 147 (71) 206 1758 (73) 2412 
Lesotho 2014 29.8 66 998.1 0.497 76.6 309 (80) 386 850 (79) 1078 
Liberia 2013 2 70 455.4 0.427 42.9 22 (47) 47 1930 (57) 3373 
Malawi 2016 11.2 84 300.8 0.476 62.1 199 (77) 258 2413 (83) 2893 
Mali 2013 1.2 35 780.5 0.442 33.1 27 (60) 45 2707 (57) 4754 
Namibia 2012 16.6 96 4140.5 0.64 88.3 17 (77) 22 3206 (60) 5365 
Niger 2013 0.5 52 363.2 0.353 15.5 295 (79) 375 1412 (78) 1817 
Rwanda 2015 3.8 82 702.8 0.498 68.3 131 (96) 137 3370 (92) 3659 
Sao T&P 2009 n/a n/a 1756.1 0.574 90.1 12 (63) 19 1471 (82) 1787 
Senegal 2011 0.6 55 958.1 0.494 42.8 21 (66) 32 3048 (75) 4071 
Sierra Leone 2013 2 87 496 0.42 32.4 44 (61) 72 3486 (70) 4952 
Swaziland 2007 34.7 95 2775.2 0.541 83.1 676 (82) 822 1303 (85) 1542 
Togo 2014 2.7 86 578.5 0.487 63.8 61 (87) 70 2496 (77) 3241 
Zambia 2014 14.5 83 1178.4 0.579 83.0 1177 (85) 1378 8533 (80) 10673 
Zimbabwe 2015 16.1 93 1008.6 0.516 88.7 371 (76) 487 2072 (77) 2696 
 
ARV: anti-retroviral drugs; Congo DR- Congo Democratic Republic, DTP3: three doses of diphtheria-tetanus-pertussis containing vaccines, GDP: gross 
domestic product, HDI: human development index, n/a: not available, PMTCT: prevention of mother-to-child transmission, Sao T&P: Sao Tome and 
Principe 
GDP - Low-income economies are defined as those with a GDP per capita of $1,025 or less; lower middle-income economies: $1,026 - $4,035; upper 
middle-income economies: $4,036 - $12,475; high-income economies: ≥ $12,476. HDI - low: <0.549; medium: 0.550 – 0.770. Percentage coverage of anti-
retroviral drugs use during PMTCT – low: ≤ 50.0; ≥ 50.1. HIV prevalence – low: ≤ 10.0; ≥ 10.1. Adult literacy rate – low: ≤ 50.0; ≥ 50.1. 
* The values for DTP3 uptake are absolute counts (percentage).                                                                                                                                                                                                                               
(Source: Demographic and Health Surveys, Joint United Nations Programme on HIV/AIDS, United Nations Development Programme)  
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Meta-analysis 
The odds ratio (OR) and 95% confidence interval (CI) from the included countries and pooled 
result are shown in Figure 1. In most countries (n=20), there was no significant difference in the 
proportion of children of mothers living with HIV who received DTP3 and the children of HIV-
uninfected mothers. In Sao Tome and Principe, and Malawi, children of mothers living with HIV 
were significantly less likely to receive DTP3 compared to the children of HIV-uninfected ones. 
However, in four countries, Cameroon, Chad, Ethiopia and Zambia, children of mothers living 
with HIV were significantly more likely to have received DTP3. Nonetheless, when the data from 
the 27 countries were pooled together using the DerSimonian-Laird method, there was no 
significant difference in DTP3 coverage between the two groups of women (OR = 1.05; 95% CI 
0.91 - 1.22), with statistically significant heterogeneity (Chi2  = 91.63 on 26 degree of freedom, P 
= 0.000, I2 = 71.6%).  
  
 
 
Figure 1: Forest plot showing the association between maternal HIV status and DTP3 coverage in 27 sub-
Saharan Africa countries 
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Sub-group analyses 
Sub-group analysis was conducted to access the effect of coverage of pregnant women who 
received antiretroviral drugs during PMTCT on the pooled estimates. The pooled estimates for 
countries with low and high coverage were calculated using the DerSimonian-Laird method. The 
pooled-effect estimates for the low-coverage countries was (OR = 1.04; 95% CI 0.90 - 1.21). The 
calculated pooled-effect estimates for the high coverage countries was (OR = 1.07; 95% CI 0.85 - 
1.33) (Table 2).  Sub-group analyses showed that differences between countries in terms of 
coverage for antiretroviral drugs, HIV prevalence, HDI, GDP, adult literacy rate, years of survey 
and sub-regions did not explain the heterogeneity of effect estimates on coverage for DTP3 vaccine 
among the sub-Saharan Africa children (Table 2). 
 
Table 2: Subgroup analysis and the univariate meta-regression analysis result
Characteristics No. of 
studies 
Subgroup  
odds ratio 
95% CI I-squared Univariate meta-regression 
β 95% CI 
Year of survey     0.97 0.92,1.02 
2003-2010 5 1.1 0.9, 1.2 87.4*   
2011-2016 22 1.0 0.9, 1.2 64.8*   
HIV prevalence female     1.00 0.98, 1.02 
Low 20 1.1 0.9, 1.3 65.4*   
High 6 1.0 0.8, 1.4 84.2*   
Pregnant women who 
receive anti-retroviral (%) 
    1.00 1.00, 1.01 
Low 12 1.0 0.9, 1.2 17.9   
High 12 1.1 0.9, 1.3 76.7*   
Gross domestic product per 
capita (US$) 
    1.00 1.00, 1.00 
Low 9 1.1 0.9, 1.3 72.3*   
Middle 18 1.0 0.8, 1.3 73.5*   
Human development index     0.83 0.10, 6.86 
Low 21 1.0 0.9, 1.2 70.1*   
Medium 6 1.1 0.9, 1.2 72.7*   
Adult literacy rate      1.00 0.99, 1.01 
Low 11 1.1 0.8, 1.5 73.4*   
High 16 1.0 0.9, 1.2 71.8*   
Regions     1.01 0.83,     1.23 
Western Africa 13 1.0 0.8, 1.2 51.5*   
Central/Eastern Africa 7 1.2 0.9, 1.7 79.5*   
Southern Africa 7 1.0 0.8, 1.3 82.5*   
Size     1.00* 1.00, 1.00 
Smaller studies 20 1.0 0.9, 1.1 44.3*   
Larger studies 7 1.4 1.0, 1.9 81.0*   
       
* p < 0.05         
Stellenbosch University  https://scholar.sun.ac.za
85 
 
Sensitivity analyses 
Figure 2 shows leave-one-country-out sensitivity analyses used to assess the stability of the meta-
analysis. For the analyses, the overall estimate was calculated by removing one of the study 
countries each time. The changes in the confidence intervals with this exclusion remain within the 
95% confidence interval for the overall estimate for all the included countries. The analyses show 
that no one country survey had an undue influence on the estimate of the association between 
maternal HIV status and DTP3 uptake. The outcome of these sensitivity analyses indicated the 
stability of the result. 
 
 
 
Figure 2: A plot showing the influence of each country on the overall pooled result using -leave-one-country-
out’ sensitivity analysis 
 
 
Meta-regression analysis 
Meta-regression analysis was performed to explore factors that might account for heterogeneity 
with respect to the country-level characteristics. We found that the coverage of antiretroviral drugs 
use during PMTCT was not significantly associated with the childhood DTP3 vaccination 
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coverage (p= 0.543). Likewise, other characteristics were not significantly associated with the 
DTP3 coverage except the sample size (p= 0.020) (Table 2).  
 
Meta-regression plot of the natural logarithm of the odds ratio of DTP3 coverage regressed against 
the coverage of pregnant women who received antiretroviral drugs for PMTCT in each country 
(Figure 3). The circles represent a country and the size of each circle mirrors the effect of that 
country on the model. Although there was no significant relationship between the natural logarithm 
of the odds ratio of DTP3 coverage and the coverage of pregnant women who received 
antiretroviral drugs, however, the plot shows that the DTP3 coverage slightly increases as PMTCT 
coverage increases (β = 1.00, 95% Cl 0.99 - 1.01, p= 0.543) (Figure 3). Figure 4 also shows a 
bubble plot of DTP3 coverage slightly reducing as HIV prevalence increases. 
 
 
 
 
 
Figure 3: The association between the natural logarithm of the odds ratio for DTP3 coverage and coverage of 
women who received antiretroviral drugs for PMTCT in each included country 
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Figure 4:  The association between the natural logarithm of the odds ratio for DTP3 coverage and adult 
female HIV prevalence in each included country 
 
 
Discussion 
 
The overall findings of the meta-analysis involving data from 27 sub-Saharan African countries 
showed that there is no significant difference in the DTP3 coverage among the infants of women 
living with HIV and those who are not HIV infected. The findings from this socio-ecological study 
show that there is low coverage of DTP3 vaccination among the HIV-exposed children, however, 
the DTP3 coverage among this group of children is higher than the HIV non-exposed children. 
Studies by Eley and Seste et al. show that HIV-infected and HIV-exposed uninfected children are 
at risk for low immunisation coverage22,23 while another study shows that the children of women 
living with HIV had more than a two-fold likelihood of being under-immunised than the children 
of mothers who are not HIV-infected.24  A Nigerien study shows that children of HIV-infected 
women were less likely to receive second and third doses of DTP-containing vaccines while 
another study conducted in South Africa shows that HIV-exposed children are also less likely to 
complete the uptake of routine childhood vaccinations in comparison with the children of HIV-
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uninfected women.9,25 These African studies were conducted in rural and urban poor communities 
in Uganda, South Africa, Zambia and Niger with small sample sizes. Most of these studies were 
conducted prior to the era of comprehensive PMTCT programmes in Africa. This period witnessed 
unnecessary delays in implementing treatment policies, non-integration of services, Acquired 
Immunodeficiency Syndrome (AIDS) denialism views, lack of political will, widespread stigma 
and discrimination.25,26 There were also issues of a weak health system and inadequate information 
about immunisation in most of the African countries at the time.9,26,27  
It is worthy to note that the meta-regression analytic findings were not significant for most of the 
country characteristics apart from the sample size for individual country but the bubble plots show 
certain patterns that may explain some of the findings of the meta-analysis. DHS are large size 
cross-sectional surveys and likely to have a significant relationship with DTP3 coverage, however, 
the survey sample sizes do not have direct policy implication on the country DTP3 coverage. Meta-
regression plot shows that DTP3 coverage slightly increases as the coverage of the pregnant 
women who received antiretroviral drugs for PMTCT increases (Figure 4). Likewise, the DTP3 
coverage slightly reduces as the adult female HIV prevalence increases.  Coverage of antiretroviral 
drugs for PMTCT and HIV prevalence for females are both important indicators which may 
contribute to the slight edge in DTP3 coverage recorded by the HIV-exposed children and explain 
the result of the meta-analysis.  
The included DHS were mostly conducted post-2009 after the launch of the Global Plan towards 
the elimination of new HIV infections among children by 2015 and keeping their mothers alive. 
The Global Plan has the goal of reducing new HIV infections in children, decreasing the mother-
to-child transmission rate of HIV and increasing the coverage of antiretroviral therapy in mothers 
and children.27,28 The integration of PMTCT services into broad-based maternal, newborn, and 
child health services in many African countries in recent years has improved the quality and 
coverage of mother-child pair care support given to women living with HIV during the post-
delivery and breastfeeding periods. There was a dramatic increase of about fivefold in the 
percentage of mothers or infants on antiretroviral therapy during breastfeeding from 2009 to 
2013.29 The mother-child pairs are now seen together and this gives easier access for early infant 
diagnosis, scheduled immunisation, timely initiation of antiretroviral treatment, cotrimoxazole 
prophylaxis, etc.30 As shown by the findings of the meta-analysis and meta-regression, all these 
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interventions targeted at the women living with HIV and their children have not yielded significant 
differences in terms of vaccination coverage among this group. It is expected that level of DTP3 
coverage in HIV-exposed children would be significantly higher especially with frequent routine 
clinic visits and scheduled immunisations. However, the reality on the ground shows that the 
mothers and caregivers of HIV-exposed children are faced with various challenges such as poor 
socio-economic status, stigma, discrimination especially at community level, poor awareness of 
immunisation benefits and negative attitudes of healthcare workers.23,24,29,30 As is the case in the 
general population, low coverage of vaccination in HIV-exposed children could also be due to 
barriers that arise from the national healthcare system, healthcare providers and caregivers.31 
As of 2016, Nigeria, Central African Republic, Niger, Chad, South Sudan, the Democratic 
Republic of the Congo, Mozambique, Madagascar, Uganda, Kenya, Somalia and Ethiopia were 
among the seriously challenged countries that needed Global Alliance for Vaccines and 
Immunisation (GAVI) support to meet their national immunisation targets.32 The GVAP goal of 
achieving nationwide DTP3 vaccination coverage of at least 90% was not achieved in many of the 
included countries at the time of their surveys.10 Only Rwanda achieved DTP3 uptake of more 
than 90% for the children of both HIV-infected and uninfected mothers. At the time of their 
surveys, Angola, Chad, the Democratic Republic of the Congo, Gabon, Guinea and Ethiopia 
recorded less than 50% coverage either for one or both of the two groups. DTP3 coverage,  the 
proxy indicator of the performance of the national immunisation programmes, is relatively low in 
sub-Saharan Africa at 74% by the end of 2016.33 The disparity in vaccination coverage among 
African countries could be as a result of conflict, economic decline or climate-related pressures.32 
Efforts should be made to remove the barriers of vaccination uptake for the HIV-exposed and non-
exposed children.26,29 Implementing public-health interventions such as home visits to identify 
under-vaccinated or non-vaccinated children and regular immunisation outreach together with 
household incentives will help in improving the DTP3 coverage. Social determinants could help 
in transforming the DTP3 uptake irrespective of maternal HIV status by exploring the behavioural 
pattern of individuals and communities via well-structured interventions.34Interventions like the 
integration of immunisation activities into existing public healthcare programmes such as maternal 
and child health, antenatal care, PMTCT, antiretroviral treatment, HIV counselling and testing, 
and women-empowerment programmes will go a long way to improve DTP3 coverage.35 
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Improving DTP3 coverage among HIV-exposed and non-exposed children especially those living 
in the rural and urban poor areas requires a multidimensional collaboration.30,31 This entails 
vaccinating eligible children at every opportunity, address community stigma, mapping out low-
coverage areas, community mobilisation and referral for immunisation.30,36 
 
Limitations and strengths 
Conducting this meta-analysis permits the synthesis of findings and allows comparison across 
numerous studies.37 DHS being a nationally represented survey has many advantages over primary 
studies that are limited to geographical locations. This study has several limitations such as the 
non-inclusion of data from South Africa and Nigeria that are the two countries with the largest 
population of women living with HIV and HIV-infected children. The two countries were excluded 
due to the lack of a DHS HIV data set. As an ecological study with cross-sectional design and 
likeness of ecological fallacy, care must be taken in attributing the causal relationships detected in 
this research. 
 
Conclusions 
In conclusion, the findings from this study will be beneficial to the public healthcare system in 
terms of improving the vaccination coverage of HIV-exposed children in sub-Saharan Africa. The 
study indicates that there is no significant difference in the DTP3 coverage among infants 
concerning maternal HIV status in sub-Saharan Africa, however, there is a significant variation in 
terms of the estimates among the sub-Saharan African countries. The DTP3 coverage for both 
HIV-exposed children and non-exposed children is still below the required target. Improved 
PMTCT and maternal and child health services across the board might have contributed to the 
better uptake of DTP3 vaccination among the HIV-exposed children than the non-exposed 
children. There is also the need to address various barriers impeding successful uptake of 
vaccination among HIV-exposed and non-exposed children. Collaboration is required to improve 
vaccination coverage of HIV-exposed children and to reduce the risk of contracting vaccine-
preventable diseases. 
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CHAPTER 5: Non-uptake of childhood vaccination among 
the children of HIV-infected mothers in sub-Saharan Africa: 
A multilevel analysis 
 
Olatunji O. Adetokunboh, Olalekan A. Uthman and Charles S. Wiysonge 
 
Abstract 
The aim of this study was to develop and test models for non–uptake of three doses of diphtheria-
tetanus-pertussis containing vaccines (DTP3) among children of women living with HIV in sub-
Saharan Africa. The study used demographic and health survey data from 27 sub-Saharan African 
countries that have the required HIV and immunisation data sets. Multivariable logistic regression 
models were used to assess the relationship between individual and contextual factors associated with 
non-uptake of DTP3 among the children. At the individual level, the odds of non-uptake of DTP3 
decreased with formal education, increasing age and access to media. The full model shows that the 
odds of non-uptake of DTP3 are increased among unemployed women, those living in communities 
with high illiteracy rates and in countries with low adult literacy levels. For a child who moves to 
another country or community with a higher probability of DTP3 non-uptake, the median increase for 
the odds of DTP3 non-uptake would be 2.24% and 1.22% respectively for country and community. 
This study shows that individual and contextual factors contributed significantly to non-uptake of 
DTP3 among the children of women living with HIV. Interventions should be focused on women living 
with HIV who are young mothers, unemployed women, those without formal education, individuals 
living in communities with high illiteracy rates and in countries with low adult literacy rates. The use 
of mass-media tools and the creation of more employment opportunities for HIV-infected women 
could improve vaccination coverage amongst their children.  
Keywords: diphtheria-tetanus-pertussis; HIV; vaccine-preventable diseases; sub-Saharan Africa; 
demographic and health survey 
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Introduction 
Research studies have shown that routine vaccination coverage is inadequate in several African 
countries and unable to meet national targets for Global Vaccine Action Plan (GVAP).1–3 Sub-
Saharan Africa, which has high HIV prevalence, needs adequate vaccination coverage especially 
among the HIV-infected and HIV-exposed children because they are highly susceptible to severe 
forms of some vaccine-preventable diseases with a resultant increased risk of mortality.4,5 The 
children of HIV-infected mothers are at greater risk of mortality than non-exposed children 
because HIV-infected mothers may not take their children for vaccination as scheduled due to 
generalised weakness and non-availability of transport fees to get to the healthcare facilities.6,7 
Vaccination of both HIV-infected and uninfected children also plays a critical role in achieving 
Millennium Development Goal 4 which is targeted at reducing deaths in children under-five years 
of age.8 Sustainable Development Goal 3.8 is also connected to vaccination strategies especially 
the achievement of Universal Health Coverage via vaccines for all age groups.9 
Studies show that children born to HIV-infected mothers were less likely to receive all the basic 
vaccination according to schedule through the avoidance of community health facilities owing to 
stigma and discrimination.6,7,10 The association between maternal HIV status and childhood 
vaccination is of public-health significance in countries with high HIV prevalence. However, there 
is uncertainty and limited information on factors that influence the association between maternal 
HIV status and childhood vaccination coverage in sub-Saharan Africa.10 
It has been established that there is an association between maternal education and vaccine uptake, 
however, this varies across different regions and settings across the world.11 Studies have also 
shown that the odds of childhood vaccination are greater in children whose mothers had secondary 
or higher education.11,12 Poor socio-economic status and non-empowerment of women are 
important factors related to poor uptake of childhood vaccination.12 Immunisation coverage is low 
in urban poor and deprived neighbourhoods. These neighbourhoods usually also  have poor mother 
and child healthcare services, maternal illiteracy, poor household socio-economic status and 
gender inequality.13 
The per capita gross domestic product (GDP) is a key factor in the usage of vaccines in low-income 
countries that have high mortality rates due to vaccine-preventable diseases. It is expected that 
good vaccine uptake in these countries will be cost-effective on the long run and this depends 
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largely on the cost of the vaccination programme relative to GDP,14 Vaccination plays an important 
role in economic growth. It has an impact on a country’s healthcare with resultant reduction in 
mortality and morbidity, thereby contributing to the GDP.15 
Efforts such as WHO-UNICEF Global Immunization Vision and Strategy, GAVI Alliance 
Strategy, Global Vaccine Action Plan (GVAP) and Expanded Programme on Immunisation (EPI) 
were put in place to improve vaccination coverage sub-Saharan Africa and other parts of the world. 
GVAP Global Vaccine is a framework for achieving the delivery of universal access to 
immunisation.3 There is a dearth of information concerning interventions or programmes targeted 
at improving vaccination coverage specifically for HIV-infected and HIV-exposed uninfected 
children in Africa. Vaccination programmes target all children irrespective of their HIV status or 
that of their mothers although there are some specific recommendations for HIV-infected 
children.16 A multilevel study is specifically needed to evaluate the independent contributions of 
individual, community, and country-level factors to non-vaccination among the children of HIV-
infected women in sub-Saharan African countries.  
The aim of this study was to develop and test models for non-uptake of the third dose of diphtheria-
tetanus-pertussis containing vaccines (DTP3) among the children of HIV-infected mothers. DTP-
containing vaccines provide immunity against diphtheria, tetanus and pertussis. These three 
infectious diseases lead to significant morbidity and mortality in children especially in countries 
with poor vaccination coverage. The World Health Organization (WHO) recommends the uptake 
of three doses of primary vaccination of DTP-containing vaccines followed by three booster 
doses.16 
 
Methods 
 
Study design 
This study consisted of secondary data analyses of the cross-sectional population-based 
demographic health surveys (DHS) from 27 sub-Saharan African countries namely: Angola, 
Burkina Faso, Burundi, Cameroon, Chad, the Democratic Republic of the Congo, Cote d'Ivoire, 
Ethiopia, Gabon, The Gambia, Ghana, Guinea, Kenya, Lesotho, Liberia, Malawi, Mali, Namibia, 
Niger, Rwanda, Sao Tome and Principe, Senegal, Sierra Leone, Swaziland, Togo, Zambia and 
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Zimbabwe. Only 27 African countries with available DHS HIV and vaccination data sets were 
included in this study. 
 
Sampling technique 
The DHS were conducted in different African countries with focus on health, demographic, socio-
economic and environmental indicators from a representative sample of women and men in 
households across the included countries. The DHS sampling frame is made up of enumeration 
areas (clusters) established in each of these countries. A two-stage probabilistic sampling method 
was also used for survey cluster selection.  
 
Data collection 
Data were collected by the use of standardised questionnaires administered to various respondents 
by trained interviewers. The implementation of the surveys was spearheaded in each country by 
the National Ministry/Department of Health or other responsible agencies with technical assistance 
from MEASURE DHS, ICF International, Calverton, Maryland, USA.  Development partners such 
as the United States Agency for International Development (USAID), the Global Fund to Fight 
AIDS, Tuberculosis and Malaria (Global Fund), etc. provided some of the funds for the project. 
This study included countries that collected data on uptake of the three doses of diphtheria-tetanus-
pertussis containing vaccines (DTP3) as well as HIV voluntary counselling and testing in the 
participating women up to November 2017. 
   
The participating women were aged between 15 and 49 years and tested for HIV during the 
household survey with consent. Field staff with the required skills and experience were recruited 
to work as interviewers and were trained according to the DHS training procedures. The 
interviewers identified members of the household eligible for biomarker collection. The 
interviewers explained the purpose of the HIV testing to eligible respondents and assured them of 
confidentiality prior to the test.  HIV data were collected from eligible, consenting women after 
the completion of their individual interview. The interviewers collected finger-prick dried blood-
spot samples for laboratory HIV testing. The DHS data collection and analysis used a programme 
protocol specifically designed to include the outcomes like laboratory HIV test and other data 
attributed to each participating respondent. The women were asked detailed information on their 
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children’s vaccination history and vaccination cards were also checked to verify the mother’s 
claims.  
 
Ethical consideration  
The data used for this study were obtained from an existing DHS database. All the identifier 
information was removed so that the data cannot be traced to a particular individual. Each DHS 
was approved by the respective National Health Research Ethics Committees of the participating 
countries and Institutional Review Boards of the ICF International, Calverton and the Centers for 
Disease Control and Prevention, Atlanta, USA. 
 
Outcome variable 
The outcome is defined as a binary variable with the value of ‘1’ if there was no uptake of DTP3 
and ‘0’ if there was an uptake among children aged 12-23 months at any time before the survey as 
reported on their vaccination cards or by their mothers during interviews. The analysis is limited 
to the children of HIV-infected mothers. 
 
 
Determinant variables 
 
Individual-level factors 
The study included the following individual-level factors in the models: the child’s gender (male 
or female), the age of the mother in completed years (15 to 24, 25 to 34, 35 and above), educational 
status of the mother (no basic education, primary, secondary or higher), employment status of the 
mother (whether unemployed or employed), and wealth index (poorer, middle or richer).  
 
Community-level factors 
The following community-level factors were included in the model: neighbourhood poverty rate 
(percentage of households that are below 20% of the wealth index), illiteracy rate (the percentage 
of women without formal education within the community), unemployment rate (percentage of 
women unemployed in the community) and place of residence (either urban or rural). The rates 
were classified as low or high.  
Country-level factors 
The following country-level factors were included in the model: gross domestic product per capita, 
adult literacy rate and health expenditure per capita. These data were obtained from World Bank 
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Data.17 The country-level variables were also categorised into either low or high in order to assess 
nonlinear effects and for easy interpretation of results for policy decision making.  
 
Statistical analyses 
The statistical analyses were done with STATA 14.0 (Stata Statistical Software: Release 14. 
College Station, TX: StataCorp LP).18 The distribution of respondents was expressed as 
percentages. Pearson Chi-Square was used to assess the relationship between DTP3 uptake and 
various variables. Multivariable logistic regression models were used to analyse the association 
between individual and contextual factors associated with non-uptake of the third dose of DTP3 
vaccines among the children of women living with HIV. A three-level model for binary response 
reporting non-uptake of DTP3 vaccination among the children of women living with HIV (level 
1), in a particular community (level 2) and living in a particular country (level 3). Figure 1 shows 
the conceptual framework for the models at different levels. This framework will guide towards 
understanding the objectives of this study. 
 
The study used five models namely: 
First model: empty null model, an unconditional model without any explanatory variables. 
Second model: for only individual-level factors. 
Third model: for only community-level factors. 
Fourth model: for only country-level factors. 
Fifth model (Full model): that controlled for individual-, community- and country-level factors 
simultaneously. 
 
The fixed-effects (measure of association) results were reported as odds ratios (ORs) with their 
corresponding 95% credible intervals (CrIs). The random-effects (measures of variation) results 
such as variance, intra-cluster correlation (ICC), and median odds ratio (MOR) were also reported. 
The MLwinN software, version 3.01 was used for model fit analyses19,20 while Wald test21 was 
used to calculate the statistical significance of covariates. The significance tests were two-tailed 
and significance defined at the 5% α- level. 
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Figure 1: Conceptual framework showing the factors determining non-uptake of DTP3-containing 
vaccines by the children of HIV-infected mothers 
 
Results 
Sample characteristics 
Table 1 shows the summary of individual, community and country characteristics, and DTP3 
coverage among the children of HIV-infected mothers. A total of 5,537 children aged 12-23 
months, within 2841 communities and from 27 countries in sub-Saharan Africa were involved in 
this study. About one-fourth of the children of HIV-infected mothers did not receive DTP3 prior 
to the survey. The numbers of male and female children were fairly and evenly distributed. Table 
1 shows that there was an association between DTP3 uptake and variables such as age, level of 
education, employment status, access to media, wealth index and illiteracy rate. The table also 
shows that DTP3 vaccination is not significantly associated with years of survey. Country-level 
characteristics are shown in Table 2. The surveys were conducted between 2003 and 2016 in the 
included countries with the years 2013 and 2014 having five surveys each.  
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Measures of associations (fixed effects) 
Table 3 shows the results of different models. At the individual level, the odds of non-uptake of 
DTP3 decreased with formal education, increasing age and access to media. At community level, 
the odds of DTP3 non-uptake increased with being resident in communities with high illiteracy 
rates. The full model shows that the odds of the children of women living with HIV not receiving 
DTP3 vaccination increased with being unemployed, such that the children of unemployed women 
were 17% more likely not to take DTP3 (OR = 1.171, 95% CrI 1.012 to1.372). The odds of not 
completing the vaccination schedule decreased with older maternal age, such that children of 
women aged 35-49 years were 29% less likely to miss DTP3 compared to children of women aged 
15-24 years old (OR = 0.711, 95% CrI 0.584 to 0.856). Other factors that decreased the odds of 
not completing the vaccination schedule were formal education and access to media (Table 3).  
 
There was also a significant association between non-uptake of DTP3 and countries with low adult 
literacy rate (Table 3). Countries such as Burkina Faso, Chad, Cote d'Ivoire, Ethiopia, The Gambia, 
Guinea, Liberia, Mali, Niger, Senegal and Sierra Leone which are mainly West African countries 
are the ones with low adult literacy rate (Table 2). Women living with HIV in these countries are 
less likely to have their children vaccinated with DTP3. 
 
Measures of variations (random effects) 
In model 1 (unconditional model), there was a significant variation in the odds of non-vaccination 
with DTP3 of the children of HIV-infected mothers across the countries (σ2 = 0.852, 95% CrI 
0.457 to 1.503) and across the communities (σ2 = 0.002, 95% CrI 0.000- 0.004) (as shown in Table 
3). The intra-country and intra-community correlation coefficients show that 20.57% and 20.61% 
of the variance in odds of non-uptake of DTP3 are linked to country- and community-level factors 
respectively. The variance in odds of not being vaccinated with DTP3 was also attributable to the 
country- and community-level factors respectively. From the full model (Model 5), it is assumed 
that a child who moved to another country or community with a higher probability of DTP3 non-
uptake, the median increase in the odds of DTP3 non-uptake would be 2.24% and 1.22% 
respectively. 
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Table 1: Summary of characteristics at different levels and DTP3 uptake among children of HIV-infected mothers 
 DTP3 uptake 
Variables Sample size Percentage No*  Yes* p-value 
DTP3 non-uptake 1,350 24.4    
DTP3 uptake 4,187 75.6    
Years of survey      
2003-2010 1,230 22.2 275 (20.4) 955 (22.8) 0.061 
2010-2011 4,307 77.8 1,075 (79.6) 3,232 (77.2)  
Individual-level factors 
Gender      
Female 2,734 49.4 673 (49.8) 2,061 (49.2) 0.688 
Male 2,803 50.6 677 (50.2) 2,126 (50.8)  
Age (in years) 
15-24 1,352 24.4 355 (26.3) 997 (23.8) 0.003 
25-34 2,828 51.1 710 (52.6) 2,118 (50.6)  
35-49 1,357 24.5 285 (21.1) 1,072 (24.5)  
Education 
No education 855 15.4 315 (23.3) 540 (12.9) 0.000 
Primary 2,363 42.7 541 (40.1) 1,822 (43.5)  
Secondary+ 2,319 41.9 494 (36.6) 1,825 (43.6)  
Employment status 
Unemployed 2,093 37.8 552 (40.9) 1,541 (36.8) 0.007 
Employed 3,444 62.2 798 (59.1) 2,646 (63.2)  
Wealth index 
Poorer 1,514 27.3 397 (29.4) 1,117 (26.7) 0.000 
Middle 1,694 30.6 447 (33.1) 1,247 (29.8)  
Richer 2,329 42.1 492 (37.5) 1,823 (43.5)  
Access to media      
Nil 1,302 23.5 398 (29.5)      904 (21.6) 0.000 
Access to 1 outlet 1,697 30.7 418 (31.0) 1,279 (30.6)  
Access to 2 outlets 1,578 28.5 347 (25.7) 1,231 (29.4)  
Access to all outlets 960 17.3 187 (13.9) 773 (18.5)  
Community-level factors 
Place of residence 
Urban 2,477 44.7 603 (44.7) 1,874 (44.8) 0.953 
Rural 3,060 55.3 747 (55.3) 2,313 (55.2)  
Poverty rate 
Low  3,421 61.8 805 (59.6) 2,616 (62.5) 0.061 
High 2,116 38.2 545 (40.4) 1,571 (37.5)  
Unemployment rate 
Low 2,816 50.9   675 (50.0) 2,141 (51.1) 0.468 
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High 2,721 49.1 675 (50.0) 2,046 (48.9)  
Illiteracy rate 
Low 3,609 65.2 804 (59.6) 2,805 (67.0) 0.000 
High 1,928 34.8 546 (40.4) 1,382 (33.0)  
* The values for DTP3 uptake are absolute counts (percentage). 
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Table 2: Country-level characteristics of the 27 included countries  
Country Year of survey GDP per capita (US$) Adult literacy rate  
Health expenditure 
per capita (US $) 
 
Angola 2016 3110.8 66.0 179.4 
Burkina Faso 2010 649.7 34.6 35.2 
Burundi 2011 285.7 61.6 21.6 
Cameroon 2011 1032.6 71.3 58.7 
Chad 2015 664.3 22.3 37.1 
Congo DR 2014 444.5 77.0 19.1 
Cote d'Ivoire 2012 1526.2 43.9 88.4 
Ethiopia 2003 706.8 39.0 26.6 
Gabon 2012 7179.3 82.3 321.3 
The Gambia 2013 473.2 42.0 30.7 
Ghana 2014 1513.5 71.5 57.9 
Guinea 2012 508.1 32.0 37.3 
Kenya 2009 1455.4 78.7 77.7 
Lesotho 2014 998.1 76.6 105.1 
Liberia 2013 455.4 42.9 46.3 
Malawi 2016 300.8 62.1 29 
Mali 2013 780.5 33.1 47.8 
Namibia 2012 4140.5 88.3 499 
Niger 2013 363.2 15.5 24.4 
Rwanda 2015 702.8 68.3 52.5 
Sao T&P 2009 1756.1 90.1 165.6 
Senegal 2011 958.1 42.8 49.5 
Sierra Leone 2013 496 32.4 85.9 
Swaziland 2007 2775.2 83.1 247.9 
Togo 2014 578.5 63.8 33.9 
Zambia 2014 1178.4 83.0 85.9 
Zimbabwe 2015 1008.6 88.7 57.7 
 
Congo DR - Congo Democratic Republic, GDP: gross domestic product, Sao T&P: Sao Tome and Principe; US$: United States Dollars 
GDP - Low-income economies are defined as those with a GDP per capita of $1,025 or less; lower middle-income economies: $1,026 - $4,035; 
upper middle-income economies: $4,036 - $12,475;  Adult literacy rate – low: ≤ 50.0; high: ≥ 50.1; Health expenditure – low: ≤ 100.0; Average: 
≥ 100.1.                                                                                                                                                                                                                                     
(Source: World Bank, United Nations Development Programme) 
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Table 3: Factors associated with non-uptake of DTP3-containing vaccines by children of HIV-infected women 
identified by multilevel multivariate logistic-regression models 
 Model 1a Model 2b Model 3c Model 4d Model 5e 
 OR (95% Crl) OR (95% Crl) OR (95% Crl) OR (95% Crl) OR (95% Crl) 
Fixed-effect      
Individual-effect factors      
Male (vs female)  0.961 (0.844-1.095)   0.959 (0.838-1.091) 
Age (in completed years)      
15-24  1 (reference)   1 (reference) 
25-34  0.932 (0.793-1.089)   0.937 (0.793-1.087) 
35-49  0.699 (0.574-0.844)*   0.706 (0.575-0.849)* 
Wealth index      
Poorer  1 (reference)   1 (reference) 
Middle  1.094 (0.907-1.307)   1.055 (0.860-1.286) 
Richer  0.880 (0.718-1.076)   0.830 (0.639-1.069) 
Education      
No education  1 (reference)   1 (reference) 
Primary  0.700 (0.564- 0.860)*   0.768 (0.612-0.957)* 
Secondary+  0.656 (0.519-0.831)*   0.719 (0.566-0.927)* 
Not employment  1.149 (0.990-1.327)   1.172 (1.001-1.365)* 
Access to media  0.899 (0.828- 0.974)*   0.893 (0.826-0.962)* 
Community-level factors      
Rural (vs urban)   1.085 (0.903-1.288)  0.965 (0.795-1.182) 
High (vs low) poverty rate   0.999 (0.943-1.056)  0.965 (0.899-1.032) 
High (vs low) unemployment rate   0.992 (0.950-1.041)  0.980 (0.924-1.042) 
High (vs low) illiteracy rate   1.099 (1.050-1.152)*  1.052 (0.995-1.110) 
Country-level factors      
Middle (vs low) GDP     1.496 (0.531-2.920) 1.561 (0.585-3.046) 
High (vs low) Adult literacy rate    0.482 (0.207-1.139) 0.489 (0.230-0.936)* 
Average (vs low) Health 
expenditure 
   2.289 (0.665-6.258) 2.235 (0.570 -5.480) 
Random effects      
Country-level      
Variance (95 Crl) 0.852 (0.457-1.503) 0.785 (0.415-1.420) 0.826 (0.439-1.478) 0.732 (0.371- 1.371) 0.723 (0.364-1.347) 
ICC (%) 20.57  19.26 20.06 18.18 17.83 
MOR ((%, 95% Crl) 2.40  2.32 2.37 2.25 2.24 
Explained variation (%) Reference 7.90 3.10 14.20 15.20 
Community-level       
Variance (95 Crl) 0.002 (0.000- 0.004) 0.002 (0.001 to 0.003) 0.003 (0.001-0.005) 0.003 (0.001- 0.005) 0.042 (0.014-0.072) 
ICC (%) 20.61 19.30 20.12 18.24 18.87 
MOR ((%, 95% Crl) 1.04  1.04 1.05 1.05 1.22 
Explained variation (%) Reference -10.50 -68.70 -70.40 -2679.90 
Model fit statistics      
DIC 5641 5593 5629 5640 5584 
DIC - Deviance Information Criterion; ICC – intra-cluster correlation; MOR – median odds ratio; OR- odds ratio; CrI – credible interval. 
aModel 1 is a null model, baseline model without any determinant variable.        bModel 2 is additionally adjusted for individual-level factors. 
cModel 3 is additionally adjusted for community-level factors.                              dModel 4 is additionally adjusted for country-level factors. 
eModel 5 is additionally adjusted for individual-, community-, and country-level factors.   *: p < 0.05   
Stellenbosch University  https://scholar.sun.ac.za
109 
 
 
Discussion 
 
Main findings 
This study demonstrated that the individual, community and country contexts in which the children 
of HIV-infected mothers live are closely associated with non-uptake of DTP3. These factors are 
significant in explaining the variations in non-uptake of DTP3 in the children of HIV-infected 
mothers in the selected sub-Saharan African countries. Non-uptake of DTP3 is less likely in 
children of women living with HIV who were employed, within the age group 35-49 years, 
educated and with access to media. It could then be extrapolated that the children of HIV-infected 
women who were unemployed, younger, uneducated, and without access to media are more likely 
to miss out on DTP3 uptake. DTP3 non-uptake is also associated with the children of HIV-infected 
women living in communities with high illiteracy levels and in countries with low adult literacy 
rates. Some of these findings conform to an earlier South African study.22  
These findings show that the unemployed status of HIV-infected mothers contributes to their 
children being incompletely vaccinated. Unemployment at the individual level was not significant 
for non-vaccination but with other factors interplaying at the community and country levels, 
unemployment became a significant factor. The inability of the unemployed and poorer mothers 
to source funds for transport to health centres for scheduled vaccinations may be a vital reason for 
the non-uptake of the vaccines.23,24 Unemployment leads to poverty, and studies have shown that 
the more the poverty level of a household, the more likely it is that its children would be 
incompletely vaccinated.25 Lack of basic resources leads to poor health-seeking behaviour and 
deprivation of required immunisation, and subsequently being exposed to vaccine-preventable 
diseases.25 
The low likelihood of the younger HIV-infected mother, possibly having her first child, to take her 
child for vaccination may be as the result of lack of information concerning the importance of 
immunisation. Older women, having cared for many children, are likely to know the importance 
of immunisation.25,26 This study shows that education plays a major role in improving vaccination 
coverage. The probability of a child of an HIV-infected mother not taking DTP3 is reduced in 
women with any form of formal education compared to their uneducated counterparts. This gives 
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credence to similar studies on immunisation in the general population in some African countries.23-
25,27  Many of the countries that have low adult literacy rates are also among the countries that are 
in dire need of support by GAVI in order to meet their individual national immunisation targets.28 
All of this shows that literacy level has a significant impact on vaccination coverage and national 
immunisation programmes. Furthermore, our findings demonstrate the clustering effects of non-
uptake of vaccinations at community and country levels. This implies that HIV-exposed children 
from the same communities were inclined to have similar vaccination status and are subjected to 
similar contextual characteristics within the communities.29 
 
Policy implications 
There is a need for an evidence-based methodology to investigate why various immunisation 
programmes are not reaching the expected targets. Understanding the factors responsible for 
successful implementation of immunisation programmes among HIV-exposed children in sub-
Saharan Africa is crucial for policy making. Appropriate approaches are needed to tackle various 
identified gaps in immunisation programmes specifically among HIV-exposed children. Evidence-
based approaches are also needed to manage scarce resources needed for health interventions and 
disease prevention.30,31 The findings from this multilevel analysis show that mothers who were 
educated, older, employed and have access to media were less likely to have had their children 
vaccinated with DTP3. These findings also imply that lack of education, age, unemployment and, 
lack of access to media are significant contributory factors to the problem of non-uptake of life-
saving vaccines among the children of women living with of HIV in sub-Saharan Africa. Non-
uptake of DTP3 was also found to cluster within communities, thus escalating the risk of vaccine-
preventable diseases among HIV-exposed and infected children. 
Public-health interventions should be designed specifically for women living with HIV who are 
young mothers, unemployed and without formal education. The remedial interventions should also 
focus on HIV-infected women who are resident in communities with high illiteracy rates in Africa. 
Our findings show that access to media reduces non-uptake, therefore, intervention such as the use 
of mass media should be in place in the areas with need. The use of  multimedia interventions has 
been proven to be effective and useful for childhood immunisation programmes among sub-
Saharan African countries and could be adapted for HIV-exposed and infected children.32 The use 
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of interactive clinician-delivered communication tools have been found to improve mothers’ 
knowledge and understanding of good health.33  
Immunisation activities should be promoted among HIV-infected parents right from the time of 
the antenatal care and also integrated as part of broader prevention of mother-to-child HIV 
transmission programme.34 Interventions that provide parents, caregivers and other community 
members with information on the benefits of immunisation may improve childhood vaccination 
coverage in communities and countries.35,36 All these interventions should also be in place for 
people who are not HIV-infected as well. There should be renewed efforts to educate the girl child 
in Africa as it has been proven that being educated improves vaccination uptake. Special attention 
is needed in countries with high rates of illiteracy since this impacts negatively on vaccine uptake. 
Factors like wealth index, residency, gender and GDP were not associated with DTP3 non-uptake 
and therefore warrant lesser attention in terms of interventions and policy changes.   
 
Limitations and strengths of this study 
DHS are considered as very reliable source of population-health data in low- and middle-Income 
countries. DHS are large, nationally representative surveys involving every section/region of the 
included countries and with high response rates. The surveys are, however, subject to social 
desirability and recall bias.  As they are cross-sectional studies, the data cannot be used to assess 
causal relationships between the variables. The included surveys were conducted at different times 
across the countries within a 13-year timeframe, however, Table 1 shows that this did not impact 
negatively on the study findings.  
 
Conclusion                                                                                                                                                                  
This study shows that individual and contextual factors contributed significantly to non-uptake of 
DTP3 among the children of HIV-infected women across sub-Saharan Africa. Policy making 
regarding childhood vaccination and public-health interventions targeted at improving childhood 
immunisation uptake among HIV-exposed and HIV-infected children should incorporate all the 
contributory factors during the planning, designing and implementation. The interventions should 
be developed with focus on young mothers, unemployed women, those without formal education 
and those living in communities with high illiteracy rates. Particular attention should also be given 
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to women living with HIV who are residents of African countries with low adult literacy rates. The 
use of mass-media tools will help improve the mothers’ knowledge and understanding of 
immunisation good health. Efforts should also be made to create more employment opportunities 
for unemployed women living with HIV.  
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CHAPTER 6: Morbidity benefit conferred by childhood 
immunisation in relation to maternal HIV status: a meta-
analysis of demographic and health surveys 
 
Olatunji O. Adetokunboh, Olalekan A. Uthman and Charles S. Wiysonge 
 
Abstract 
The study determined the prevalence of acute respiratory infections and diarrhoea among sub-
Saharan African children. It also examined if there was any significant morbidity benefit conferred 
by three doses of diphtheria-tetanus-pertussis containing vaccines (DTP3) with respect to maternal 
HIV status. Data were obtained from the Demographic and Health Survey (DHS) program, United 
Nations Development Programs, the World Bank and Joint United Nations Programme on 
HIV/AIDS. Pooled odds ratio (OR) and 95% confidence intervals (CI) were calculated for the 
countries. Tests of heterogeneity, sensitivity analyses and meta-regression were also conducted. 
The prevalence of acute respiratory infections and diarrhoea were similar between the children 
that were vaccinated and those who were not vaccinated with DTP3. The pooled result shows that 
children who did not receive DTP3 were more likely to have symptoms of acute respiratory 
infections than children who had DTP3 (OR 1.09, 95% CI 1.02 to 1.17); with low heterogeneity 
across the countries. The combined result for diarrhoea shows that children who did not receive 
DTP3 were less likely to have episodes of diarrhoea than children who received DTP3 (OR 0.83, 
95% CI 0.74 to 0.92); with substantial heterogeneity across the countries. There was no difference 
between the estimates of DTP3 vaccinated and unvaccinated children of HIV-infected mothers 
with respect to symptoms of acute respiratory infections or episodes of diarrhoea. Tackling various 
causes and risk factors for respiratory-tract infections and diarrhoeal diseases should be a priority 
for various stakeholders in sub-Saharan Africa.  
Keywords: Acute respiratory infections; diarrhoea; HIV; sub-Saharan Africa; demographic and 
health surveys 
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Background 
 
There were 5.9 million deaths in children under-five worldwide in 2015 with half caused by 
vaccine-preventable diseases.1,2 Medical conditions such as pneumonia and diarrhoea were leading 
causes of death among children under-five in sub-Saharan Africa.1 Acute respiratory infections 
(such as pneumonia) and diarrhoeal diseases place a considerable burden on health services, 
including multiple hospital visits and admissions.3 Human immunodeficiency virus (HIV) 
infection is a leading cause of disease burden and years of life lost in sub-Saharan Africa.4,5 The 
region is home to 75% of global burden of HIV.6-8 Globally, in 2016, it was estimated that 2.1 
million children aged under 15 years were living with HIV with about 90% of these  in sub-Saharan 
Africa.7 HIV infection is a major contributor to under-five mortality in sub-Saharan Africa.7 It is 
also estimated that about 80% of people living with HIV will develop a respiratory infection at 
some time in the course of their disease.9,10 HIV-infected individuals also have an increased risk 
of diarrhoeal diseases.11,12 
The Integrated Global Action Plan for the Prevention and Control of Pneumonia and Diarrhoea 
(GAPPD) proposed vaccination as one of the key interventions against pneumonia and diarrhoea.13 
Vaccine use in Global Alliance for Vaccines and Immunisation (GAVI)-supported countries led 
to a drop in the child mortality rate from 76 to 63 deaths per 1,000 live births between 2010 and 
2015.14,15 In spite of the progress made in vaccination coverage in many African countries, there 
are still many unvaccinated and under-vaccinated children with the high possibility of the children, 
especially HIV-exposed children, dying from various vaccine-preventable diseases.16,17  
Most studies on acute respiratory infections and diarrhoeal diseases among HIV-exposed children 
do not take immunisation status into account.16,17 There is also a lack of information concerning 
morbidity differentials and benefits of immunisation among children with respect to HIV status. 
There is evidence that children of HIV-infected mothers are more susceptible to acute respiratory 
infections and diarrhoeal diseases in comparison to the HIV non-exposed children.15,16 However, 
this finding is from a few observational studies mainly conducted in Africa. There is need for a 
large study to resolve these competing conclusions, and the Demographic and Health Survey 
(DHS) is a good source of data to meet this need. This research determined the prevalence of 
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symptoms of acute respiratory infections and episodes of diarrhoea; and assessed if there was any 
significant morbidity benefit conferred by diphtheria-tetanus-pertussis (DTP3) vaccination among 
children in sub-Saharan Africa. This study also examined if maternal HIV status affects morbidity 
benefits of DTP3 uptake among sub-Saharan African children. Uptake of three doses of vaccines 
containing DTP3 by one year of age is considered to be a proxy for the immunisation status of 
children.18 
Methods 
 
Data sources 
Data sets were obtained from the DHS program,19 United Nations Development Programs,20 , the 
World Bank21 and Joint United Nations Programme on HIV/AIDS.4 The study countries were 
selected based on the availability of DHS data on childhood immunisation coverage; HIV testing; 
recent symptoms of acute respiratory infection and episodes of acute diarrhoea two weeks prior to 
the conduct of the surveys. The included countries were as follows: Angola, Burkina Faso, 
Burundi, Cameroon, Chad, the Democratic Republic of the Congo, Cote d'Ivoire, Ethiopia, Gabon, 
The Gambia, Ghana, Guinea, Kenya, Lesotho, Liberia, Malawi, Mali, Namibia, Niger, Rwanda, 
Sao Tome and Principe, Senegal, Sierra Leone, Swaziland, Togo, Zambia and Zimbabwe.  
 
Variables 
Main outcomes 
The main outcomes for this study were recent symptoms of acute respiratory infections or episodes 
of diarrhoea in DTP3 vaccinated children aged 12-23 months.  
Country-level factors 
The following country-level characteristics were included in this study: GDP per capita, adult 
literacy rate, human development index (HDI), health expenditure, coverage of pregnant women 
who received antiretroviral drugs during pregnancy, households using an improved water source, 
households with improved, non-shared toilet facilities and households with daily smoking in the 
household.20,22 The country-level variables were divided into low and high categories for better 
interpretation in relation to the policy formulation.  
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Data analysis 
The distribution of respondents were expressed as percentages. The Pearson's chi-squared test was 
used for analysing the contingency tables and multiple logistic regressions to examine variations 
across socio-economic factors. The DerSimonian-Laird method23 was used for the random-effects 
model and for the calculation of the pooled prevalence estimates. Higgin’s I2 statistics was used to 
describe the percentage of variation across studies.24,25 Leave-one-country-out sensitivity analysis 
was used to assess the stability of the meta-analysis.26 The level of statistical significance for the 
analyses was p < 0.05 with two-tailed comparisons. Statistical analyses were performed with Stata 
14.0.27 
 
Ethical considerations 
This study was conducted as a secondary data analysis. Ethics approval was given for the primary 
data by the Ethics Committee of the ICF International, Calverton, USA and National Ethics 
Committee of the included countries. The study participants gave consent before participation. The 
participant’s confidentiality was also protected and all the identifier information was removed. 
 
Results 
 
Description of included surveys 
This study used nationally-representative DHS conducted in 27 sub-Saharan African countries. 
These countries were included because their individual DHS has data sets on HIV status and 
vaccination.  
The included surveys were conducted between 2003 and 2016.   Table 1 shows the year of the 
survey, use of antiretroviral drugs during pregnancy, gross domestic product (GDP) per capita, 
HDI, adult literacy rate, percentage of households using an improved water source, percentage of 
households with improved non-shared toilet facilities, and percentage of households in which there 
is daily smoking. The GDP per capita ranged from $285.7 in Burundi to $7,179.3 in Gabon. The 
adult literacy rate ranged from 15.5% in Niger to 88.7% in Zimbabwe. HIV prevalence among 
women aged 15-49 years old ranged from 0.5% in Niger to 34.7% in Swaziland. The percentage 
of HIV-infected women who were pregnant and received antiretroviral drugs during pregnancy 
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varied from 35% in Mali to 96% in Namibia. The percentage of households using an improved 
water source varied from 5.8% in Sao Tome and Principe to 45.9% in Angola, while households 
with improved and non-shared toilet facilities varied from 6.6% in Chad to 54.1% in Rwanda.  
Table 2 shows the number of children who developed symptoms of acute respiratory infections 
and episodes of diarrhoea by DTP3 status in each country. The prevalence of acute respiratory 
infections among children who did not receive DTP3 varied between 6% in Angola and 79% in 
Burundi; and among children who received DTP3, it varied from 8% in Angola to 79% in Burundi. 
The combined prevalence of symptoms of acute respiratory infections in the 27 countries was 
37.2% (4,523 / 12,158) among children who did not receive DTP3, and 37.4% (8,153 / 21,801) 
among children who received DTP3. The prevalence of episodes of diarrhoea ranged from 5% in 
Rwanda to 26% in Liberia among children who did not receive DTP3, and from 9% in Mali to 
29% in Malawi among children who received DTP3. The combined prevalence of diarrhoea was 
16.0% (6,808 / 42,592) among children who did not receive DTP3 and 17.3% (12,845 / 74,188) 
among children who received DTP3.   
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 GDP: gross domestic product, HDI: human development index, n/a: not available) 
GDP - Low-income economies are defined as those with a GDP per capita of $1,025 or less; lower middle-income economies: $1,026 - $4,035; upper middle-income economies: $4,036 - $12,475; 
 high-income economies: ≥ $12,476. HDI - low: <0.549; medium: 0.550 – 0.770. 
(Source: Demographic and Health Surveys, World Bank, Joint United Nations Programme on HIV/AIDS, United Nations Development Program
 
 
 
 
 
 
Table 1: Year of DHS survey and socio-economic characteristics of 27 study countries in sub-Saharan Africa 
Country 
Year of 
survey 
GDP per 
capita  HDI 
Adult 
literacy 
rate  
Health 
expenditure  
Antiretroviral 
drug coverage 
during PMTCT 
HIV 
prevalence 
(adult 
female) 
Households using 
an improved water 
source 
Households 
with 
improved, 
non-shared 
toilet facilities 
Households 
with smoking 
in the 
household 
daily 
Angola 2016 3110.8 0.533 66 179.4 44 2.2 45.9 32.2 13.1 
Burkina Faso 2010 649.7 0.402 34.6 35.2 83 1.1 23 15.2 n/a 
Burundi 2011 285.7 0.404 61.6 21.6 84 1.3 23.4 31.4 27.3 
Cameroon 2011 1032.6 0.518 71.3 58.7 74 5.1 28.4 35.9 n/a 
Chad 2015 664.3 0.396 22.3 37.1 63 1.6 44.5 6.6 12.8 
Congo DR 2014 444.5 0.435 77 19.1 70 1 51 18.4 23 
Cote d'Ivoire 2012 1526.2 0.474 43.9 88.4 73 3.5 20.9 18 21.8 
Ethiopia 2003 706.8 0.448 39 26.6 69 1.3 38.4 6.8 7.1 
Gabon 2012 7179.3 0.697 82.3 321.3 76 5.3 6.2 33.7 20.2 
The Gambia 2013 473.2 0.452 42 30.7 69 2 8.1 37 24 
Ghana 2014 1513.5 0.579 71.5 57.9 56 2.1 10.2 13.6 9.3 
Guinea 2012 508.1 0.414 32 37.3 43 1.9 25.1 19 22.8 
Kenya 2009 1455.4 0.555 78.7 77.7 80 6.9 35.5 22.7 n/a 
Lesotho 2014 998.1 0.497 76.6 105.1 66 29.8 16.4 47.1 16.3 
Liberia 2013 455.4 0.427 42.9 46.3 70 2 27.3 14.2 12.7 
Malawi 2016 300.8 0.476 62.1 29 84 11.2 12.7 51.8 12.1 
Mali 2013 780.5 0.442 33.1 47.8 35 1.2 34 22 17.1 
Namibia 2012 4140.5 0.64 88.3 499 96 16.6 10.4 33.5 n/a 
Niger 2013 363.2 0.353 15.5 24.4 52 0.5 32.9 9.3 n/a 
Rwanda 2015 702.8 0.498 68.3 52.5 82 3.8 27 54.1 14.6 
Sao T&P 2009 1756.1 0.574 90.1 165.6 n/a 
                   
n/a 5.8 30.4 n/a 
Senegal 2011 958.1 0.494 42.8 49.5 55 0.6 19.5 41.1 28.6 
Sierra Leone 2013 496 0.42 32.4 85.9 87 2 39.1 9.6 37.6 
Swaziland 2007 2775.2 0.541 83.1 247.9 95 34.7 29.9 9.3 n/a 
Togo 2014 578.5 0.487 63.8 33.9 86 2.7 35.8 12.2 13.5 
Zambia 2014 1178.4 0.579 83 85.9 83 14.5 34.5 25.4 n/a 
Zimbabwe 2015 1008.6 0.516 88.7 57.7 93 16.1 21.8 37 10.8 
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Table 2: Number of cases and percentages of symptoms of acute respiratory infections and episodes of diarrhoea among 
the children with respect to DTP3 vaccination in 27 countries in sub-Saharan Africa 
 
 
 
Table 3 shows the number of cases of acute respiratory infections and episodes of diarrhoea among 
children who received DTP3, grouped by the HIV status of their mothers. Among the children who 
received DTP3, the prevalence of symptoms of acute respiratory infections varied between 9% in 
Mali and 24% in Zimbabwe for children of HIV-uninfected mothers; and between 4% in Ethiopia 
 Symptoms of acute respiratory 
infections Episodes of diarrhea 
 DTP3 non-uptake DTP3 uptake DTP3 non-uptake DTP3 uptake 
Country No of cases Percent 
(%) 
No of cases Percent 
(%) 
No of cases Percent 
(%) 
No of cases Percent 
(%) 
Angola 164 6 92 8 
417 16 264 23 
Burkina Faso 60 47 231 40 175 13 865 16 
Burundi 133 79 908 79 
85 20 812 26 
Cameroon 267 56 470 45 
329 20 559 18 
Chad 381 58 154 57 759 19 274 19 
Congo DR 566 42 513 37 765 18 685 16 
Cote d'Ivoire 132 49 163 41 
260 19 361 19 
Ethiopia 786 60 417 59 
1069 16 492 14 
Gabon 344 42 206 40 
431 19 202 16 
The Gambia 65 71 236 62 
133 17 513 19 
Ghana 32 49 149 47 
40 6 293 14 
Guinea 259 68 168 61 
314 17 229 16 
Kenya 88 49 258 50 
123 18 323 17 
Lesotho 16 27 117 36 
25 9 137 12 
Liberia 205 48 256 49 
374 26 427 23 
Malawi 60 11 354 14 
80 15 762 29 
Mali 57 45 92 41 
153 7 249 9 
Namibia 153 51 198 44 
281 13 478 15 
Niger 46 39 210 43 
63 15 328 20 
Rwanda 20 38 382 42 
14 5 424 12 
Sao T&P 30 57 175 53 40 13 184 13 
Senegal 115 65 366 60 
213 21 603 20 
Sierra Leone 176 66 437 62 137 10 410 12 
Swaziland 45 54 308 54 
41 12 287 15 
Togo 103 54 373 53 
102 14 431 17 
Zambia 151 33 680 30 
272 12 1679 18 
Zimbabwe 69 9 240 10 113 15 574 24 
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and 30% in Chad for children of HIV-infected mothers. The combined prevalence of acute 
respiratory infections among children who received DTP3 was 38.0% (7,726 / 20,320) for children 
born of HIV-uninfected mothers and 28.8% (427/ 1481) for children of women living with HIV. 
 
Regarding episodes of diarrhoea among children who received DTP3, the prevalence varied 
between 8% in Angola and 79% in Burundi in children of HIV-uninfected mothers; and between 
0% in Namibia and 73% in Sierra Leone among the children of HIV-infected mothers. The 
combined prevalence of diarrhoea among children who received DTP3 was 17.4% (12,184 / 
70,161) for children born of HIV-uninfected mothers and 16.4% (661 / 4,027) for children of 
mothers living with HIV. 
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Table 3: Number of cases and percentages of symptoms of acute respiratory infections and episodes of diarrhoea among 
the children with uptake of DTP3 and maternal HIV status in 27 countries in sub-Saharan Africa 
 
Symptoms of acute respiratory 
infections Episodes of diarrhea 
 HIV-uninfected HIV-infected HIV-uninfected HIV-infected 
Country 
No of 
cases 
Percent 
(%) 
No of 
cases 
Percent 
(%) 
No of 
cases 
Percent 
(%) 
No of 
cases 
Percent 
(%) 
Angola 258 23 6 29 91 8 1 5 
Burkina Faso 857 16 8 16 228 40 3 50 
Burundi 789 26 23 30 887 79 21 70 
Cameroon 536 18 23 16 451 45 19 46 
Chad 266 19 8 30 150 58 4 50 
Congo DR 681 16 4 11 507 37 6 33 
Cote d'Ivoire 355 19 6 10 160 42 3 30 
Ethiopia 489 14 3 4 413 59 4 33 
Gabon 198 16 4 8 198 40 8 36 
Gambia 505 19 8 20 233 63 3 60 
Ghana 290 14 3 7 144 47 5 50 
Guinea 222 16 7 29 164 61 4 57 
Kenya 291 17 32 22 237 50 21 51 
Lesotho 105 13 32 11 92 36 25 36 
Liberia 425 23 2 10 254 49 2 33 
Malawi 712 30 50 25 330 14 24 12 
Mali 246 9 3 11 90 41 2 40 
Namibia 476 15 2 12 198 44 0 0 
Niger 271 20 57 21 172 43 38 44 
Rwanda 412 12 12 10 370 42 12 48 
Sao T&P 183 13 1 8 175 53 n/a n/a 
Senegal 602 20 1 5 365 60 1 33 
Sierra Leone 407 12 3 7 429 62 8 73 
Swaziland 200 16 87 14 205 54 103 55 
Togo 421 17 10 17 363 54 10 44 
Zambia 1,485 18 194 17 608 30 72 27 
Zimbabwe 502 24 72 20 212 10 28 8 
 
 
 
Association between DTP3 status and acute respiratory infections or diarrhoea 
Figures 1 and 2 are forest plots of meta-analyses of the association between DTP3 status and acute 
respiratory infections or diarrhoea in each country at the time of the surveys. The combined result 
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shows that children who did not receive DTP3 were more likely to have symptoms of acute 
respiratory infections than children who had DTP3: odds ratio (OR) 1.09, 95% confidence interval 
(CI) 1.02 to 1.17). There was low heterogeneity in results across countries (I2 = 32.6%) (Figure 1). 
 
 
Figure 1: Forest plot showing the prevalence of estimates of symptoms of acute respiratory infections among 
the children with respect to DTP3 vaccination in 27 sub-Saharan Africa countries  
 
The combined result for diarrhoea shows that children who did not receive DTP3 were less likely 
to have episodes of diarrhoea at the time of the survey than children who received DTP3 (OR 0.83, 
95% CI 0.74 to 0.92); with substantial heterogeneity in results across countries (I2 = 88.3%) 
(Figure 2). 
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Figure 2: Forest plot showing the prevalence of estimates of episodes of diarrhoea among the children with 
respect to DTP3 vaccination in 27 sub-Saharan Africa countries 
 
Figure 3 shows estimates of the association between receipt of DTP3 and presence of symptoms 
of acute respiratory infections among the children of HIV-infected mothers in each country at the 
time of the survey. The pooled result shows no significant difference in the odds of having 
symptoms of acute respiratory infections between children who did not receive and those who 
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received DTP3 (OR 0.99, 95% CI 0.74 to 1.32), with low heterogeneity across countries (I2 = 
0.0%). Only 19 countries were included in this analysis. 
 
 
Figure 3: Forest plot showing the prevalence of estimates of symptoms of acute respiratory infections among 
the children of HIV-infected mothers with respect to DTP3 vaccination in selected sub-Saharan Africa 
countries 
 
 
Figure 4 shows estimates of the association between receipt of DTP3 and episodes of diarrhoea 
among the children of HIV-infected mothers at the time of the survey in each country. The 
combined result shows no difference in the occurrence of episodes of diarrhoea between children 
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who did not receive DTP3 and those who received DTP3 (OR 0.85, 95% CI 0.62 to 1.07), with 
low heterogeneity across countries (I2 = 11.1%). Only 24 countries were included in this analysis. 
 
 
 
Figure 4: Forest plot showing the prevalence of estimates of episodes of diarrhoea among the children of HIV-
infected mothers with respect to DTP3 vaccination in selected sub-Saharan Africa countries 
 
When we combined the data for the prevalence of symptoms of acute respiratory infections across 
the study countries, there was no significant difference between the children of HIV-uninfected 
mothers who were vaccinated with DTP3 and those of mothers living with HIV (OR 1.04, 95% CI 
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0.86 to 1.26); with low heterogeneity across countries (I2 = 0.0%) (Figure 5). Similarly, there was 
no difference in the combined prevalence of episodes of diarrhoea between the children of HIV-
uninfected mothers who were vaccinated with DTP3 and those of mothers living with HIV (OR 
0.90; 95% CI 0.80 to 1.01); with low heterogeneity in results among countries (I2 = 18.4%) (Figure 
6). 
 
 
 
 
Figure 5: Forest plot showing the prevalence of  estimates of symptoms of acute respiratory infections among 
the children who were vaccinated with DTP3 with respect to the maternal HIV status in 27 sub-Saharan Africa 
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countries 
 
 
 
 
 Figure 6:Forest plot showing the prevalence of estimates of episodes of diarrhoea among the children who were 
vaccinated with DTP3 with respect to the maternal HIV status in 26 sub-Saharan Africa countries 
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Leave-one-country-out sensitivity analyses show that no country had an undue influence on the 
pooled estimate of episodes of acute respiratory infections and diarrhoea (Figures 7 and 8). The 
variations in the CIs with the exclusion of each country remains within the 95% confidence interval 
for the overall estimates. The stability of the overall results for both episodes of acute respiratory 
infections and diarrhoea was justified by the outcome of the sensitivity analyses. 
 
 
 
 
 
Figure 7: A plot showing the influence of each country on the overall pooled result for estimates of acute 
respiratory infections using ’leave-one-country-out’ sensitivity analysis 
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Figure 8: A plot showing the influence of each country on the overall pooled result for estimates of diarrhoea 
using ’leave-one-country-out’ sensitivity analysis 
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Sub-group analyses 
In order to assess the effect of various country-level characteristics on the pooled estimates, 
subgroup analyses were conducted using the DerSimonian-Laird method. Results from the 
subgroup analyses show that the differences between countries in HDI, GDP, adult literacy rate, 
years of survey, sub-regions (West Africa, Central/East Africa, Southern Africa), households using 
an improved water source, and households with improved non-shared toilet facilities did not 
explain the heterogeneity of estimates of episodes of diarrhoea among the children (Table 4). 
 
 
Meta-regression analysis  
Meta-regression analyses were conducted to investigate which country-level characteristics might 
account for the heterogeneity in the association between receipt of DTP3 and prevalence of 
diarrhoea (Figure 2). Table 4 shows that year of the survey was a significant predictor of the 
association between DTP3 uptake and diarrhoea. HDI, GDP, adult literacy rate, sub-regions, 
households using an improved water source, and households with improved non-shared toilet 
facilities were not significantly associated with the episodes of diarrhoea in children vaccinated 
with DTP3 (Table 4). 
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Table 4: Subgroup analysis and the univariate meta-regression analysis results (for diarrhoea)
Characteristics No of 
studies 
Subgroup  
odds ratio 
95% CI I-squared P-value* Univariate meta-regression 
 #β (p-value)* 95% CI 
Year of survey      0.95 (0.009) 0.91,0.99 
2003-2007 2 0.98 0.61, 1.57 85.2 0.000   
2008-2012 10 0.97 0.87, 1.09 70.0 0.000   
2013-2016 15 0.72 0.61, 0.85 90.1 0.000   
Gross domestic product per capita 
(US$) 
     0.98 (0.862) 0.75, 1.28 
Low 18 0.84 0.73, 0.95 87.8 0.000   
Middle 9 0.83 0.67, 0.99 88.1 0.000   
Human development index      1.01 (0.950) 0.74, 1.37 
Low 21 0.83 0.73, 0.93 87.6 0.000   
Medium 6 0.83 0.62, 1.09 90.7 0.000   
Adult literacy rate       1.00 (0.273) 0.99, 1.00 
Low 11 0.95 0.85, 1.06 77.4 0.000   
Average 9 0.70 0.54, 0.90 86.8 0.000   
High 7 0.80 0.64, 1.02 92.4 0.000   
Households using an improved 
water source 
     1.12 (0.356) 0.87, 1.44 
Low 12 0.77 0.65, 0.92 87.1 0.000   
Medium 15 0.87 0.76, 1.00 88.8 0.000   
Households with improved, non-
shared toilet facilities 
     0.85 (0.195) 0.67, 1.09 
Low 14 0.90 0.80, 1.02 82.9 0.000   
Medium 13 0.76 0.63, 0.91 89.5 0.000   
Regions      0.88 (0.073) 0.76, 1.01 
Western Africa 13 0.88 0.78, 0.99 76.9 0.000   
Central/Eastern Africa 7 1.00 0.85, 1.17 82.5 0.000   
Southern Africa 7 0.64 0.54, 0.75 75.5 0.000   
 
* p < 0.05                       #β- Beta coefficient          
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Discussion 
This research illustrates that DTP vaccination had some benefit in terms of reduced odds of 
developing acute respiratory infections but not for diarrhoeal episodes among children in sub-
Saharan Africa. We found no significant difference in the estimates of having symptoms of acute 
respiratory infections and episodes of diarrhoea among the DTP3 vaccinated children of HIV-
infected mothers and HIV-uninfected mothers. Morbidity benefit in terms of acute respiratory 
infections and diarrhoea varied across sub-Saharan African countries. The prevalence of acute 
respiratory infections was higher among the vaccinated children of HIV-uninfected mothers than 
the children of HIV-infected mothers. The children of HIV-uninfected women also had more 
episodes of diarrhoea than the vaccinated children of women living with HIV.  
This research contrasts with the findings of a Malawian study among HIV-infected, HIV-exposed 
uninfected and HIV-unexposed children which showed morbidity benefit for both diarrhoea and 
respiratory infection among the children of HIV-uninfected mothers.17 A cohort study of a 
Congolese birth cohort of 429 infants born to HIV-infected and HIV-uninfected mothers shows 
that two-thirds of the infant had at least one episode of acute diarrhoea within the 16-month study 
period.28 The study showed that HIV-infected children had diarrhoea incidence of 170 episodes 
per 100 child-years while the uninfected infants had 100 per 100 child-years.28 However, both 
HIV-exposed uninfected children and the infants of HIV-uninfected mothers had similar overall 
diarrhoeal incidence rates.28 Findings from a South African study among breastfed infants revealed 
that there were more cases of severe infectious morbidity among HIV-exposed infants than the 
HIV-uninfected infants who were breastfed.29 However, there was no significant difference 
between the HIV-exposed and HIV-uninfected infants with respect to infectious causes leading to 
hospitalisation or mortality at six months of life.29 It should be noted that unlike the respondents 
of this particular study who were all vaccinated with DTP3, the participants of the Congolese and 
South African studies had varying coverage of vaccination.28,29 
Meta-regression analyses were conducted to assess the relationship between various covariates 
and the dependent variables. The meta-regression analytic findings for episodes of diarrhoea were 
not significant for the country-level characteristics except for the year of the survey. The included 
surveys were conducted over a decade and the long span of time between the surveys could explain 
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the significant heterogeneity finding of the meta-analysis for the estimates of episodes of diarrhoea 
among sub-Saharan African children. The meta-regression findings show that the year of survey 
is an important predictor of episodes of diarrhoea as it relates to uptake of DTP3. There have been 
progressive changes in terms of healthcare coverage, introduction of newer vaccines, etc. in 
different countries over the years and this could well explain the widely varying changes in 
episodes of diarrhoea over the years. 
 
Vaccination against vaccine-preventable diseases is not the only factor linked to the occurrence of 
diarrhoea and respiratory infections. The state of health care infrastructure and lack of resources 
could be one of the reasons for the huge differences in the prevalence of acute respiratory diseases 
and diarrhoea among the African countries. Improved water supply is linked to reduction in 
episodes of diarrhoea.30 It has been proven that households with improved water supply could 
reduce incidence of diarrhoea among under-five children in sub-Saharan Africa.30 The use of pipe-
borne water supply within a private household or yard is a major source of improved water supply. 
Other improved drinking water sources are public water taps, protected deep wells, boreholes, 
collected rainwater and protected springs.31 Diarrhoeal diseases could be reduced by 11% if the 
users of unimproved water sources switched to improved water sources and by 23% if switched to 
private household piped water.32 The use of water treatment such as boiling, filtration and proper 
storage could reduce diarrhoea by 45%.32 Consistent handwashing with soap could reduce the risk 
of diarrhoeal disease by at least 48%.33 Moderate-severe diarrhoea is also reduced by the use of 
private household toilet in comparison to sharing with other households.34 
 
Smoking is a major risk factor for respiratory tract infections secondary to bacterial and fungal 
agents. There is an increased risk of respiratory tract infections due to both active and passive 
smoke exposures. There are strong links between smoking and serious respiratory infections such 
as invasive pneumococcal disease, influenza and tuberculosis.35 Indoor air pollution particularly 
from the use of household biomass fuels is linked to respiratory tract infections and is a 
contributory factor to these infections in children.36 
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Policy implications 
Implementation of GAPPD is essential in ending preventable childhood deaths due to pneumonia 
and diarrhoea by 2025.13  Tackling various causes and risk factors for respiratory-tract infections 
and diarrhoeal diseases should be a priority for various stakeholders in sub-Saharan Africa. There 
is need for the introduction and scaling up of the use of newer vaccines such as Haemophilus 
influenzae type B, pneumococcus, and rotavirus vaccines especially in African countries that are 
yet to include them in their national immunisation programmes. Rotavirus is the most common 
cause of severe and fatal diarrhoea in children while Streptococcus pneumonia and Haemophilus 
influenzae cause pneumonia, meningitis, otitis media, sinusitis, etc. in children.37,38  The inclusion 
of these newer vaccines will further reduce the incidence of diarrhoea and pneumonia. African 
government officials, policy makers, developmental agencies and healthcare workers should 
ensure the availability and easy access to routine licensed vaccines. The health systems in some 
African countries are very weak and need to be strengthened with efforts channelled towards 
improving low vaccination coverage.14,39 In addition to ensuring optimal immunisation 
programming, there is also need to promote other strategies such as vitamin-A supplementation, 
use of zinc supplements, the prevention of low birth weight, breastfeeding, personal hygiene and 
weaning education.40 
 
Investing in various methods of effective household water treatment in combination with proper 
safe water storage can lead to substantial reductions in cases of diarrhoeal diseases. The provision 
and use of improved toilet facilities in households can also lead to further reduction in diarrhoea 
among African children. Prevalence of handwashing is very low in most low- and middle-income 
countries which are also the countries with the highest levels of pneumonia and diarrhoea. There 
is also need to reduce household air pollution with the provision and use of improved stoves which 
has been shown to reduce severe pneumonia.13 
 
Strengths and limitations 
This study used DHS data which are based on countrywide surveys and therefore have advantages 
over primary studies which are limited to just a few communities. The meta-analyses permitted the 
synthesis of different findings across countries and gave room for assessment across various 
surveys.41 DHS provides a good source for large maternal HIV and child immunisation data sets 
and the ability to merge mother and child data. 
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The use of rotavirus and pneumococcal vaccination data would have provided some additional 
information with respect to incidence of diarrhoea and pneumonia. However, the majority of the 
DHSs did not include these newer vaccines as, at the time of the DHS, most countries had not 
adopted the vaccines as part of the national immunisation programmes. The use of DTP3 is 
expected to reflect the national vaccination coverage since it is the benchmark for the national 
programme. However, one of the reasons for lack of significant association of DTP3 with reduced 
acute respiratory infections and diarrhoea could be that the immunisation programmes have 
expanded, and DTP3 may not be an accurate indicator for protection against vaccine-preventable 
diseases, e.g. diarrhoea, respiratory infections, measles, etc. thus the need for more indicators for 
childhood immunisation.  
As this study is an ecological study with cross-sectional design, care must be taken in crediting 
detected causal relationship directly to this study. This study was limited by the non-availability 
of data on children’s HIV status and had to use maternal HIV as a reference for the children’s HIV 
status. The surveys were conducted over a decade and this is likely to have some influence on the 
study findings. Three of the meta-analyses did not include all the 27 study countries due to non-
availability of data sets on episodes of diarrhoea and symptoms of acute respiratory infections 
especially in children of women living with HIV.  
  
Conclusions 
In conclusion, the prevalence of acute respiratory infections and diarrhoea were similar between 
the children who were vaccinated and those who were not vaccinated with DTP3. Both the 
symptoms of acute respiratory infections and episodes of diarrhoea among DTP3 vaccinated and 
unvaccinated children shows significant differences in the overall estimates between the two 
groups of children. The data for symptoms of acute respiratory infections were pooled together 
with no statistical difference in the overall estimates between the children of HIV-infected mothers 
that were vaccinated with DTP3 and those who were not vaccinated. The data for episodes of 
diarrhoea were pooled together with resultant nil significant difference in the overall estimates 
between the children of HIV-infected mothers who were vaccinated with DTP3 and the ones who 
were not vaccinated. There was no significant difference in the overall estimates between the 
children of HIV-uninfected mothers who were vaccinated with DTP3 and those of mothers living 
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with HIV with respect to the prevalence of symptoms of acute respiratory infections and episodes 
of diarrhoea across the study countries. Many African countries recorded high rates of respiratory 
infections and diarrhoeal diseases. Extra efforts should be targeted at tackling various causes and 
risk factors for respiratory-tract infections and diarrhoeal diseases especially among HIV-exposed 
children in sub-Saharan Africa.  
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CHAPTER 7: Non-specific effects of childhood vaccines on 
acute childhood morbidity among HIV-exposed children in 
sub-Saharan Africa: a multilevel analysis 
 
Olatunji O. Adetokunboh, Olalekan A. Uthman and Charles S. Wiysonge 
 
Abstract 
We examined the roles of determining factors responsible for acute respiratory infections and 
diarrhoea among immunised human immunodeficiency virus (HIV)-exposed children in sub-
Saharan Africa. This study used demographic and health surveys obtained from 27 sub-Saharan 
African countries. The outcome variable is defined as symptoms of acute respiratory infections or 
episodes of diarrhoea in the child of an HIV-infected mother who is vaccinated with the third dose 
of diphtheria-tetanus-pertussis containing vaccines. Multivariable logistic regression models were 
used to analyse the association between individual and contextual factors. The odds of developing 
symptoms of acute respiratory infections increased among those living in communities with high 
unemployment rates (Odds ratio = 1.15, 95% credible interval 1.05 to 1.26). The odds of 
developing diarrhoea increased among young mothers such that children of women aged 15-24 
years were two times more likely to develop diarrhoea compared to children of women aged 35-
49 years (Odds ratio = 2.22, 95% credible interval 1.66 to 2.93). Public healthcare programmes 
should target adolescent and young women, and their family members on how to prevent 
diarrhoea. Efforts should be made to identify the hotspots for the development of acute respiratory 
diseases especially in communities with high rates of unemployment and to develop strategies to 
combat the diseases in such communities. Initiatives such as the integrated Global Action Plan for 
the Prevention and Control of Pneumonia and Diarrhoea which recommends an interrelated 
approach for the elimination of preventable diarrhoea and pneumonia deaths should be adopted. 
Keywords: Acute respiratory infections; diarrhoea; HIV; sub-Saharan Africa; demographic and 
health surveys; multilevel analysis. 
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Background 
 
Acute diarrhoea disease and pneumonia are major causes of morbidity and mortality among 
children especially among the human immunodeficiency virus (HIV)-exposed and infected ones.1 
Acute respiratory infections and diarrhoeal diseases are vaccine-preventable diseases and are 
avoidable if children are properly immunised.1,2 In addition to diarrhoea and pneumonia, HIV still 
contributes substantially to child mortality especially in Africa and South East Asia which  are the 
regions with the highest burden of HIV.3,4  
Immunisation programmes have proven to be a successful and cost-effective global public health 
interventions.5,6 The Expanded Programme on Immunization (EPI) has led to considerable 
declines in the morbidity and mortality attributed to vaccine-preventable diseases.7 Global 
Alliance for Vaccines and Immunisation (GAVI) initiatives have been recording reductions in 
childhood morbidity and mortality due to vaccine-preventable diseases among supported countries 
primarily as a result of vaccines use.2 More disease and death could be averted if there is an 
improvement in the global vaccination coverage.2 Africa accounts for a substantial proportion of 
the global vaccine-preventable diseases burden and for the highest proportion of under-five 
mortality from these diseases.8,9 Meanwhile, only 74% of the World Health Organization (WHO) 
African member states achieved ≥ 90% national coverage for the three doses of diphtheria-tetanus-
pertussis vaccines (DTP3) by 2016.2  
Understanding the association between HIV status, uptake of childhood vaccination, acute 
respiratory infections and diarrhoeal diseases is of great importance in countries with high HIV 
prevalence especially in the sub-Saharan African region.  Despite the high prevalence of HIV in 
many African countries, HIV testing is still not optimal. Knowledge of status among people living 
with HIV ranged between 29-87%. There is lack of information on socio-economic factors such 
as employment status, education status, mother’s age, wealth index and residence which are the 
likely determinants of morbidities like acute respiratory infections, diarrhoeal diseases, fever, etc. 
among the immunised children of HIV-infected mothers. Adequate knowledge of these 
determining factors is crucial in making recommendations concerning public-health interventions 
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for the prevention of acute respiratory infections and diarrhoeal diseases among immunised and 
HIV-exposed children. 
We examined the roles of the socio-economic factors in relation to uptake of DTP3 vaccines 
among HIV-exposed children. DTP3 is a key indicator used for assessing the effectiveness of 
childhood immunisation services. DTP can prevent diphtheria, pertussis and tetanus in children. 
DTP-containing vaccines are given in three doses with three booster doses and diphtheria toxoid-
containing vaccines given to the older children as a booster vaccine.10 A multilevel study was 
designed to assess the independent contributions of individual, community, and country-level 
socio-economic factors. We also developed and tested a model for the determinants as they relate 
to non-uptake of DTP3 vaccines among HIV-exposed children (Figure 1). 
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Figure 1: Conceptual framework showing the factors determining episodes of diarrhoea or symptoms of acute respiratory 
infections among HIV-exposed children vaccinated with DTP3 vaccines 
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Methods 
 
Data sources 
This study used 27 nationally represented and cross-sectional surveys as of November 2017. The 
Demographic and Health Surveys (DHS) were implemented by different national institutions and 
ICF International, Calverton, Maryland, USA. The United States Agency for International 
Development, the Global Fund to Fight AIDS, Tuberculosis and Malaria, and others provided 
financial support. The survey methods and data-collection procedures were described in another 
publication.11 Included DHS were selected based on the availability of data on childhood 
immunisation, maternal HIV status, symptoms of acute respiratory infections and diarrhoea. DHS 
data were household sample surveys and the sampling design involved selecting and interviewing 
samples of women aged 15–49 years based on multi-stage cluster sampling. The DHS  instruments 
were standardised questionnaires administered by interviewers. Women aged 15-49 years were 
tested for HIV infection but children were not tested. 
 
Outcome variable                                                                                                                                                     
The outcome variable is defined as a DTP3 vaccinated child of an HIV-infected mother with 
symptoms of acute respiratory infections or an episode of diarrhoea two weeks prior to the survey. 
The vaccinees were within the 12-23 months age range at the time of the surveys and at that age 
they were expected to have taken most of the basic childhood vaccines as specified by each 
country. 
 
DHS defined symptoms of acute respiratory infections as a cough associated with short and rapid 
breathing in an ill under-five child within the two weeks preceding the survey. Diarrhoea is 
characterised by loose and watery stools three or more times a day in children. 
 
Determinant variables 
 
Individual-level factors 
Five measures of individual socio-economic position were considered in the model, namely:  age 
of the mother, educational level, wealth index, employment status and place of residence. The age 
of the mother was in completed years (15 to 24, 25 to 34, 35 to 49); level of education as no formal 
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education, primary education, and secondary or higher education; wealth index as either poorer, 
middle and richest; and employment status as currently employed or unemployed. 
 
Community-level factors 
We included the following community-level factors in the model: neighbourhood poverty rate 
defined as the percentage of households that are below 20% of wealth index; illiteracy rate which 
is the percentage of women without formal education within the community; unemployment rate 
defined as the percentage of women who are currently unemployed within the community; and, 
place of residence which is either urban or rural. We also classified the rates as low or high.  
 
Country-level factors 
The study included the following country-level factors in the model: gross domestic product (GDP) 
per capita, adult literacy rate and health expenditure (Table 1). We obtained these data from the 
World Bank database.12 The country-level variables were also categorised into either low or high 
classes in order to assess nonlinear effects and for easy interpretation of results for policy decision 
making.  
 
Statistical analyses 
The distribution of respondents by various key variables were expressed as percentages. Pearson's 
chi-squared test was used for analysing contingency tables. We used individual weights for the 
descriptive statistics reported by this study. Multivariable logistic regression models were used to 
analyse the association between individual and contextual factors associated with symptoms of 
acute respiratory infections or diarrhoea among the children of women living with HIV and with 
the history of uptake of DTP3 vaccines. 
 
We used a five-level model for the binary variable, namely:  
First model: empty null model, an unconditional model without any explanatory variables. 
Second model: for only individual-level factors. 
Third model: for only community-level factors. 
Fourth model: for only country-level factors. 
Fifth model (Full model): that controlled for individual-, community- and country-level factors 
simultaneously (Figure 1). 
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The fixed-effects model results were presented as odds ratio (ORs) with 95% credible intervals 
(CrIs). The random effects measures included intra-cluster correlation (ICC) and variance partition 
coefficient and median odds ratio (MOR). We calculated ICC by the use of formula described by 
Snijders and Bosker.13 The method used for the calculation of MOR was described by Larsen et 
al.14,15 All the included tests were two tailed with the probability level of less than 0.05 considered 
to be significant. The models were fitted with MLwiN 3.01.16 Statistical analysis were performed 
with the use of STATA 14.0.17 
 
Ethics statement 
This research was a secondary analysis of existing survey data which were obtained with 
permission from the DHS programme database.11 These surveys were conducted after ethics 
approval by the Institutional Review Board of ICF International, Calverton, Maryland, USA and 
by respective National Ethical Review Committees in Angola, Burkina Faso, Burundi, Cameroon, 
Chad, the Democratic Republic of the Congo, Cote d'Ivoire, Ethiopia, Gabon, Gambia, Ghana, 
Guinea, Kenya, Lesotho, Liberia, Malawi, Mali, Namibia, Niger, Rwanda, Sao Tome and 
Principle, Senegal, Sierra Leone, Swaziland, Togo, Zambia and Zimbabwe. The study participants 
gave informed consent at the time of the surveys and their confidentiality was respected.   
 
Results  
 
Sample characteristics 
The country surveys were conducted between 2003 and 2016 in the included countries (Table 1). 
Adult literacy rate in the included countries ranged from 15.5% in Niger to 90.1% in Sao Tome 
and Principe. The health expenditure per capita ranged from US$19.1 in Niger to US$321.3 in 
Gabon. GDP per capita data show that Gabon and Namibia are upper middle-income countries 
while eight other countries namely; Angola, Cameroon, Cote d’Ivoire, Ghana, Kenya, Senegal, 
Swaziland and Zambia are lower middle-income countries and the rest are low-income countries.  
 
Table 2 shows the summary of symptoms of acute respiratory infections and episodes of diarrhoea 
among the children of HIV-infected mothers vaccinated with DTP3 at different levels in this study. 
For the summary of symptoms of acute respiratory infections, a total of 1,482 children aged 12-23 
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months (Level 1), within 1076 communities (Level 2), from 26 countries (Level 3) in sub-Saharan 
Africa were included.  For the episodes of diarrhoea, a total of 4,027 children aged 12-23 months 
(Level 1), within 2267 communities (Level 2), from 27 countries (Level 3) in sub-Saharan Africa. 
Male and female children of HIV-infected women were evenly distributed. An estimated half of 
the included mothers were aged between 25 and 34 years, about three-fifths were not employed 
and two-fifths were in the richer wealth-index group. Most of the respondents were living in rural 
areas, within low poverty-rate and low literacy-rate groups. 
 
Acute respiratory infections  
Measures of associations (fixed effects) 
Table 3 shows the multilevel multivariate logistic-regression models of the factors associated with 
symptoms of acute respiratory infections by children of HIV-infected women. At the community-
level, the odds of developing symptoms of acute respiratory infections increased among those 
living in communities with high unemployment rates such that the children were 15% more likely 
to develop acute respiratory infections (odds ratio [OR] = 1.15, 95% credible interval [CrI] 1.05 
to 1.26). 
 
 
Measures of variations (random effects) 
In model 1 (unconditional model), there was a significant variation in the odds of developing 
symptoms of acute respiratory infections among the children of HIV-infected mothers across the 
countries (σ2 = 0.763, 95% CrI 0.359 to 1.514) and across the communities (σ2 = 0.002, 95% CrI 
0.001 - 0.006) (as shown in Table 3). The intra-country and intra-community correlation 
coefficients show that 18.81% and 18.85% of the variance in odds of developing symptoms of 
acute respiratory infections are linked to country- and community-level factors respectively. From 
the full model (Model 5), it is assumed that a child who moved to another country or community 
with a higher probability of developing symptoms of acute respiratory infections, the median 
increase in the odds of developing symptoms of acute respiratory infections would be 20.92% and 
21.00% respectively.  
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Episodes of diarrhoea 
Measures of associations (fixed effects) 
Table 4 shows the multilevel multivariate logistic-regression models of the factors associated with 
episodes of diarrhoea by children of HIV-infected women. At the individual level, the odds of 
developing diarrhoea increased among young mothers such that children of women aged 15-24 
years were twice as likely to develop diarrhoea compared to children of women aged 35-49 years 
(OR= 2.22, 95% Crl 1.66 to 2.93).  
 
 
Measures of variations (random effects) 
 
In model 1, there was a significant variation in the odds of developing diarrhoea among the 
children of HIV-infected mothers across the countries (σ2 = 0.223, 95% CrI 0.058 to 0.532) and 
across the communities (σ2 = 0.744, 95% CrI 0.302- 1.273) (as shown in Table 4). The intra-
country and intra-community correlation coefficients show that 5.23% and 22.71% of the variance 
in odds of developing diarrhoea are linked to country- and community-level factors respectively. 
The variance in odds of not developing diarrhoea was also attributable to the country- and 
community-level factors respectively. From the full model (Model 5), it is assumed that a child 
who moved to another country or community with a higher probability of developing diarrhoea, 
the median increase in the odds of developing diarrhoea would be 5.63% and 26.73% respectively.  
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      Table 1: Year of DHS survey and country level characteristics of 27 study countries in sub-Saharan Africa  
Country 
Year of 
survey GDP per capita  Adult literacy rate  Health expenditure  
Angola 2016 3110.8 66 179.4 
Burkina Faso 2010 649.7 34.6 35.2 
Burundi 2011 285.7 61.6 21.6 
Cameroon 2011 1032.6 71.3 58.7 
Chad 2015 664.3 22.3 37.1 
Congo DR 2014 444.5 77 19.1 
Cote d'Ivoire 2012 1526.2 43.9 88.4 
Ethiopia 2003 706.8 39 26.6 
Gabon 2012 7179.3 82.3 321.3 
Gambia 2013 473.2 42 30.7 
Ghana 2014 1513.5 71.5 57.9 
Guinea 2012 508.1 32 37.3 
Kenya 2009 1455.4 78.7 77.7 
Lesotho 2014 998.1 76.6 105.1 
Liberia 2013 455.4 42.9 46.3 
Malawi 2016 300.8 62.1 29 
Mali 2013 780.5 33.1 47.8 
Namibia 2012 4140.5 88.3 499 
Niger 2013 363.2 15.5 24.4 
Rwanda 2015 702.8 68.3 52.5 
Sao T&P 2009 1756.1 90.1 165.6 
Senegal 2011 958.1 42.8 49.5 
Sierra Leone 2013 496 32.4 85.9 
Swaziland 2007 2775.2 83.1 247.9 
Togo 2014 578.5 63.8 33.9 
Zambia 2014 1178.4 83 85.9 
Zimbabwe 2015 1008.6 88.7 57.7 
 
 
 
GDP: gross domestic product, HDI: human development index, n/a: not available) 
GDP - Low-income economies are defined as those with a GDP per capita of $1,025 or less; lower middle-income economies: $1,026 - $4,035; 
upper middle-income economies: $4,036 - $12,475; high-income economies: ≥ $12,476. HDI - low: <0.549; medium: 0.550 – 0.770. 
(Source: Demographic and Health Surveys, World Bank, Joint United Nations Programme on HIV/AIDS, United Nations Development 
Programme)  
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Table 2: Summary of symptoms of acute respiratory infections and episodes of diarrhoea among the children of HIV-
infected mothers with DTP3 uptake at different levels 
 
 
Symptoms of acute respiratory infections 
  
Episodes of diarrhoea   
Variables No Yes p-value No Yes p-value 
Individual-level factors  
Gender          
Female 533 (50.6) 196 (45.9) 0.104 1,663 (49.4) 324 (49.0) 0.855 
Male 521 (49.4) 231 (54.1)   1,703 (50.6) 337 (51.0)  
Age (in years)  
15-24 269 (25.5) 115 (26.9) 0.592 751 (22.3) 197 (29.8) 0.000 
25-34 512 (48.6) 212 (49.7)   1,706 (50.7) 333 (50.4)  
35-49 273 (25.9) 100 (23.4)   909 (27.0) 131 (19.8)  
Education  
No education 74 (7.0) 62 (14.5) 0.000 451 (13.4) 78 (11.8) 0.072 
Primary 479 (45.5) 175 (41.0)   1,448 (43.0) 316 (47.8)  
Secondary+ 501 (47.5) 190 (44.5)   1,467 (43.6) 267 (40.4)  
Employment status  
Unemployed 636 (60.3) 270 (63.2) 0.301 2,115 (62.8) 425 (64.3) 0.476 
Employed 418 (39.7) 157 (36.8)   1,251 (37.2) 236 (35.7)  
Wealth index  
Poorer 325 (30.8) 126 (29.5) 0.842 893 (26.5) 197 (29.8) 0.165 
Middle 305 (28.9) 129 (30.2)   996 (29.6) 196 (29.7)  
Richer 424 (40.3) 172 (40.3)   1,477 (43.9) 268 (40.5)  
Access to media          
Nil 298 (28.3)      92 (21.5) 0.035 715 (21.3)      162 (24.5) 0.195 
Access to 1 outlet 309 (29.3) 139 (32.6)   1,041 (30.9) 290 (31.6)  
Access to 2 outlets 289 (27.4) 117 (27.4)   991 (29.4) 181 (27.4)  
Access to all outlets 158 (15.0) 96 (18.5)   619 (18.4) 109 (16.5)  
Community-level factors  
Place of residence  
Urban 444 (42.1) 166 (38.9) 0.250 1,494 (44.4) 283 (42.8) 0.457 
Rural 610 (57.9) 261 (61.1)   1,872 (55.6) 378 (57.2)  
Poverty rate  
Low  625 (59.3) 258 (60.4) 0.690 2,103 (62.5) 391 (59.2) 0.107 
High 429 (40.7) 169 (39.6)   1,263 (37.5) 270 (40.8)  
Unemployment rate  
Low 526 (49.9) 194 (45.4) 0.119 1,723 (51.2) 329 (49.8) 0.506 
High 528 (50.1) 233 (54.6)   1,643 (48.8) 332 (50.2)  
Illiteracy rate  
Low 744 (70.6) 271 (63.5) 0.008 2,264 (67.3) 424 (64.2) 0.120 
High 310 (29.4) 156 (36.5)   1,102 (32.7) 237 (35.8)   
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Table 3: Factors associated with symptoms of acute respiratory infections by children of HIV-infected women identified 
by multilevel multivariate logistic-regression models 
 Model 1a Model 2b Model 3c Model 4d Model 5e 
 OR (95% Crl) OR (95% Crl) OR (95% Crl) OR (95% Crl) OR (95% Crl) 
Fixed-effect      
Individual-effect factors      
Male (vs. female)  1.23 (0.95 -1.58)   1.22 (0.94 - 1.57) 
Mother’s age (in  years)      
35-49  1 (reference)   1 (reference) 
25-34  1.18 (0.86 - 1.58)   1.19 (0.86 - 1.59) 
15-24    1.11 (0.76 - 1.54)   1.11 (0.75 - 1.58) 
Wealth index      
Richer    1 (reference)   1 (reference) 
Middle  1.10 (0.78 - 1.50)   1.00 (0.67 - 1.40) 
Poorer  1.04 (0.71 - 1.48)   0.94 (0.56 - 1.43) 
Education      
Secondary+   1 (reference)   1 (reference) 
Primary  0.84 (0.62-  1.11)   0.83 (0.61 – 1.11) 
No education  1.55 (0.95 – 2.37)   1.52 (0.88 - 2.43) 
Not employment  1.02 (0.77 - 1.35)   0.84 (0.60 - 1.15) 
Access to media  1.02 (0.88 -  1.18)   1.01 (0.88 - 1.19) 
Community-level factors      
Rural (vs. urban)   1.26 (0.88 - 1.77)  1.35 (0.91 – 2.00) 
High (vs. low) poverty rate   0.98 (0.87 - 1.10)  0.99 (0.87 - 1.12) 
High (vs. low) unemployment rate   1.15 (1.05 - 1.26)*  1.17 (1.05 - 1.30)* 
High (vs. low) illiteracy rate   1.01 (0.93 - 1.10)  0.98 (0.89 - 1.08) 
Country-level factors      
Middle (vs. low) GDP     1.16 (0.40 – 2.52) 1.15 (0.36 – 2.90) 
High (vs. low) Adult literacy rate     0.68 (0.27 - 1.37) 0.64 (0.21 - 1.44) 
Average (vs. low) Health 
expenditure 
   1.06 (0.28 - 3.11) 1.23 (0.24 - 3.19) 
Random effects      
Country-level      
Variance (95 Crl) 0.763 (0.359 – 1.514) 0.734 (0.341 – 1.460) 0.788 (0.359 – 1.578) 0.830 (0.363 - 1.691) 0.871 (0.378 – 1.792) 
ICC (%) 18.81 18.21 19.27 20.13 20.92 
MOR ((%, 95% Crl) 2.29 2.26 2.32 2.38 2.43 
Explained variation (%) Reference 3.7 -3.3 -8.8 -14.2 
Community-level       
Variance (95 Crl) 0.002 (0.001 - 0.006) 0.008 (0.002 – 0.017) 0.012 (0.001-0.416) 0.001 (0.000 - 0.004) 0.003 (0.001 - 0.009) 
ICC (%) 18.85 18.42 19.56 20.16 21.00 
MOR ((%, 95% Crl) 1.04 1.09 1.11 1.03 1.05 
Explained variation (%) Reference -380.2 -566.0 26.6 -79.4 
Model fit statistics      
DIC 1550 1529 1548 1551 1556 
 
DIC - Deviance Information Criterion; ICC – intra-cluster correlation; MOR – median odds ratio; OR- odds ratio; CrI – credible interval. 
aModel 1 is a null model, baseline model without any determinant variable.                                        bModel 2 is additionally adjusted for individual-level factors. 
cModel 3 is additionally adjusted for community-level factors.                                                              dModel 4 is additionally adjusted for country-level factors. 
eModel 5 is additionally adjusted for individual-, community-, and country-level factors 
Stellenbosch University  https://scholar.sun.ac.za
157 
 
Table 4: Factors associated with episodes of diarrhoea by children of HIV-infected women identified by 
multilevel multivariate logistic-regression models 
 Model 1a Model 2b Model 3c Model 4d Model 5e 
 OR (95% Crl) OR (95% Crl) OR (95% Crl) OR (95% Crl) OR (95% Crl) 
Fixed-effect      
Individual-effect factors      
Male (vs. female)  1.00 (0.83 -1.20)   1.01 (0.83 - 1.22) 
Mother’s age (in years)      
35-49  1 (reference)   1 (reference) 
25-34  1.52 (1.15 – 1.95)*   1.58 (1.23 – 2.02)* 
15-24  2.13 (1.57 – 2.80)*   2.22 (1.66 – 2.93)* 
Wealth index      
Richer  1 (reference)   1 (reference) 
Middle  1.05 (0.80 - 1.32)   1.04 (0.77 - 1.38) 
Poorer  1.20 (0.90 - 1.58)   1.17 (0.82 - 1.66) 
Education      
Secondary+  1 (reference)   1 (reference) 
Primary  1.24 (0.98 - 1.57)   1.27 (0.98 - 1.57) 
No education  0.94 (0.63 - 1.32)    0.90 (0.58 - 1.28)  
Not employment  0.82 (0.66 – 1.00)   0.82 (0.65 - 1.03) 
Access to media  0.97 (0.87 -  1.08)   1.00 (0.88 - 1.11) 
Community-level factors      
Rural (vs. urban)   0.96 (0.73 - 1.24)  0.96 (0.69 - 1.29) 
High (vs. low) poverty rate   1.05 (0.96 - 1.15)  1.02 (0.92 - 1.14) 
High (vs. low) unemployment 
rate 
  0.98 (0.91 - 1.06)  1.00 (0.93 - 1.09) 
High (vs. low) illiteracy rate   1.04 (0.97 - 1.13)  1.06 (0.98 - 1.15) 
Country-level factors      
Middle (vs. low) GDP     0.91 (0.61 - 1.35) 0.89 (0.44 - 1.69) 
High (vs. low) Adult literacy rate     1.29 (0.86 - 1.92) 1.32 (0.62 – 2.58) 
Average (vs. low) Health 
expenditure 
   0.68 (0.42 - 1.08) 0.69 (0.34 - 1.27) 
Random effects      
Country-level      
Variance (95 Crl) 0.223 (0.058 - 0.532) 0.241 (0.072 – 0.566) 0.229 (0.056 – 0.556) 0.083 (-0.010- 0.178) 0.253 (0.039 - 0.673) 
ICC (%) 5.23 5.57 2.16 5.37 5.63 
MOR ((%, 95% Crl) 1.57 1.59 1.32 1.58 1.61 
Explained variation (%) Reference -8.3 62.4 -4.4 -13.5 
Community-level       
Variance (95 Crl) 0.744 (0.302 – 1.273) 0.801 (0.437 - 0.122) 0.846 (0.510-1.246) 0.501 (0.251- 0.751) 0.947 (0.494 - 1.432) 
ICC (%) 22.71 24.06 15.09 24.03 26.73 
MOR ((%, 95% Crl) 2.27 2.34 1.96 2.35 2.52 
Explained variation (%) Reference -7.7 32.7 -8.6 -27.3 
Model fit statistics      
DIC 3501 3534 3494 3495 3470 
DIC - Deviance Information Criterion; ICC – intra-cluster correlation; MOR – median odds ratio; OR- odds ratio; CrI – credible interval. 
aModel 1 is a null model, baseline model without any determinant variable.        bModel 2 is additionally adjusted for individual-level factors.                                         
cModel 3 is additionally adjusted for community-level factors.                              dModel 4 is additionally adjusted for country-level factors. 
eModel 5 is additionally adjusted for individual-, community-, and country-level factors 
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Discussion 
 
Main findings 
This study shows that the individual, community and country contexts are significant in explaining 
the variations in acute respiratory infections and diarrhoea among the children of HIV-infected 
mothers in the selected sub-Saharan African countries. Developing symptoms of acute respiratory 
infections are more likely in the children of HIV-infected women who live in communities with 
high unemployment rates. Our findings show that children of young HIV-infected women are more 
likely to develop diarrhoea than the children of older women in sub-Saharan African countries.  
 
Communities with high unemployment rates have the characteristics of poor neighbourhoods such 
as poor housing, limited access to public services like healthcare, transportation, etc.18 High-
unemployment communities are linked with lower socio-economic status and are characterised by 
crowded rooms, poor nutrition, poor sanitation and unhygienic conditions.19  Women living with 
HIV in these communities more or less belong to the lower socio-economic status.20 Deprived 
neighbourhoods with high unemployment rates are associated with increased risk of mortality.21 
Cohen also shows that unemployment status is strongly associated with increased susceptibility to 
acute respiratory infection in humans due to reduced resistance to infection and increased exposure 
to infectious agents.19 There is also a strong correlation between parental unemployment and 
children’s poor health outcomes.22 
  
Multinational research in developing countries located in Africa, the Americas, Asia and the 
Pacific shows the prevalence of acute respiratory infections among both HIV-infected and HIV-
uninfected children to be 13%. The study also shows that factors like living in a high-risk indoor 
environment, male gender, employed mothers and low birthweight were positively associated with 
acute respiratory infections. Planned pregnancy, maternal education, older maternal age, 
breastfeeding for more than six months, and immunisation were associated with reductions in 
respiratory infections.23 
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Younger mothers are not as experienced as older women and are mostly learning to care for their 
first child.24 The first child of adolescent and young mothers are most susceptible to both poor 
health outcomes and mortality.24 The children of first–time, young mothers are at higher risk of 
developing diarrhoea, stunting and anaemia.24 A multinational study on acute diarrhoea in 
developing countries among both immunised and non-immunised children shows that country 
inequalities, maternal illiteracy and unemployment were associated with diarrhoea.25 Female 
children, normal birthweight, older children, complete immunisation coverage, advanced maternal 
age, planned pregnancy, good sanitation and rich households were associated with a reduction in 
episodes of diarrhoea.25  
 
Furthermore, the findings from the multinational studies23,25 involving children who were both 
immunised and unimmunised, HIV-exposed and non-exposed show an association with many 
factors while this multilevel analytic research included only HIV-exposed children who were 
vaccinated with DTP3 shows fewer associations. 
 
Consistent, equitable availability and access to vaccination especially among the most vulnerable 
and poorest communities is essential in addressing non-uptake of basic vaccines in HIV-exposed 
children. The Integrated Global Action Plan for the Prevention and Control of Pneumonia and 
Diarrhoea (GAPPD) which recommends an interrelated approach for the elimination of 
preventable diarrhea and pneumonia deaths has vaccination as one of the key interventions.26 
GAPPD brings together essential services and interventions such as promotion of practices that 
can protect children from these respiratory and diarrhoeal diseases and make sure that every child 
has access to suitable preventive measures and proper treatment.27  
 
Strengths and limitations  
The use of DHS gives this study a good quality and representation because the surveys were done 
in different regions of the included countries. However, this study has certain significant 
limitations. Firstly, the surveys were not conducted concurrently and within the same timeframe 
in each of the countries. Social conditions do change and are expected to change over time in these 
countries. The surveys were conducted in different countries over a time space of a decade and 
this may have some effect on the study findings. Secondly, DHS methodology being cross-
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sectional, it does not give room for establishing causality. Haemophilus Influenzae type b (Hib) 
vaccine and rotavirus vaccine coverage as at 2016 were 74% and 43% among African countries. 
Pneumococcal vaccine global coverage was estimated at 42% in 2016.27 The use of pneumococcal 
and rotavirus vaccination data would have provided added information with respect to independent 
contributions of various factors because, at the time when the surveys were conducted, most of the 
African countries were yet to introduce Hib, pneumococcal and rotavirus vaccines. Another gap 
in this study is the lack of information about the HIV status of the children.  
 
 
Conclusions 
 
This study gives insight concerning the determinants of key morbidity factors among immunised 
and HIV-exposed children in sub-Saharan Africa. The study reveals that residence in communities 
with high unemployment was an independent predictor of acute respiratory infections among 
immunised and HIV-exposed children. HIV-exposed children born to women aged 15-24 or 25-
34 years old were significantly more likely to develop diarrhoeal diseases in sub-Saharan Africa.  
 
These findings are important because they have policy implications on the implementation of child 
healthcare programmes for respiratory infections and diarrhoeal diseases particularly among HIV-
exposed and infected children in sub-Saharan Africa. Public healthcare programmes should target 
adolescent and young women and their family members on how to prevent diarrhoea. Efforts 
should be made to identify the hotspots for acute respiratory diseases, especially in communities 
with high rates of unemployment, and to develop strategies to combat the diseases in such 
communities. 
 
Further large data research is needed to study the effect of rotavirus, pneumococcal and Hib 
vaccines on the prevalence of diarrhoea and respiratory infection in sub-Saharan Africa 
populations. It is recommended that DHS should include the newer vaccines and HIV status for 
the children as part of the collected data so as to have a large database for a robust study of vaccine-
preventable diseases in HIV-infected children across developing countries.  
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CHAPTER 8: Concluding remarks and recommendations for 
future work 
 
Conclusion 
 
This thesis provides an overview of the burden of vaccine-preventable diseases, efficacy and 
effectiveness of vaccines, vaccination coverage and contributory factors for non-uptake of vaccines 
among HIV-infected and HIV-exposed children in sub-Saharan Africa. This research determined 
the prevalence of symptoms of acute respiratory infections and episodes of diarrhoea; and assessed 
if there was any significant morbidity benefit conferred by vaccination. This study also examined 
the roles of the socio-economic factors in relation to vaccine uptake among HIV-infected and HIV-
exposed children in sub-Saharan Africa.  
The overall conclusions of this thesis are as follows:  
i. The burden of vaccine-preventable diseases is still high among HIV-infected and HIV-
exposed children in sub-Saharan Africa.  
            Methodology: Systematic review and meta-analysis. 
 
ii. Several routine vaccines show possibilities for direct and indirect protection against various 
vaccine-preventable diseases among HIV-infected and HIV-exposed children. However, 
HIV-infected children are less likely to be protected against vaccine-preventable diseases 
compared to unexposed children. HIV-infected children who are on antiretroviral therapy 
and with good viral suppression are also more likely to be protected.  
Methodology: Systematic review and meta-analysis. 
 
iii. There is no significant difference in the uptake of the full series of three doses of diphtheria-
tetanus-pertussis containing vaccines (DTP3) among infants of HIV-infected mothers and 
those of uninfected mothers in sub-Saharan Africa. However, there is a significant variation 
in terms of the estimates among the sub-Saharan African countries. 
      Methodology: Meta-analysis and meta-regression  
Stellenbosch University  https://scholar.sun.ac.za
167 
 
iv. DTP3 coverage for both HIV-exposed children and non-exposed children is still sub-
optimal. Improved prevention of mother-to-child transmission services might have 
contributed to some extent to the higher DTP3 vaccination coverage among the HIV-
exposed children. 
      Methodology: Meta-analysis and meta-regression. 
 
v. Individual and contextual factors such as maternal age, educational level, unemployment 
and adult literacy level contributed significantly to non-uptake of DTP3 among the children 
of HIV-infected women across sub-Saharan Africa. 
      Methodology: Multilevel multivariate regression modelling.  
 
vi. The symptoms of acute respiratory infections show no statistical difference in the overall 
estimates between the children of HIV-infected mothers who were vaccinated with DTP3 
and the ones who were not vaccinated. The data for episodes of diarrhoea were pooled 
together with resultant nil significant difference in the overall estimates between the 
children of HIV-infected mothers vaccinated with DTP3 and the ones that were not 
vaccinated. There was no significant difference in the overall estimates between the 
children of HIV-uninfected mothers who were vaccinated with DTP3 and those of mothers 
living with HIV with respect to the prevalence of symptoms of acute respiratory infections 
and episodes of diarrhoea across the study countries.  
     Methodology: Meta-analysis. 
 
vii. Many African countries recorded high rates of respiratory infections and diarrhoeal 
diseases. This necessitates the need for accelerating the introduction of newer vaccines 
such as rotavirus, pneumococcal conjugate and Heamophilus influenzae type b vaccines in 
countries that are yet to introduce them as part of their national immunisation programme. 
            Methodology: Meta-analysis and meta-regression. 
 
viii. Residence in communities with high unemployment was an independent predictor of acute 
respiratory infections among immunised and HIV-exposed children while those born to 
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women aged 15-24 or 25-34 years old were significantly more likely to develop diarrhoeal 
diseases in sub-Saharan Africa.  
      Methodology: Multilevel multivariate regression modelling. 
 
Recommendations for future research  
 
These findings are important because they have policy implications for the implementation of child 
healthcare programmes particularly among HIV-exposed and infected children in sub-Saharan 
Africa. These findings would be useful in advocating for an equitable share of healthcare resources 
for services like childhood vaccination etc.  
This research also raises many issues that need to be investigated and I propose the following areas 
to be addressed in future research: 
1. This thesis shows that there is a dearth of studies on the incidence, prevalence and case-
fatality rates for various vaccine-preventable diseases among HIV-infected and HIV-
exposed uninfected children in African countries. There is need for future studies that 
will showcase the real burden of vaccine-preventable diseases. The studies could be 
prospective or retrospective in nature. (Chapter 2).  
 
2. There are few studies on vaccine efficacy and effectiveness specifically among HIV-
infected and exposed children. There is a knowledge gap on vaccine efficacy and 
effectiveness of vaccines with a focus on HIV-infected and exposed children. 
Outcomes of interest for these studies should include the development of clinical 
features or laboratory confirmation of vaccine-preventable diseases (Chapter 3). 
 
3. There is poorer vaccine efficacy among HIV-infected children and this necessitates the 
development of newer and more efficacious vaccines (Chapter 3).   
4. There is a need for large data sets such as the demographic and health surveys to include 
new vaccines like rotavirus and pneumococcal conjugate vaccines. These are required 
to study the effects of these vaccines on the prevalence of diarrhoea and respiratory 
infections in sub-Saharan Africa populations.  Future surveys should also include the 
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HIV status of the children as part of the collected data so as to have a large database 
for a robust study of vaccine-preventable diseases in HIV-infected and exposed 
children in African countries (Chapters 6 and 7). 
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